Tetracycline derivatives and their uses
By designing tetracycline derivative compounds lacking antibiotic activity, the shortcomings of existing tetracycline derivatives in the treatment of central nervous system and peripheral diseases have been overcome. Effective blood-brain barrier penetration and bioactivity have been achieved, making them suitable for the treatment of diseases such as Fragile X syndrome.
Patent Information
- Application Number
- CN202580022765.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-14
- Filing Date
- 2025-02-13
- Publication Date
- 2026-11-10
AI Technical Summary
Existing tetracycline derivatives are mainly used for antibiotic treatment, lacking biological effects beyond antibiotic activity, such as anti-inflammatory and anti-apoptotic activities, and are difficult to treat central nervous system diseases and peripheral diseases.
A series of tetracycline derivative compounds, including minocycline and kaempferol skeleton compounds, are provided, designed to lack significant antibiotic activity but have the ability to cross the blood-brain barrier for the treatment of central nervous system and peripheral diseases.
These compounds can effectively cross the blood-brain barrier and are used to treat central nervous system diseases and peripheral diseases. They have anti-inflammatory and anti-apoptotic activities and are suitable for treating protein synthesis disorders such as Fragile X syndrome.
Smart Images

Figure CN123076591A_ABST
Abstract
Description
Cross-reference to related applications
[0001] This application claims priority and benefit to U.S. Provisional Patent Application No. 63 / 553,511, filed February 14, 2024, and U.S. Provisional Patent Application No. 63 / 553,576, filed February 14, 2024, the disclosure of which is incorporated herein by reference in its entirety. Technical Field
[0002] This disclosure generally relates to tetracycline derivatives, and more specifically to compositions and methods utilizing tetracycline skeletons (including minocycline and oxalicycline skeletons). Background Technology
[0003] Minocycline and kaempferol are new-generation semi-synthetic tetracyclines. For example, minocycline is currently primarily used to treat acne vulgaris and some sexually transmitted diseases. Certain tetracycline derivatives have been reported to possess a variety of biological effects independent of their antimicrobial activity, including anti-inflammatory and anti-apoptotic activities, as well as inhibition of protein hydrolysis, angiogenesis, and tumor metastasis. What is needed in this field are tetracycline derivatives that can serve as a novel therapeutic approach beyond antibiotics. Summary of the Invention
[0004] In some respects, compounds of formula (Ia), (Ib), (II), (III), (IV-a), (IV-b), (Va), or (Vb) are provided: (Ia) (Ib) (II) (III) (IV-a) (IV-b) (Va) (Vb), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. In some variations, isomers of the compounds provided herein are provided, including stereoisomers and tautomers.
[0005] In other aspects, compositions (including pharmaceutical compositions) and kits comprising said compounds are also provided, as well as methods for using said compounds and for preparing said compounds. In some embodiments, the compounds lack significant antibiotic activity. In one embodiment, certain compounds can be used to treat peripheral diseases or disorders. In another embodiment, other compounds can be used to treat diseases or disorders of the central nervous system. Attached Figure Description
[0006] This application can be understood by referring to the following description in conjunction with the accompanying drawings.
[0007] Figure 1 The effect of the test compound in open-field testing is shown.
[0008] Figure 2 The effect of the tested compound on self-combing was shown.
[0009] Figure 3 The effects of the tested compound on dietary insufficiency were shown.
[0010] Figure 4 The effects of the tested compounds on nest-building behavior were shown.
[0011] Figure 5 The effect of the test compound in the recognition of new objects was shown.
[0012] Figure 6 The effect of the test compound in the partition test is shown.
[0013] Figure 7 The effects of the test compound on the attack behavior are shown.
[0014] Figure 8 The effects of the tested compound in a study of auditory-induced epilepsy were demonstrated. Detailed Implementation
[0015] The following description illustrates exemplary compositions, methods, parameters, etc. However, it should be understood that such description is not intended to limit the scope of this disclosure, but is instead provided as a description of exemplary embodiments.
[0016] In some aspects, this document provides compounds utilizing tetracycline skeletons (including minocycline and kaempferol skeletons), as well as corresponding compositions and methods. In some embodiments, the compounds provided herein lack significant antibiotic activity. In some variations, certain compounds are suitable for treating peripheral diseases, and such compounds may not have a good ability to cross the blood-brain barrier. In other variations, certain other compounds are suitable for treating indications of the central nervous system, and such compounds have a good ability to cross the blood-brain barrier. In still other variations, the compounds provided herein are suitable for treating age-related diseases or diseases in which protein synthesis is disordered. For example, in one variation, such a disease is Fragile X syndrome.
[0017] Compound of formula (Ia) In some respects, compounds of formula (Ia) are provided: (Ia), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 For H or OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u , Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H, NHR y Or halogenated, Where R y For H or -C(=O)(CH2) n NR v R w , Where n is an integer greater than or equal to 1; Each R v and R w Independently H or optionally substituted alkyl, or R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0018] In some implementation schemes, R 1 and R 2 All are H. In other implementations, R 1 and R 2All are optionally substituted alkyl groups. In other embodiments, R 1 and R 2 All are alkyl groups that have been independently chosen and optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more (e.g., any one of one, two, three, four, or five) halogenated (e.g., F, Cl, Br, or I). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 1 and R 2 All are methyl groups.
[0019] In some implementation schemes, R m For H, and R a2 For OH. In other embodiments, R m The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R m It is a methyl group.
[0020] In some implementation schemes, R b1 OR p In some implementations, R p For H, and R b1 For OH. In other embodiments, R p The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R p It is a methyl group.
[0021] In some implementation schemes, R b2 For H. In other implementations, R x For H, and R b2 For OH. In other embodiments, R x The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 alkyl.
[0022] In some implementation schemes, R d1H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u In one implementation, R d1 Not for use as a substitute for halogenated products.
[0023] In some implementation schemes, R d1 For H. In some implementations, R d1 Not H. In some variations, R d1 It is a haloalkyl, alkenyl, cycloalkyl, or heteroaryl group, wherein the cycloalkyl and heteroaryl groups are optionally substituted with alkyl, haloalkyl, or halogen. In some embodiments, R d1 Cycloalkyl groups optionally substituted with alkyl, haloalkyl, or halogenated alkyl groups (e.g., C10, C20, C30, C40, C50, C60, C7 ...70, C6 3-12 cycloalkyl, C 3-10 cycloalkyl or C 3-6 (Cycloalkyl). In some embodiments, R d1 It is a heteroaryl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group (e.g., 5- to 12-membered heteroaryl, 5- to 10-membered heteroaryl, or 5- to 6-membered heteroaryl). In some embodiments, R d1 It is an unsubstituted heterocyclic alkyl group. In some embodiments, R d1 It is a heterocyclic alkyl group that has been substituted with an alkyl group, a haloalkyl group, or a haloalkyl group. In some embodiments, R d1 It is an unsubstituted heterocyclic alkenyl group. In some embodiments, R d1 It is a heterocyclic alkenyl group that is substituted with alkyl, haloalkyl, or haloalkyl groups.
[0024] In other implementations, R d1 The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more (e.g., any one, two, three, four, or five) halogenated groups (e.g., F or Cl). In some of the variations described above, the alkyl group is C. 1-10 Alkyl, C 1-6 Alkyl or C 1-4 Alkyl group. In some variants, R d1 It is a haloalkyl group. In one variant, R d1 It is (R)-3-trifluoro-2-propyl or (S)-3-trifluoro-2-propyl. In one embodiment, R d1 For CF3. In one implementation, R d1 It is CH(CH3)CF3.
[0025] In other implementations, R d1The alkenyl group is optionally substituted. In some variations, the alkenyl group is unsubstituted. In other variations, the alkenyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkenyl group is C10. 2-10 alkenyl or C 2-6 Alkenyl group.
[0026] In other implementation schemes, R d1 For NR t R u In some variations, R t For H, and R u The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0027] In some implementation schemes, R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Substituted cyclopentyl, Optional substituted heterocyclic groups, wherein the heterocyclic groups are selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , Wherein R is H or an optionally substituted alkyl group (e.g., a C group optionally substituted with one or more halogens). 1-6 Alkyl groups, wherein each of the heterocyclic groups is optionally substituted.
[0028] In some variations, R d1 It is an optionally substituted nitrogen-containing heterocyclic butyl group. In some variations, R d1 It is an unsubstituted nitrogen-containing heterocyclic butyl group. In one variant, R d1 for .
[0029] In some variations, R d1 It is an optionally substituted oxocyclic butyl group. In some variations, R d1 It is an unsubstituted oxocyclic butyl group. In one variant, R d1 for .
[0030] In some implementation schemes, R d1 The heterocyclic group is optionally substituted, wherein the heterocyclic group is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , and R is H or an optionally substituted alkyl group (e.g., a C group optionally substituted with one or more halogenated groups). 1-6 Alkyl groups), wherein each of the heterocyclic groups is optionally substituted. In some embodiments, R d1 It is an unsubstituted heterocyclic group. In some embodiments, R d1 For one or more independently selected alkyl groups (e.g., C10, C20, C30, C40, C50, C60, C7 ... 1-6 Alkyl), haloalkyl (e.g., C18 alkyl groups optionally substituted with one or more halogens (such as F) 1-6 Alkyl), halogenated (e.g., F, Cl or Br), or -OH substituted heterocyclic groups.
[0031] In one implementation, R d1 Halogenation. In one implementation, R d1 For F. In one implementation, R d1 It is Cl.
[0032] In one implementation, R d1 It is a cycloalkyl group (e.g., C3-C8 cycloalkyl). In one embodiment, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a cyclobutyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, R d1 It is a cyclopentyl group substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a heterocyclic group optionally substituted with alkyl, haloalkyl, -OH or halogen.
[0033] In some variations, R d1 Not unsubstituted oxazolyl, furanyl (unsubstituted or substituted), unsubstituted imidazolyl, unsubstituted cyclopentyl, or unsubstituted thiophene. In some variations, when R... d1 When it is an isoxazolyl group, the isoxazolyl group is unsubstituted or substituted by a group other than a dimethyl group. In another embodiment, R d1 The heterocyclic group is optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In some embodiments, the heterocyclic group is aromatic (e.g., pyrazole). In some embodiments, the heterocyclic group is non-aromatic. In some embodiments, the heterocyclic group is linked to the rest of the compound by a heteroatom (e.g., a cyclic nitrogen atom). In some embodiments, the heterocyclic group is optionally substituted morpholine or pyrrolidine. In some embodiments, the heterocyclic group is optionally substituted cyclic amide, such as pyrrolidone.
[0034] In some variations, R d1 It is an optionally substituted nitrogen-containing heterocyclic butyl group. In some variations, R d1 It is an unsubstituted nitrogen-containing heterocyclic butyl group. In one variant, R d1 for .
[0035] In some variations, R d1 It is an optionally substituted oxocyclic butyl group. In some variations, R d1 It is an unsubstituted oxocyclic butyl group. In one variant, R d1 for .
[0036] In some implementation schemes, R d2 For H or NHR y In one implementation, R d2 For H. In another implementation, R d2 For NHR y In one variant, R y For H. In other variations, Ry For -C(=O)(CH2) n NR v R w In one variant, n is 1. In some variants, R v and R w All are H. In other variations, R v and R w Together with the nitrogen atom to which they are attached, they form optionally substituted heterocyclic alkyl groups. In other variations, R v and R w Together with the nitrogen atoms to which they are attached, they form unsubstituted pyrrolidines.
[0037] In some implementation schemes, R z For H, and R d3 For OH. In other embodiments, R z The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0038] In some variations of equation (I), when R d3 When it is OH, then R d2 For NHR y , where R y For -C(=O)(CH2) n NR v R w , where each R v and R w Independently H, alkyl, or haloalkyl; or R v and R w Together with the nitrogen atoms to which they are attached, they form cyclic groups.
[0039] In some variations of equation (I), when R d2 When it is H, then R d3 OR z , where R z It is an alkyl or haloalkyl group.
[0040] In some implementations of formula (I), R a2 OR m , where R m It is H, alkyl, or haloalkyl; and R b1 OR p , where each R pIt is H, alkyl, or haloalkyl. In some of the embodiments described above, R p It is an unsubstituted alkyl group. In some of the embodiments described above, R... p It is a methyl group.
[0041] It should generally be understood that the compounds described herein typically have a fused ring structure, and the positions and ring numbering of the ring carbon atoms can be described as follows: In some variants, the compounds provided herein have (S), (R), and (S) configurations at positions 4a, 5a, and 12a, respectively.
[0042] In some respects, a compound of formula (Iia) is provided: (Iia), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for the above formula (Ia).
[0043] In some respects, compounds of formulas (Ii-16A) and (Ii-16B) are provided: (Ii-16A) and (Ii-16B), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0044] In some aspects, a composition is provided comprising a substantially pure enantiomer of a compound of formula (Iia). In some aspects, a composition is provided comprising a substantially pure enantiomer of a compound of formula (Ii-16A) or formula (Ii-16B) or a pharmaceutically acceptable salt thereof. In some embodiments, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, and less than 0.1% of another enantiomer of said compound or a pharmaceutically acceptable salt thereof are contained in the composition. In some variations, the composition does not have a detectable amount of another enantiomer of said compound or a pharmaceutically acceptable salt thereof.
[0045] In some respects, a compound of formula (IAa) is provided: (IAa), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0046] In some embodiments of the compound of formula (IAa): Each R 1 and R2 Alkyl groups that are independently H or optionally substituted; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 For H or OR x , Where R x H or an alkyl group that is optionally substituted; R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Substituted cyclopentyl, Optional substituted 5-membered heterocyclic alkyl, or Optional substituted heterocyclic groups, wherein the heterocyclic groups are selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and , Wherein R is H or an optionally substituted alkyl group (e.g., a C group optionally substituted with one or more halogens). 1-6 Alkyl groups), wherein each of the heterocyclic groups is optionally substituted. R d2 For H or NHR y , Where R y For -C(=O)(CH2) n NR v R w , Where n is an integer greater than or equal to 1; Each R v and R w Independently H or optionally substituted alkyl, or R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0047] In some variations, R d1 For optionally substituted nitrogen-containing heterocyclic butanes. In some variants, R d1 It is an unsubstituted nitrogen-containing heterocyclic butyl group. In one variant, R d1 for .
[0048] In some variations, R d1 For optionally substituted oxobutanes. In some variants, R d1 It is an unsubstituted oxocyclic butyl group. In one variant, R d1 for .
[0049] In some variations, R d1 It is an optionally substituted 5-membered heterocyclic alkyl group. In some variations, R d1 It is an unsubstituted pyrrolidinyl or tetrahydrofuranyl. In one variant, R d1 for , , , or .
[0050] In some implementations, n is an integer between 1 and 4. In other implementations, n is any one of 1, 2, 3, or 4.
[0051] In some implementation schemes, Each R 1 and R 2 For H; R a2 It is OH; R b1 It is OH; R b2 It is OH; R d2 For H; and R d3 It is OH.
[0052] In some implementations, R d1 for: Unsubstituted cyclopropyl, or cyclopropyl substituted with one or more alkyl, haloalkyl or halogroups; Unsubstituted aza-butanediol, or aza-butanediol substituted with one or more alkyl, haloalkyl or halogroups; Unsubstituted oxetane, or oxetane substituted with one or more alkyl, haloalkyl or halogroups; Unsubstituted cyclobutyl, or cyclobutyl substituted with one or more alkyl, haloalkyl or halogroups; Cyclopentyl group substituted with one or more alkyl, haloalkyl, or halogroups; Unsubstituted 5-membered heterocyclic alkyl, or 5-membered heterocyclic alkyl substituted with one or more alkyl, haloalkyl or halogroups; An unsubstituted heterocyclic group, or a heterocyclic group substituted with one or more alkyl, haloalkyl, -OH, or halogroups; wherein the heterocyclic group is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , and , where R is H or an optionally substituted alkyl group.
[0053] In some implementations, R d1 for: Unsubstituted cyclopropyl, or cyclopropyl substituted with one or more alkyl, haloalkyl or halogroups; Unsubstituted cyclobutyl, or cyclobutyl substituted with one or more alkyl, haloalkyl or halogroups; Cyclopentyl group substituted with one or more alkyl, haloalkyl, or halogroups; Unsubstituted 5-membered heterocyclic alkyl, or 5-membered heterocyclic alkyl substituted with one or more alkyl, haloalkyl or halogroups; Unsubstituted 5-membered heteroaryl groups, or 5-membered heteroaryl groups substituted with one or more alkyl, haloalkyl, or halogroups; or An unsubstituted 6-membered heterocyclic group, or a 6-membered heterocyclic group substituted with one or more alkyl, haloalkyl, -OH or halogroups.
[0054] In some implementations, R d1 The pyrazolyl group is substituted with an alkyl group. In some of the above variations, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, the alkyl group is methyl.
[0055] In one aspect, a compound of formula (IAi) is provided: (IAi), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0056] In some embodiments of the compound of formula (IAi): Each R 1 and R 2 Independently H; and Ring D5 is: Substituted cyclopentyl, Choose any substituted 5-membered heterocyclic group from the group consisting of: , , , , , , , , , , , , , Wherein R is H or an alkyl group that is optionally substituted.
[0057] In some implementations, cycloD5 is cyclopropyl, cyclobutyl, or... , , , , , , , , , , or Each of the cyclic groups in D5 is optionally substituted with one or more optionally substituted alkyl or halogroups, and wherein R is H or alkyl. In some embodiments, cyclic D5 is... , or Where R is an alkyl group. In one embodiment, ring D5 is... R is an optionally substituted alkyl group. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 alkyl.
[0058] In some embodiments, the cyclopentyl and heterocyclic groups are substituted with one or more optionally substituted alkyl or halogroups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogroups. In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, the alkyl group is methyl.
[0059] In some variations, ring D5 is not an unsubstituted oxazolyl, furanyl (unsubstituted or substituted), unsubstituted imidazolyl, unsubstituted cyclopentyl, or unsubstituted thiophene. In some variations, when ring D5 is an isoxazolyl, the isoxazolyl is unsubstituted or substituted by a group other than a dimethyl group.
[0060] On the other hand, a compound of formula (IA-ii) is provided: (IA-ii), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0061] In some embodiments of the compound of formula (IA-ii): Each R 1 and R 2 Independently H or alkyl; and Ring D6 is a 6-membered heterocyclic group with optional substitutions selected from the group consisting of: , , , , , , , R is H or an optionally substituted alkyl group. In some variations, ring D6 is not pyridyl (unsubstituted or substituted), pyrimidinyl (unsubstituted or substituted), unsubstituted pyrazinyl, unsubstituted morpholino, or unsubstituted piperidinyl.
[0062] In some variations, R d1 The substituted 7-membered heterocyclic group is selected from the group consisting of: , and .
[0063] In some embodiments, the heterocyclic group is substituted with one or more optionally substituted alkyl, -OH, or halogroups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogroups. In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, the alkyl group is methyl. In some embodiments, the heterocyclic group is substituted with one or more -OH groups.
[0064] Compound of formula (Ib) In some respects, a compound of formula (Ib) is provided: (Ib), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g or =NOR k , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Wherein R' is H, an optionally substituted alkyl group, or an optionally substituted alkoxy group; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups. Where R k The alkyl group may be optionally substituted; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0065] In some implementation schemes, R 1 and R 2 All are H. In other implementations, R 1 and R 2 All are optionally substituted alkyl groups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 1 and R 2 All are methyl groups.
[0066] In some implementation schemes, R a1 For NR f R g In some implementations, R a1For NH2. In some implementations, R a1 For NHR f And R f Independently, it is an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or -C(=O)R', wherein R' is H, an optionally substituted alkyl, or an optionally substituted alkoxy. In some embodiments, R f It is -C(O)CH3. In some implementations, R f It is a cycloalkyl group. In some embodiments, R f It is an unsubstituted cyclobutyl group. In some embodiments, R f The cyclobutyl group is substituted with one or more alkyl groups (e.g., methyl, ethyl), halogenated, or CN, or any combination thereof. In some embodiments, R f It is a cyclobutyl group substituted with methyl and CN. In some embodiments, R f The cyclobutyl group is substituted with a halogenated group (e.g., F). In some embodiments, R f For being C 6-12 aryl-substituted alkyl groups, wherein the C 6-12 The aryl group is further substituted with -OH or alkoxy groups. In some embodiments, R f for In some implementations, R f The alkyl group is a heterocyclic substituted group, such as a 3- to 10-membered heterocycle, a 3- to 10-membered heterocyclic alkyl group, or a 3- to 6-membered heteroaryl group, wherein the heterocyclic group is optionally substituted with an alkyl group. In some embodiments, R f For being (It is an unsubstituted or methyl-substituted alkyl group.) In some embodiments, R f For being (It is an unsubstituted or methyl-substituted alkyl group.) In some embodiments, R f For being (It is an unsubstituted or methyl-substituted alkyl group.) In some embodiments, R f It is an optionally substituted heterocyclic alkyl group. In some embodiments, R f for , , ,or Each of these is optionally substituted (e.g., by an oxo, alkyl (such as methyl, ethyl), or haloalkyl (such as CF3 or CH2CHF2)), wherein R is H or an alkyl group (e.g., methyl or ethyl). In some embodiments, R f for It is substituted or unsubstituted with one or more alkyl groups. In some embodiments, R f for And R g For H. In some implementations, R f It is a tetrahydropyranyl group. In some embodiments, R f It is a -C(O)O-alkyl group. In some embodiments, R f It is -C(O)OCH3.
[0067] In some implementations, R f and R g Together with the nitrogen atom to which they are attached, they form a cyclic group optionally substituted with one or more alkyl, haloalkyl groups, wherein the alkyl group is substituted with -OR, halo, -OR, -COOR, -C(=O)R, -SO2R, or oxo. In some variations, R is independently H or an optionally substituted alkyl group each time it appears. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more haloalkyl groups. In some of the variations described above, the alkyl group is C. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R is methyl. In some embodiments, the cyclic group is... In some embodiments, the cyclic group is unsubstituted.
[0068] In some implementations, R a1 It is an optionally substituted cyclic group having 3-10 ring atoms. In some variations, the cyclic group has one or more additional ring atoms, said one or more additional ring atoms being heteroatoms independently selected from nitrogen and oxygen. In some variations, the cyclic group has two fused rings. In other variations, the cyclic group is a bridged cyclic group. In some embodiments, R a1 The cyclic group is optionally substituted, wherein the cyclic group is selected from the group consisting of: , , , , , , , , , , , ,and , where R 10The alkyl group can be optionally substituted with an alkyl group, an optionally substituted with an alkenyl group, a halogenated group, a C(=O)alkyl group, a C(=O)-O-alkyl group, an SO2(alkyl) group, an optionally substituted cycloalkyl group, an optionally substituted heterocycloalkyl group, or an optionally substituted alkoxy group. In some variations, the alkyl, alkenyl, cycloalkyl, and alkoxy groups are unsubstituted. In other variations, the alkyl, alkenyl, cycloalkyl, and alkoxy groups are substituted with one or more halogenated, OH, or alkoxy groups. In some of the variations described above, the alkyl group is C... 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 10 It is methyl. In some embodiments, R 10 It is -C(O)-O-CMe3. In some implementations, R 10 For -SO2CH3. In some implementations, R 10 It is -C(O)CH3. In some implementations, R 10 It is -CH2CH2OCH3. In some implementations, R 10 It is cyclopropyl. In some embodiments, R 10 It is an oxocyclic butyl group.
[0069] In some implementation schemes, R m For H, and R a2 For OH. In other embodiments, R m The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R m It is a methyl group.
[0070] In some implementation schemes, R b1 OR p In some implementations, R p For H, and R b1 For OH. In other embodiments, R p The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R p It is methyl. In some embodiments, R b1 For NR q R s , where each R q and R sThe alkyl group is independently H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some embodiments, R... b1 It is NH2.
[0071] In some implementation schemes, R x For H, and R b2 For OH. In other embodiments, R x The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 alkyl.
[0072] In some implementation schemes, R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u In some implementations, R d1 Not for use as a substitute for halogenated products.
[0073] In some implementation schemes, R d1 For H. In some implementations, R d1 Not H. In some variations, R d1 It is a haloalkyl, alkenyl, cycloalkyl, heterocycloalkyl, or heteroaryl group, wherein the cycloalkyl, heterocycloalkyl, and heteroaryl groups are optionally substituted with alkyl, haloalkyl, or halogen.
[0074] In other implementations, R d1 The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more (e.g., any one, two, three, four, or five) halogenated groups (e.g., F or Cl). In some of the variations described above, the alkyl group is C. 1-10 Alkyl, C 1-6 Alkyl or C 1-4 Alkyl group. In some variants, R d1 It is a haloalkyl group. In one embodiment, R d1 For CF3. In one implementation, R d1 It is CH(CH3)CF3.
[0075] In other implementations, R d1 The alkenyl group is optionally substituted. In some variations, the alkenyl group is unsubstituted. In other variations, the alkenyl group is substituted by one or more halogenations. In some of the variations mentioned above, the alkenyl group is C10. 2-10 alkenyl or C 2-6 Alkenyl group.
[0076] In other implementation schemes, R d1 For NR t R u In some variations, R t For H, and R u The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0077] In some implementation schemes, R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optionally substituted cyclopentyl groups, Optional substituted heterocyclic groups, wherein the heterocyclic groups are selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , Wherein R is H or an optionally substituted alkyl group (e.g., a C group optionally substituted with one or more halogens). 1-6 Alkyl groups, wherein each of the heterocyclic groups is optionally substituted.
[0078] In some variations, R d1 It is an optionally substituted nitrogen-containing heterocyclic butyl group. In some variations, R d1 It is an unsubstituted nitrogen-containing heterocyclic butyl group. In one variant, R d1 for .
[0079] In some variations, R d1It is an optionally substituted oxocyclic butyl group. In some variations, R d1 It is an unsubstituted oxocyclic butyl group. In one variant, R d1 for .
[0080] In some implementation schemes, R d1 The heterocyclic group is optionally substituted, wherein the heterocyclic group is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , ,and R is H or an optionally substituted alkyl group (e.g., a C group optionally substituted with one or more halogenated groups). 1-6 Alkyl groups), wherein each of the heterocyclic groups is optionally substituted. In some embodiments, R d1 It is an unsubstituted heterocyclic group. In some embodiments, R d1 For one or more independently selected alkyl groups (e.g., C10, C20, C30, C40, C50, C60, C7 ... 1-6 Alkyl), haloalkyl (e.g., C18 alkyl groups optionally substituted with one or more halogens (such as F) 1-6 Alkyl), halogenated (e.g., F, Cl or Br), or -OH substituted heterocyclic groups.
[0081] In one implementation, R d1 Halogenation. In one implementation, R d1 For F. In one implementation, R d1 It is Cl.
[0082] In one implementation, R d1 It is a cycloalkyl group (e.g., C3-C8 cycloalkyl). In one embodiment, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a cyclobutyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, Rd1 It is a cyclopentyl group that has been substituted with an alkyl group, a haloalkyl group, or a haloalkyl group.
[0083] In another implementation, R d1 The heterocyclic group is optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In some embodiments, the heterocyclic group is aromatic (e.g., pyrazole). In some embodiments, the heterocyclic group is non-aromatic. In some embodiments, the heterocyclic group is linked to the rest of the compound by a heteroatom (e.g., a cyclic nitrogen atom). In some embodiments, the heterocyclic group is optionally substituted morpholine or pyrrolidine. In some embodiments, the heterocyclic group is optionally substituted cyclic amide, such as pyrrolidone.
[0084] In some implementation schemes, R z For H, and R d3 For OH. In other embodiments, R z The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0085] It should generally be understood that the compounds described herein typically have a fused ring structure, and the positions and ring numbering of the ring carbon atoms can be described as follows: In some variants, the compounds presented herein have (S), (R), and (S) configurations at positions 4a, 5a, and 12a, respectively.
[0086] In some respects, a compound of formula (Iib) is provided: (Iib), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0087] In some respects, a compound of formula (I)-R is provided: (I)-R, Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for the above formula (Ib), and wherein the carbon atom at * has ( R ) configuration.
[0088] In some respects, a compound of formula (I)-S is provided: (I)-S, Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for the above formula (Ib), and wherein the carbon atom at * has ( S ) configuration. In some of the above variations, when R a1 When it is N(CH3)2, then R d1 Not unsubstituted cyclopropyl, unsubstituted cyclopentyl, unsubstituted thiazolyl, unsubstituted 4-isooxazolyl, 4-isooxazolyl substituted with a dimethyl group, unsubstituted thiophenyl, unsubstituted 4-pyrazolyl, N-methyl4-pyrazolyl and unsubstituted pyrrolidinyl.
[0089] In one aspect, a compound of formula (IB)-S is provided: (IB)-S, Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for the above formula (Ib).
[0090] In some implementation schemes: The carbon atom at * has ( S Configuration; Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R f H or an alkyl group that is optionally substituted; R g C is an optional replacement 2+ alkyl, R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p , Where R p H or an alkyl group that is optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; Each R t and R u Independently H or optionally substituted alkyl; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0091] In some variations, when R f When it is H, CH3 or CF3, then R g C is an optional replacement 4+ (e.g., C) 4-10 )alkyl. In other variations, R a1 It is not N(CH3)2.
[0092] In some implementation schemes, R d1 Not H.
[0093] In some implementations, a compound of formula (IBi) is provided: (IBi), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0094] On the other hand, a compound of formula (IC)-R is provided: (IC)-R, Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0095] In some implementation schemes: The carbon atom at * has ( R Configuration; Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R f H, an optionally substituted alkyl group, or an optionally substituted heterocyclic alkyl group; R g H or an alkyl group that is optionally substituted; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted heterocyclic groups; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p , Where R p H or an alkyl group that is optionally substituted; R b2 OR x , Where Rx H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; Each R t R u R n and R o Alkyl groups that are independently H or optionally substituted; R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0096] In some implementation schemes: The carbon atom at * has ( R Configuration; Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R f An alkyl group substituted with a heterocyclic group or a heterocyclic alkyl group optionally substituted with an alkyl group; R g H or C with optional substitution 1-3 alkyl; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted heterocyclic groups; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p , Where R p H or an alkyl group that is optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or halogenated; Each R t R u R n and R o Alkyl groups that are independently H or optionally substituted; R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0097] In some variations, R d1 Not N(CH3)2. In some implementations, R d1 Not H.
[0098] In other implementations, R a1 It is not N(CH3)2.
[0099] In some embodiments, a compound of formula (ICi) is provided: (ICi), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0100] In some respects, a compound of formula (ID) is provided: (ID), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0101] In some implementation schemes: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Where R' is H, alkyl, or alkoxy; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; R a2 OR m , Where R m H, an optionally substituted alkyl group, or an optionally substituted heteroaryl group; R b1 OR p or NR q R s , Each R pR q and R s Alkyl groups that are independently H or optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optionally substituted cyclopentyl groups, Choose any substituted heterocyclic group from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , Where R is H or an alkyl group; R d2 For H; and R d3 OR z , Where R z It is H or alkyl.
[0102] In some variations, R d1 The substituted 5-membered heterocyclic group is selected from the group consisting of: , , , , , , , , , , , , , , where R is H or an alkyl group. In some variations, R d1 The substituted 6-membered heterocyclic group is selected from the group consisting of: , , , , , , , and In some variations, R d1 The substituted 7-membered heterocyclic group is selected from the group consisting of: , and .
[0103] In some variations, when R d1 Cyclopropyl, cyclopentyl, or When, then (i) R a1 (ii) The compound is not N(CH3)2; or (ii) the compound has an (R) configuration at the C4 position.
[0104] In some respects, a compound of formula (IDi) is provided: (IDi), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0105] In some implementations, a compound of formula (ID)-R is provided: (ID)-R, Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above, and wherein the carbon atom at * has ( R ) configuration.
[0106] In some implementations, a compound of formula (ID)-S is provided: (ID)-S, Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above, and wherein the carbon atom at * has ( S ) configuration.
[0107] In some variations, a composition is provided comprising substantially pure compound of formula (ID)-R. In some variations, the composition has at least 90%, 95%, or 99% of compound of formula (ID)-R. In some variations, the composition has less than 10%, less than 5%, or less than 1% of compound of formula (ID)-S. In some variations, the composition does not have a detectable amount of compound of formula (ID)-S.
[0108] In other respects, a compound of formula (IE) is provided: (IE), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for formula (I) above. In some embodiments, R k It is an unsubstituted alkyl group. In some embodiments, R k It is a methyl group.
[0109] In some implementation schemes: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 =NOR k , R k The alkyl group may be optionally substituted; R a2 OR m , Where R m It is H or an optionally substituted alkyl or an optionally substituted heteroaryl; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; Each R t and R u Alkyl groups that are independently H or optionally substituted; Rd2 For H; and R d3 OR z , Where R z It is H or alkyl.
[0110] In some implementations, a compound of formula (IEi) is provided: (IEi), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (I) above.
[0111] Compound of formula (II) In some respects, a compound of formula (II) is provided: (II), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p , Each R p H or an alkyl group that is optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u , Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0112] In some implementation schemes, R 1 and R 2All are H. In other implementations, R 1 and R 2 All are optionally substituted alkyl groups. In other embodiments, R 1 and R 2 All are alkyl groups that have been independently chosen and optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 1 and R 2 All are methyl groups.
[0113] In some implementation schemes, R m For H, and R a2 For OH. In other embodiments, R m The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R m It is a methyl group.
[0114] In some implementation schemes, R b1 OR p In some implementations, R p For H, and R b1 For OH. In other embodiments, R p The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R p It is a methyl group.
[0115] In some implementation schemes, R x For H, and R b2 For OH. In other embodiments, R x The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 alkyl.
[0116] In some implementation schemes, R z For H, and Rd3 For OH. In other embodiments, R z The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0117] In some implementations of formula (II): R a2 It is OH; R b1 It is OH; R b2 It is OH; R d2 For H; and R d3 It is OH.
[0118] In some implementation schemes, R d1 For H. In some implementations, R d1 Not H. In some variations, R d1 It is a haloalkyl, alkenyl, cycloalkyl, or heteroaryl group, wherein the cycloalkyl and heteroaryl groups are optionally substituted with alkyl, haloalkyl, or halogen.
[0119] In other implementations, R d1 The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In some variants, R d1 It is a haloalkyl group.
[0120] In other implementations, R d1 The alkenyl group is optionally substituted. In some variations, the alkenyl group is unsubstituted. In other variations, the alkenyl group is substituted by one or more halogenations. In some of the variations mentioned above, the alkenyl group is C10. 2-10 alkenyl or C 2-6 Alkenyl group.
[0121] In some implementation schemes, R d1 The alkyl group is optionally substituted. In some embodiments, the alkyl group is C10. 3-10 cycloalkyl, C 3-9 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl or C 3-5Cycloalkyl. In some variations, the cycloalkyl group is unsubstituted. In some variations, the cycloalkyl group is substituted with an alkyl group, a haloalkyl group, or a haloalkyl group. In one embodiment, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a cyclobutyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, R d1 The cyclopropyl group is substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 Cyclohexyl groups optionally substituted with alkyl, haloalkyl, or halogenated groups.
[0122] In some implementation schemes, R d1 The heterocyclic group is optionally substituted. In some embodiments, the heterocyclic group is C. 3-10 Heterocyclic group, C 3-9 Heterocyclic group, C 3-7 Heterocyclic group, C 3-6 Heterocyclic group or C 3-5 Heterocyclic group. In some variations, the heterocyclic group has at least one heteroatom independently selected from S, N, or O. In some variations, the heterocyclic group has at least one heteroatom independently selected from N or O. In one variation, the heterocyclic group has 1, 2, or 3 heteroatoms independently selected from N or O. In some variations, the heterocyclic group is unsubstituted. In some variations, the heterocyclic group is substituted with an alkyl, haloalkyl, or halogenated group.
[0123] In some implementations, R d1 For the heterocyclic group with optional substitutions selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and , Wherein R is H or an alkyl group that is optionally substituted.
[0124] In some variations, R is H. In other variations, R is an optionally substituted alkyl group. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0125] In some embodiments, the heterocyclic group is substituted with one or more optionally substituted alkyl or halogroups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogroups. In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, the alkyl group is methyl.
[0126] In some implementation schemes, R d1 Halogenation. In one implementation, R d1 It is chlorine. In one implementation, R d1 It is fluorine. In one embodiment, R d1 It is bromine. In one embodiment, R d1 It is iodine.
[0127] In other implementation schemes, R d1 For NR t R u In some variations, R t For H, and R u The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0128] In some respects, a compound of formula (II-i) is provided: (II-i), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (II) above.
[0129] Compound (III) In some respects, a compound of formula (III) is provided: (III), Or its pharmaceutically acceptable salt, wherein: Each R1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Wherein R' is H, an optionally substituted alkyl group, or an optionally substituted alkoxy group; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups. R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R a3 OR L , Where R L H or an alkyl group that is optionally substituted; R b1 OR p , Each R p It is H or alkyl; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0130] In some variations, when R a1 When it is N(CH3)2, then R d1 Not H.
[0131] In some implementation schemes, R 1 and R 2 All are H. In other implementations, R 1 and R 2All are optionally substituted alkyl groups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted by one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 1 and R 2 All are methyl groups.
[0132] In some implementation schemes, R a1 For NR f R g In some implementations, R a1 For NH2. In some implementations, R a1 For NHR g And R g Independently, it is an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or -C(=O)R', wherein R' is H, an optionally substituted alkyl, or an optionally substituted alkoxy. In some embodiments, R a1 For NHR g And R g The heterocyclic alkyl group is optionally substituted. In some embodiments, the heterocyclic alkyl group is... .
[0133] In some implementations, R f and R g Together with the nitrogen atom to which they are attached, they form cyclic groups optionally substituted with one or more alkyl, haloalkyl groups, wherein the alkyl group is substituted with -OR, halo, -OR, -COOR, -C(=O)R, -SO2R, or oxo. In some variations, R is independently H or an optionally substituted alkyl group each time it appears. In some embodiments, R f and R g Together with the nitrogen atom to which they are attached, they form cyclic groups optionally substituted with one or more alkyl, haloalkyl, halogenated, -COOR, -C(=O)R, -SO2R, or oxo-substituted groups. In some variations, R is H or an optionally substituted alkyl group. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogenated groups. In some of the variations described above, the alkyl group is C. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is methyl. In other embodiments, R f and R g Together with the nitrogen atoms to which they are attached, they form unsubstituted cyclic groups. In some embodiments, the cyclic groups are heterocyclic alkyl groups. In some embodiments, the cyclic groups are... .
[0134] In some implementations, Ra1 The cyclic group is an optionally substituted cyclic group having 3-10 ring atoms. In some embodiments, the cyclic group is unsubstituted. In some variations, the cyclic group has one or more additional ring atoms, said one or more additional ring atoms being heteroatoms independently selected from nitrogen and oxygen. In some variations, the cyclic group has two fused rings. In other variations, the cyclic group is a bridged cyclic group. In some embodiments, R a1 For any substituted cyclic group selected from the group consisting of: , , , , , , , , , , , ,and , Where R 10 The alkyl group can be optionally substituted with an alkyl group, an optionally substituted with an alkenyl group, a halogenated group, a C(=O) alkyl group, an SO2 (alkyl) group, an optionally substituted cycloalkyl group, or an optionally substituted alkoxy group. In some variations, the alkyl group, alkenyl group, cycloalkyl group, and alkoxy group are unsubstituted. In other variations, the alkyl group, alkenyl group, cycloalkyl group, and alkoxy group are substituted with one or more halogenated groups. In some of the variations described above, the alkyl group is C(=O) alkyl. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 10 It is methyl. In some embodiments, R a1 for .
[0135] In some implementation schemes, R m For H, and R a2 For OH. In other embodiments, R m The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R m It is a methyl group.
[0136] In some implementation schemes, R L For H, and R a3 For OH. In other embodiments, R L The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10Alkyl or C 1-4 Alkyl group. In one variant, R L It is a methyl group.
[0137] In some implementation schemes, R b1 OR p In some implementations, R p For H, and R b1 For OH. In other embodiments, R p The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R p It is a methyl group.
[0138] In some implementation schemes, R z For H, and R d3 For OH. In other embodiments, R z The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0139] In some implementations of equation (III): R a2 It is OH; R a3 It is OH; R b1 It is OH; and R d3 It is OH.
[0140] In some implementation schemes, R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u In other implementations, R d1 The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In some variants, R d1 It is a haloalkyl group.
[0141] In other implementations, R d1The alkenyl group is optionally substituted. In some variations, the alkenyl group is unsubstituted. In other variations, the alkenyl group is substituted by one or more halogenations. In some of the variations mentioned above, the alkenyl group is C10. 2-10 alkenyl or C 2-6 Alkenyl group.
[0142] In some implementation schemes, R d1 The alkyl group is optionally substituted. In some embodiments, the alkyl group is C10. 3-10 cycloalkyl, C 3-9 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl or C 3-5 Cycloalkyl. In some variations, the cycloalkyl group is unsubstituted. In some variations, the cycloalkyl group is substituted with an alkyl group, a haloalkyl group, or a haloalkyl group. In one embodiment, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a cyclobutyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, R d1 The cyclopropyl group is substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 Cyclohexyl groups optionally substituted with alkyl, haloalkyl, or halogenated groups.
[0143] In some implementation schemes, R d1 The heterocyclic group is optionally substituted. In some embodiments, the heterocyclic group is C. 3-10 Heterocyclic group, C 3-9 Heterocyclic group, C 3-7 Heterocyclic group, C 3-6 Heterocyclic group or C 3-5 Heterocyclic group. In some embodiments, the heterocyclic group is a 3- to 12-membered heterocyclic group, a 3- to 9-membered heterocyclic group, a 3- to 8-membered heterocyclic group, or a 3- to 6-membered heterocyclic group. In some variations, the heterocyclic group has at least one heteroatom independently selected from S, N, or O. In some variations, the heterocyclic group has at least one heteroatom independently selected from N or O. In one variation, the heterocyclic group has 1, 2, or 3 heteroatoms independently selected from N or O. In some variations, the heterocyclic group is unsubstituted. In some variations, the heterocyclic group is substituted with an alkyl group, a haloalkyl group, or a haloalkyl group.
[0144] In some implementations, R d1 The heterocyclic group is optionally substituted, wherein the heterocyclic group is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and , Wherein R is H or an optionally substituted alkyl group. In some embodiments, R d1 The heterocyclic group is optionally substituted, wherein the heterocyclic group is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , Wherein R is H or an alkyl group that is optionally substituted.
[0145] In some implementations, R d1 The heterocyclic group is optionally substituted, wherein the heterocyclic group is selected from the group consisting of: , , , and , wherein R is H or an optionally substituted alkyl group. In some embodiments, R d1The heterocyclic group is optionally substituted, wherein the heterocyclic group is selected from the group consisting of: , , and R is H or an optionally substituted alkyl group. In some variations, R is H. In other variations, R is an optionally substituted alkyl group. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations described above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0146] In some embodiments, the heterocyclic group is substituted with one or more optionally substituted alkyl or halogroups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogroups. In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, the alkyl group is methyl.
[0147] In some implementation schemes, R d1 Halogenation. In one implementation, R d1 It is chlorine. In one implementation, R d1 It is fluorine. In one embodiment, R d1 It is bromine. In one embodiment, R d1 It is iodine.
[0148] In other implementation schemes, R d1 For NR t R u In some variations, R t For H, and R u The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0149] In some respects, a compound of formula (III-i) is provided: (III-i), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for equation (III) above.
[0150] Compound of formula (IV-a) In some respects, a compound of formula (IV-a) is provided: (IV-a), Or its pharmaceutically acceptable salt, wherein: Each R1 and R 2 Alkyl groups that are independently H or optionally substituted; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Where R p The alkyl group may be optionally substituted; Each R q and R s Alkyl groups that are independently H or optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u , Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H, NHR y Or halogenated, Where R y For H or -C(=O)(CH2) n NR v R w , Where n is an integer greater than or equal to 1; Each R v and R w Independently H or optionally substituted alkyl, or R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0151] In some implementation schemes, R 1 and R 2 All are H. In other implementations, R 1 and R2 All are optionally substituted alkyl groups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted by one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 1 and R 2 All are methyl groups.
[0152] In some implementation schemes, R m For H, and R a2 For OH. In other embodiments, R m The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R m It is a methyl group.
[0153] In some implementation schemes, R b1 OR p , where R p The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl. In one variant, the alkyl group is methyl, and therefore R b1 It is a methoxy group.
[0154] In some implementations, each R q and R s For H, and R b1 For NH2. In other embodiments, R q The alkyl group is optionally substituted, and R s The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, the alkyl group is methyl.
[0155] In some implementation schemes, R x For H, and R b2 For OH. In other embodiments, R x The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 alkyl.
[0156] In some implementation schemes, R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u In one implementation, R d1 Not for use as a substitute for halogenated products.
[0157] In some implementation schemes, R d1 For H. In some implementations, R d1 Not H. In some variations, R d1 It is a haloalkyl, alkenyl, cycloalkyl, or heteroaryl group, wherein the cycloalkyl and heteroaryl groups are optionally substituted with alkyl, haloalkyl, or halogen.
[0158] In other implementations, R d1 The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In some variants, R d1 It is a haloalkyl group. In one variant, R d1 It is (R)-3-trifluoro-2-propyl or (S)-3-trifluoro-2-propyl.
[0159] In other implementations, R d1 The alkenyl group is optionally substituted. In some variations, the alkenyl group is unsubstituted. In other variations, the alkenyl group is substituted by one or more halogenations. In some of the variations mentioned above, the alkenyl group is C10. 2-10 alkenyl or C 2-6 Alkenyl group.
[0160] In other implementation schemes, R d1 For NR t R u In some variations, R t For H, and R u The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0161] In some implementation schemes, R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optionally substituted cyclopentyl groups, and optionally substituted heterocyclic groups selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , Wherein R is H or an alkyl group that is optionally substituted.
[0162] In some variations, R d1 For optionally substituted nitrogen-containing heterocyclic butanes. In some variants, R d1 It is an unsubstituted nitrogen-containing heterocyclic butyl group. In one variant, R d1 for .
[0163] In some variations, R d1 For optionally substituted oxobutanes. In some variants, R d1 It is an unsubstituted oxocyclic butyl group. In one variant, R d1 for .
[0164] In one implementation, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a cyclobutyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 Cyclohexyl groups optionally substituted with alkyl, haloalkyl, or halogenated groups.
[0165] In some implementation schemes, R d2 For H or NHR y In one implementation, R d2 For F. In another implementation, R d2 For NHR yIn one variant, R y For H. In other variations, R y For -C(=O)(CH2) n NR v R w In one variant, n is 1. In some variants, R v and R w All are H. In other variations, R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted heterocyclic alkyl groups.
[0166] In some implementation schemes, R z For H, and R d3 For OH. In other embodiments, R z The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0167] In some respects, a compound of formula (IV-ia) is provided: (IV-ia), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for formula (IV-a) above.
[0168] Compound of formula (IV-b) In some respects, a compound of formula (IV-b) is provided: (IV-B), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Wherein R' is H, an optionally substituted alkyl group, or an optionally substituted alkoxy group; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups, Ra2 OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Where R p The alkyl group may be optionally substituted; Each R q and R s Alkyl groups that are independently H or optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0169] In some implementation schemes, R 1 and R 2 All are H. In other implementations, R 1 and R 2 All are optionally substituted alkyl groups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted by one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 1 and R 2 All are methyl groups.
[0170] In some implementation schemes, R a1 For NH2. In some implementations, R f and R gTogether with the nitrogen atom to which they are attached, they form cyclic groups optionally substituted with one or more alkyl, haloalkyl, halogenated, -COOR, -C(=O)R, -SO2R, or oxo-substituted groups. In some variations, R is H or an optionally substituted alkyl group. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogenated groups. In some of the variations described above, the alkyl group is C. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0171] In some implementations, R a1 It is an optionally substituted cyclic group having 3-10 ring atoms. In some variations, the cyclic group has one or more additional ring atoms, said one or more additional ring atoms being heteroatoms independently selected from nitrogen and oxygen. In some variations, the cyclic group has two fused rings. In other variations, the cyclic group is a bridged cyclic group. In some embodiments, R a1 For any substituted cyclic group selected from the group consisting of: , , , , , , , , , , , ,and , Where R 10 The alkyl group can be optionally substituted with an alkyl group, an optionally substituted with an alkenyl group, a halogenated group, a C(=O) alkyl group, an SO2 (alkyl) group, an optionally substituted cycloalkyl group, or an optionally substituted alkoxy group. In some variations, the alkyl group, alkenyl group, cycloalkyl group, and alkoxy group are unsubstituted. In other variations, the alkyl group, alkenyl group, cycloalkyl group, and alkoxy group are substituted with one or more halogenated groups. In some of the variations described above, the alkyl group is C(=O) alkyl. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 10 It is a methyl group.
[0172] In some implementation schemes, R m For H, and R a2 For OH. In other embodiments, R m The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, Rm It is a methyl group.
[0173] In some implementation schemes, R b1 OR p , where R p The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl. In one variant, the alkyl group is methyl, and therefore R b1 It is a methoxy group.
[0174] In some implementations, each R q and R s For H, and R b1 For NH2. In other embodiments, R q The alkyl group is optionally substituted, and R s The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, the alkyl group is methyl.
[0175] In some implementation schemes, R x For H, and R b2 For OH. In other embodiments, R x The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 alkyl.
[0176] In some implementation schemes, R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u In one implementation, R d1 Not halogenated. In other implementations, R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u .
[0177] In some implementation schemes, R d1 For H. In some implementations, R d1 Not H. In some variations, R d1It is a haloalkyl, alkenyl, cycloalkyl, or heteroaryl group, wherein the cycloalkyl and heteroaryl groups are optionally substituted with alkyl, haloalkyl, or halogen.
[0178] In other implementations, R d1 The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In some variants, R d1 It is a haloalkyl group. In one variant, R d1 It is (R)-3-trifluoro-2-propyl or (S)-3-trifluoro-2-propyl.
[0179] In other implementations, R d1 The alkenyl group is optionally substituted. In some variations, the alkenyl group is unsubstituted. In other variations, the alkenyl group is substituted by one or more halogenations. In some of the variations mentioned above, the alkenyl group is C10. 2-10 alkenyl or C 2-6 Alkenyl group.
[0180] In other implementation schemes, R d1 For NR t R u In some variations, R t For H, and R u The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0181] In some implementation schemes, R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optionally substituted cyclopentyl groups, Choose any substituted heterocyclic group from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , Wherein R is H or an alkyl group that is optionally substituted.
[0182] In some implementation schemes, R d1 for , , or Each of these is an optional substitution.
[0183] In some variations, R d1 It is an optionally substituted nitrogen-containing heterocyclic butyl group. In some variations, R d1 It is an unsubstituted nitrogen-containing heterocyclic butyl group. In one variant, R d1 for .
[0184] In some variations, R d1 It is an optionally substituted oxocyclic butyl group. In some variations, R d1 It is an unsubstituted oxocyclic butyl group. In one variant, R d1 for .
[0185] In one implementation, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a cyclobutyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 Cyclohexyl groups optionally substituted with alkyl, haloalkyl, or halogenated groups.
[0186] In some implementation schemes, R z For H, and R d3 For OH. In other embodiments, R z The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0187] In some implementation schemes: R a2 It is OH; R a3 It is OH; and R d3 It is OH.
[0188] In some embodiments, a compound of formula (IV-ib) is provided: (IV-ib), Or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for the above formula (IV-b).
[0189] Compound of formula (Va) In some respects, a compound of formula (Va) is provided: (Va), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b2 For H or OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclic or NR t R u , Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H, NHR y Or halogenated, Where R y For H or -C(=O)(CH2) n NR v R w , Where n is an integer greater than or equal to 1; Each R v and R wIndependently H or optionally substituted alkyl, or R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; and R d3 OR z , Where R z It is H or an alkyl group that is optionally substituted.
[0190] In some implementation schemes, R 1 and R 2 All are H. In other implementations, R 1 and R 2 All are optionally substituted alkyl groups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted by one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 1 and R 2 All are methyl groups.
[0191] In some implementation schemes, R m For H, and R a2 For OH. In other embodiments, R m The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R m It is a methyl group.
[0192] In some implementation schemes, R b2 For H. In other implementations, R x For H, and R b2 For OH. In other embodiments, R x The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 alkyl.
[0193] In some implementation schemes, R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u In one implementation, R d1 Not for use as a substitute for halogenated products.
[0194] In some implementation schemes, Rd1 For H. In some implementations, R d1 Not H. In some variations, R d1 It is a haloalkyl, alkenyl, cycloalkyl, cycloalkenyl, or heteroaryl group, wherein the cycloalkyl, cycloalkenyl, and heteroaryl groups are optionally substituted with alkyl, haloalkyl, or halogen. In some embodiments, R d1 It is a cycloalkyl group optionally substituted with an alkyl, haloalkyl, or halogenated form. In some embodiments, R d1 C 3-12 Cycloalkenyl, C 3-10 Cycloalkenyl or C 3-6 Cycloalkenyl. In some embodiments, R d1 The heteroaryl group is optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In some embodiments, the heteroaryl group is a 5- to 12-membered heteroaryl group, a 5- to 10-membered heteroaryl group, or a 5- to 6-membered heteroaryl group.
[0195] In other implementations, R d1 The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In some variants, R d1 It is a haloalkyl group. In one variant, R d1 It is (R)-3-trifluoro-2-propyl or (S)-3-trifluoro-2-propyl.
[0196] In other implementations, R d1 The alkenyl group is optionally substituted. In some variations, the alkenyl group is unsubstituted. In other variations, the alkenyl group is substituted by one or more halogenations. In some of the variations mentioned above, the alkenyl group is C10. 2-10 alkenyl or C 2-6 Alkenyl. In some embodiments, R d1 C replaced by one to three Fs 2-6 Alkenyl. In some embodiments, R d1 It is 3,3,3-trifluoropropene.
[0197] In other implementation schemes, R d1 For NR t R u In some variations, R t For H, and R u The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0198] In some implementation schemes, R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optionally substituted cyclopentyl groups, Optionally substituted cyclopentenyl group Choose any substituted heterocyclic group from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , Wherein R is H or an alkyl group that is optionally substituted.
[0199] In some implementation schemes, R d1 for , , or Each of these is an optional substitution.
[0200] In some variations, R d1 For optionally substituted nitrogen-containing heterocyclic butanes. In some variants, R d1 It is an unsubstituted nitrogen-containing heterocyclic butyl group. In one variant, R d1 for .
[0201] In some variations, R d1 For optionally substituted oxobutanes. In some variants, R d1 It is an unsubstituted oxocyclic butyl group. In one variant, R d1 for .
[0202] In one implementation, R d1The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a cyclobutyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, R d1 It is a cyclopropyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, R d1 The cyclopentenyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 Cyclohexyl groups optionally substituted with alkyl, haloalkyl, or halogenated groups.
[0203] In some implementation schemes, R d2 For H or NHR y In one implementation, R d2 For F. In another implementation, R d2 For NHR y In one variant, R y For H. In other variations, R y For -C(=O)(CH2) n NR v R w In one variant, n is 1. In some variants, R v and R w All are H. In other variations, R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted heterocyclic alkyl groups.
[0204] In some implementation schemes, R z For H, and R d3 For OH. In other embodiments, R z The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0205] In some respects, a compound of formula (Via) is provided: (Via), Or its pharmaceutically acceptable salt, wherein the variables are as defined for the above formula (Va).
[0206] It should be understood that the structures and other compounds and portions discussed in this application also include all their tautomers. For example, in some variants, the tautomers of formula (Va) have the following structures: , Or its pharmaceutically acceptable salt, wherein the variables are as defined for the above formula (Va).
[0207] Compound of formula (Vb) In some respects, a compound of formula (Vb) is provided: (Vb), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g or =NOR k , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Wherein R' is H, an optionally substituted alkyl group, or an optionally substituted alkoxy group; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; Where R k The alkyl group may be optionally substituted; R a2 OR m , Where R m H or an alkyl group that is optionally substituted; R b2 OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u , where each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 OR z , Where R z It is H or alkyl.
[0208] In some implementation schemes, R1 and R 2 All are H. In other implementations, R 1 and R 2 All are optionally substituted alkyl groups. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is halogenated by one or more (e.g., any one, two, three, four, or five). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 1 and R 2 All are methyl groups.
[0209] In some implementation schemes, R a1 =NOR k In some implementations, R k The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more (e.g., any one of one, two, three, four, or five) halogenated (e.g., F, Cl, Br, or I). In some of the variations described above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R k It is a methyl group.
[0210] In some implementation schemes, R a1 For NH2. In some implementations, R a1 For NHR g And R g Independently, it is an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or -C(=O)R', wherein R' is H, an optionally substituted alkyl, or an optionally substituted alkoxy. In some embodiments, R a1 For NR f R g And R f and R g Both are optionally substituted alkyl groups. In some embodiments, R a1 For NR f R g And R f and R g Both are methyl groups.
[0211] In some implementations, R f and R gTogether with the nitrogen atom to which they are attached, they form cyclic groups optionally substituted with one or more alkyl, haloalkyl groups, wherein the alkyl group is substituted with -OR, halo, -OR, -COOR, -C(=O)R, -SO2R, cycloalkyl, or oxo. In some variations, R is independently H or an optionally substituted alkyl group each time it appears. In some embodiments, R f and R g Together with the nitrogen atom to which they are attached, they form cyclic groups optionally substituted with one or more alkyl or haloalkyl groups, wherein the alkyl group is OR, halo, -COOR, -C(=O)R, -SO2R, cycloalkyl, or oxosubstituted. In some variations, R is H or an optionally substituted alkyl group. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halosubstituted groups. In some of the variations described above, the alkyl group is C. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R is methyl.
[0212] In some implementations, R a1 It is an optionally substituted cyclic group having 3-10 ring atoms. In some variations, the cyclic group has one or more additional ring atoms, said one or more additional ring atoms being heteroatoms independently selected from nitrogen and oxygen. In some variations, the cyclic group has two fused rings. In other variations, the cyclic group is a bridged cyclic group. In some embodiments, R a1 The cyclic group is optionally substituted, and the cyclic group is selected from the group consisting of: , , , , , , , , , , , ,and , Where R 10 The alkyl group can be optionally substituted with an alkyl group, an optionally substituted with an alkenyl group, a halogenated group, a C(=O) alkyl group, an SO2 (alkyl) group, an optionally substituted cycloalkyl group, or an optionally substituted alkoxy group. In some variations, the alkyl group, alkenyl group, cycloalkyl group, and alkoxy group are unsubstituted. In other variations, the alkyl group, alkenyl group, cycloalkyl group, and alkoxy group are substituted with one or more halogenated groups. In some of the variations described above, the alkyl group is C(=O) alkyl. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R 10 It is a methyl group.
[0213] In some implementations, R a1The cyclic group is optionally substituted, and the cyclic group is selected from the group consisting of: , and Each of these is an optional substitution.
[0214] In some variations, R a1 It can be optionally substituted with piperidinyl, optionally substituted with piperazine, or optionally substituted with morpholino.
[0215] In some implementation schemes, R m For H, and R a2 For OH. In other embodiments, R m The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R m It is a methyl group.
[0216] In some implementation schemes, R x For H, and R b2 For OH. In other embodiments, R x The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 alkyl.
[0217] In some implementation schemes, R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u In one implementation, R d1 Not for use as a substitute for halogenated products.
[0218] In some implementation schemes, R d1 For H. In some implementations, R d1 Not H. In some variations, R d1 It is a haloalkyl, alkenyl, cycloalkyl, or heteroaryl group, wherein the cycloalkyl and heteroaryl groups are optionally substituted with alkyl, haloalkyl, or halogen.
[0219] In other implementations, R d1 The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In some variants, R d1It is a haloalkyl group. In one variant, R d1 It is (R)-3-trifluoro-2-propyl or (S)-3-trifluoro-2-propyl.
[0220] In other implementations, R d1 The alkenyl group is optionally substituted. In some variations, the alkenyl group is unsubstituted. In other variations, the alkenyl group is substituted by one or more halogenations. In some of the variations mentioned above, the alkenyl group is C10. 2-10 alkenyl or C 2-6 Alkenyl group.
[0221] In other implementation schemes, R d1 For NR t R u In some variations, R t For H, and R u The alkyl group is H or optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C. 1-10 Alkyl or C 1-4 alkyl.
[0222] In some implementation schemes, R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optionally substituted cyclopentyl groups, Choose any substituted heterocyclic group from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , Wherein R is H or an alkyl group that is optionally substituted.
[0223] In some variations, R d1 It is an optionally substituted nitrogen-containing heterocyclic butyl group. In some variations, R d1 It is an unsubstituted nitrogen-containing heterocyclic butyl group. In one variant, R d1 for .
[0224] In some variations, R d1 It is an optionally substituted oxocyclic butyl group. In some variations, R d1 It is an unsubstituted oxocyclic butyl group. In one variant, R d1 for .
[0225] In some implementation schemes, R d1 The heterocyclic group is optionally substituted, wherein the heterocyclic group is selected from the group consisting of: , and , where R is H or an optionally substituted alkyl group.
[0226] In one implementation, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 It is a cyclobutyl group optionally substituted with an alkyl, haloalkyl, or haloalkyl group. In yet another embodiment, R d1 The cyclopropyl group is optionally substituted with an alkyl, haloalkyl, or halogenated group. In another embodiment, R d1 Cyclohexyl groups optionally substituted with alkyl, haloalkyl, or halogenated groups.
[0227] In some implementation schemes, R z For H, and R d3 For OH. In other embodiments, R z The alkyl group is optionally substituted. In some variations, the alkyl group is unsubstituted. In other variations, the alkyl group is substituted with one or more halogens. In some of the variations mentioned above, the alkyl group is C10. 1-10 Alkyl or C 1-4 Alkyl group. In one variant, R z It is a methyl group.
[0228] In some implementation schemes: R a2 It is OH; R a3 It is OH; R b1 It is OH; and R d3 It is OH.
[0229] In some implementations, a compound of formula (Vib) is provided: (Vib), Or its pharmaceutically acceptable salt, wherein the variables are as defined for the above formula (Vb).
[0230] It should be understood that the structures and other compounds and portions discussed in this application also include all their tautomers. For example, in some variants, the tautomers of formula (Vb) have the following structures: , Or its pharmaceutically acceptable salt, wherein the variables are as defined for the above formula (Vb).
[0231] It is worth noting that the structures of some compounds of the present invention include asymmetric carbon atoms. Therefore, it should be understood that, unless otherwise stated, isomers resulting from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of the present invention. Such isomers can be obtained in substantially pure form by classical separation techniques and stereochemically controlled synthesis. For example, individual enantiomers or diastereomers, such as optically active forms, can be obtained by asymmetric synthesis or by the decomposition of racemates. The separation of racemates can be accomplished, for example, by conventional methods, such as crystallization in the presence of a solvent, or by chromatography using, for example, a chiral high-performance liquid chromatography (HPLC) column.
[0232] In some aspects, compositions are provided comprising any of the compounds disclosed herein, including compounds of formulas (Ia), (Ib), (II), (III), (IV-a), (IV-b), (Va), and (Vb), and the compounds of Tables 1A and 1B having an (R) configuration at the C4 position. In some embodiments described above, the composition comprises less than 5%, less than 1%, or less than 0.1% of a compound having an (S) configuration at the C4 position. In one variant, the composition comprises substantially pure compounds having an (R) configuration at the C4 position.
[0233] In other respects, compositions comprising any of the compounds disclosed herein (including compounds of formulas (Ia), (Ib), (II), (III), (IV-a), (IV-b), (Va), and (Vb), and compounds of Tables 1A and 1B having an (S) configuration at the C4 position) are provided. In some embodiments described above, the composition comprises less than 5%, less than 1%, or less than 0.1% of a compound having an (R) configuration at the C4 position. In one variant, the composition comprises substantially pure compounds having an (S) configuration at the C4 position.
[0234] As used herein, "alkyl" refers to a monoradical unbranched or branched saturated hydrocarbon chain. In some embodiments, the alkyl group has 1 to 20 carbon atoms. Right now C 1-20 Alkyl groups, 1 to 8 carbon atoms ( Right now C 1-8 Alkyl groups, 1 to 6 carbon atoms ( Right now C 1-6 Alkyl groups or 1 to 4 carbon atoms Right now C 1-4 Alkyl groups. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When naming alkyl residues having a specific number of carbon atoms, all geometric isomers having said number of carbon atoms may be covered; thus, for example, "butyl" may include n-butyl, sec-butyl, isobutyl, and tert-butyl; "propyl" may include n-propyl and isopropyl. In some embodiments, "C 1+ "Alkyl" refers to an alkyl group having at least one carbon atom, and includes, for example, methyl, ethyl, propyl, etc. Similarly, "C 2+ "Alkyl" refers to an alkyl group having at least two carbon atoms, and includes, for example, ethyl, propyl, butyl, etc.
[0235] "Halogenated alkyl" refers to an unbranched or branched alkyl group as defined above, in which one or more hydrogen atoms are replaced by a halogen. For example, when a residue is substituted by more than one halogen, it can be referred to by using a prefix corresponding to the number of halogen moieties attached. Examples of halogenated alkyl groups include difluoromethyl (-CHF2) and trifluoromethyl (-CF3). It should be understood that trifluoromethyl (-CF3) can also be called perfluoromethyl.
[0236] As used herein, “cyclic group” means cycloalkyl and heterocyclic groups as defined herein, including heterocyclic alkyl and heteroaryl groups.
[0237] "Cycloalkyl" refers to a cyclic alkyl group. In some embodiments, the cycloalkyl group has 3 to 20 cyclic carbon atoms. Right now C 3-20 cycloalkyl), or 3 to 12 cyclic carbon atoms ( Right now C 3-12 cycloalkyl), or 3 to 8 cyclic carbon atoms ( Right now C 3-8 Cycloalkyl groups. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0238] A "heterocyclic group" refers to a cyclic group having one or more cyclic heteroatoms. In some embodiments, the cyclic heteroatoms are independently selected from nitrogen, sulfur, and oxygen. Heterocyclic groups include heterocyclic alkyl, heterocyclic alkenyl, and heteroaryl groups.
[0239] "Heterocyclic alkyl" refers to a cyclic alkyl group having one or more heterocyclic atoms. In some embodiments, the heterocyclic alkyl group has 2 to 20 cyclic carbon atoms. Right now C 2-20 Heterocyclic alkyl groups, 2 to 12 cyclic carbon atoms ( Right now C 2-12 Heterocyclic alkyl groups or 2 to 8 cyclic carbon atoms ( Right now C 2-8 Heterocyclic alkyl groups; and 1 to 5 cyclic heteroatoms, 1 to 4 cyclic heteroatoms, 1 to 3 cyclic heteroatoms, 1 or 2 cyclic heteroatoms, or 1 cyclic heteroatomium, wherein the cyclic heteroatoms are independently selected from nitrogen, sulfur, and oxygen. In one example, the heterocyclic alkyl group has 2 to 8 cyclic carbon atoms and 1 to 3 cyclic heteroatoms independently selected from nitrogen, sulfur, and oxygen. Examples of heterocyclic alkyl groups may include pyrrolidinyl, piperidinyl, piperazineyl, oxetaneyl, dioxopentaneyl, azironeyl, and morpholinyl.
[0240] "Heteroaryl" refers to an aromatic group containing one or more heteroatom rings, having a single ring, multiple rings, or multiple fused rings. In some embodiments, the heteroaryl is an aromatic monocyclic or bicyclic ring containing one or more heteroatoms independently selected from nitrogen, sulfur, and oxygen, wherein the remaining ring atoms are carbon. In some embodiments, the heteroaryl has 3 to 20 ring carbon atoms (…). Right now C 3-20 heteroaryl), 3 to 12 cyclic carbon atoms ( Right now C 3-12 (heteroaryl) or 3 to 8 cyclic carbon atoms ( Right now C 3-8 The heteroaryl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 cyclic heteroatoms, 1 or 2 cyclic heteroatoms, or 1 cyclic heteroatom, wherein the heteroatoms are independently selected from nitrogen, sulfur, and oxygen. In one example, the heteroaryl group has 3 to 8 cyclic carbon atoms and 1 to 3 cyclic heteroatoms independently selected from nitrogen, sulfur, and oxygen. Examples of heteroaryl groups include pyridinyl, pyridazinyl, pyrimidinyl, benzothiazolyl, and pyrazolyl. The heteroaryl group does not encompass or overlap with an aryl group, which is an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple fused rings (e.g., naphthyl).
[0241] In some variations, the term "substitution" means that any one or more hydrogen atoms on a specified atom or group are partially replaced by substances other than hydrogen, provided that the valence of the specified atom is not exceeded. In some variations, "substituted" can also cover cases where one or more substitutions do not replace hydrogen. For example, in some embodiments, substitution covers the formation of N-oxides, S-oxides, and quaternized N. For example, heterocycles substituted with oxo groups can cover, for example,... and . group.
[0242] symbol Whether shown as a bond or perpendicular to a bond, it indicates the point where the shown portion is attached to the rest of the molecule.
[0243] In some aspects, a compound selected from the compounds in Table 1A below, or a pharmaceutically acceptable salt thereof, including any isomers and tautomers thereof, is provided. In some embodiments, compounds 1, 2A, 2B, 3-15, 16-1, 16-2, 16A, 16B, and 17-48, or pharmaceutically acceptable salts thereof, are provided. In some variations of the above compounds (e.g., in Table 1A), the compound is in salt form, such as an HCl salt, or in free base form.
[0244] Table 1A. Exemplary Compounds In some aspects, a compound selected from the compounds in Table 1B below, or a pharmaceutically acceptable salt thereof, including any isomers and tautomers thereof, is provided. In some variations of the above-mentioned compounds (e.g., in Table 1B), the compound is in salt form, such as an HCl salt, or in free base form.
[0245] Table 1B. Exemplary Compounds In some embodiments, this document provides a compound selected from the group consisting of: (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyridazin-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-4-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-3-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyridazin-4-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1-isopropyl-1H-pyrazol-3-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-7-(3,6-dihydro-2H-pyran-4-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(tetrahydro-2H-pyran-4-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(tetrahydro-2H-pyran-4-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(3,3,3-trifluoroprop-1-en-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-((S)-1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-((R)-1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-methylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-vinyl-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(2-methyl-2H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-methyl-1,2,4-oxadiazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,12a-dihydroxy-10,12-dimethoxy-N,N-dimethyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,12,12a-trihydroxy-10-methoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-12,12a-dihydroxy-3,10-dimethoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-(2-(pyrrolidone-1-yl)acetamido)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (5aS,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,5,5a,6,11,12a-hexahydrotetraphenyl-2-carboxamide, (4aS,12aS)-7-(cyclopent-1-en-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4aS,12aS)-7-cyclopentyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4aS,12aS)-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-(tetrahydro-2H-pyran-4-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4aS,12aS)-7-cyclobutyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4aS,12aS)-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-(3,3,3-trifluoroprop-1-en-2-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (12aS)-3,10,11,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,12aS)-7-(3-Cyclopropylisoxazol-5-yl)-3,10,11,12a-Tetrahydroxy-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4aS,12aS)-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-(1,1,1-trifluoropropane-2-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4aS)-3,10,11-trihydroxy-1,12-dioxo-7-(1,1,1-trifluoropropane-2-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-7-(azacyclobutane-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-hydroxyazacyclobutane-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR)-7-cyclobutyl-3,10,12-trihydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR)-1,3,10,12-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4aS,12aS)-7-cyclopropyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(2-oxaspiro[3.3]hept-5-en-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(2-oxaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(2-oxaspiro[3.3]heptane-6-yl)-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, Stereochemical name (4R,4aS,5aR,12aS)-4-(diethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (5aR,12aS,Z)-3,10,12,12a-tetrahydroxy-4-(hydroxyimino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(ethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dipropylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(propylamino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-acetamido-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, ((1R,4aS,11aR,12aS)-3-carbamoyl-2,4a,5,7-tetrahydroxy-4,6-dioxo-1,4,4a,6,11,11a,12,12a-octahydrotetraphenyl-1-yl)carbamate, (4R,4aS,5aR,12aS)-4-(cyclobutylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(cyclobutyl(methyl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS,Z)-3,10,12,12a-tetrahydroxy-4-(methoxyimino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR,12aR)-4-amino-3,10,12-trihydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-11-oxo-4-(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-11-oxo-4-(piperidin-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-7-cyclobutyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclobutyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopropyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-7-cyclopropyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopropyl-4-(diethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopentyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-7-cyclopentyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-4-(diethylamino)-1,3,10,12-tetrahydroxy-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-4-amino-7-cyclopropyl-1,3,10,12-tetrahydroxy-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide (4R,4aR,5aR)-7-cyclopropyl-4-(dimethylamino)-1,3,10,12-tetrahydroxy-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide (4R,4aR,5aR)-7-cyclopropyl-4-(diethylamino)-1,3,10,12-tetrahydroxy-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS,Z)-3,10,12,12a-tetrahydroxy-4-(methoxyimino)-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-4-amino-1,3,10,12-tetrahydroxy-11-oxo-7-(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 4-((1R,4aS,11aR,12aS)-3-carbamoyl-2,4a,5,7-tetrahydroxy-4,6-dioxo-1,4,4a,6,11,11a,12,12a-octahydrotetraphenyl-1-yl)piperazine-1-carboxylic acid tert-butyl ester, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(piperazin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(4-methylpiperazin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(4-acetylpiperazin-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(4-(methylsulfonyl)piperazin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(4-cyclopropylpiperazin-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(4-(2-methoxyethyl)piperazin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS,Z)-3,10,12,12a-tetrahydroxy-7-isopropyl-4-(methoxyimino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(diethylamino)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-4-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,12aS,Z)-7-cyclopropyl-3,10,12,12a-tetrahydroxy-4-(methoxyimino)-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-4-amino-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-7-cyclopropyl-4-(diethylamino)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-7-cyclopropyl-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-isopropyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-isopropyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-7-(1-isopropyl-1H-pyrazol-3-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,12aS,Z)-3,10,11,12a-tetrahydroxy-4-(methoxyimino)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4S,4aS,12aS)-4-(dimethylamino)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(piperazin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(4-acetylpiperazin-1-yl)-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopropyl-3,10,12,12a-tetrahydroxy-4-(4-(methylsulfonyl)piperazin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-7-(3-methylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-methylisoxazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-4-(4-acetylpiperazin-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-4-(4-(methylsulfonyl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-1,12-dioxo-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-4-(4-(2-methoxyethyl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-4-(4-cyclopropylpiperazin-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopropyl-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,12aS)-7-cyclobutyl-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,12aS)-7-cyclobutyl-4-(diethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-12-amino-4-(dimethylamino)-3,10,12a-trihydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-4-(dimethylamino)-12,12a-dihydroxy-3,10-dimethoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-12,12a-dihydroxy-3,10-dimethoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-((4-methoxybenzyl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-((4-methoxybenzyl)(methyl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(methylamino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,12aS)-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(piperazin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,12aS)-7-cyclobutyl-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,12aS)-4-(4-acetylpiperazin-1-yl)-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS,Z)-3,10,12,12a-tetrahydroxy-4-(methoxyimino)-7-(1-methyl-1H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-1,2,3-triazol-4-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4aS,5aR,12aS,Z)-3,10,12,12a-tetrahydroxy-4-(methoxyimino)-7-(2-methyl-2H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(2-methyl-2H-1,2,3-triazol-4-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(1,4-oxazacycloheptane-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(1,4-oxazetane-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(azacycloheptane-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(azacyclooctane-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((1S,5R)-7-oxo-3,6-diazabicyclo[3.2.1]octane-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(4,4-difluoropiperidin-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((1R,5S)-3-azabicyclo[3.1.0]hexane-3-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(5-oxo-1,4-diazacycloheptane-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-methyl-1,2,4-oxadiazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-4-amino-3,10,11,12a-tetrahydroxy-7-isopropyl-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-7-isopropyl-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-methylisothiazo-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-(dimethylamino)-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-7-(3-methylisoxazol-5-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-4-(4-(2-methoxyethyl)piperazin-1-yl)-7-(3-methylisoxazol-5-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-7-isopropyl-4-(4-(2-methoxyethyl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-4-amino-3,10,11,12a-tetrahydroxy-7-(3-methylisothiazo-5-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-7-(3-methylisothiazo-5-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-4-(4-(2-methoxyethyl)piperazin-1-yl)-7-(3-methylisothiazo-5-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropyl-1H-pyrazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-7-(3-cyclopropylisoxazol-5-yl)-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-4-(4-(2-hydroxyethyl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-4-(4-(oxecyclobutan-3-yl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,5aR,12aS)-3,10,12,12a-tetrahydroxy-4,7-dimorpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-4-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-4-morpholino-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-(pyrimidin-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,12,12a-tetrahydroxy-4-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,7-bis(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-4-morpholino-11-oxo-7-(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(ethylamino)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-4,7-dimorpholino-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-7-(oxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(isoxazo-4-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(methyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-4-morpholino-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-11-oxo-4,7-bis(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,11,12a-tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,11-tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-4-morpholino-12-oxo-4,4a,5,5a,6,12-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-(1H-pyrrolo-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4S,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-(1H-pyrrolo-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,11,12a-tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide (4R,4aR,5aR)-1,3,10,12-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-11-oxo-4-((tetrahydro-2H-pyran-4-yl)amino)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-11-oxo-4-((tetrahydro-2H-pyran-4-yl)amino)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropylthiazo-2-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-7-(4-isopropylthiazo-2-yl)-4-morpholino-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,5aR,12aS)-7-(azacyclobutane-1-yl)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(diethylamino)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-1,3,10,12-tetrahydroxy-11-oxo-7-(pyrrolidone-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-3,10,12,12a-tetrahydroxy-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, (4R,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,5aR,12aR)-4-(dimethylamino)-3,10,12-trihydroxy-7-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,5aR,12aS)-7-(azacyclobutane-1-yl)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,5aR,12aS)-4,7-bis(azacyclobutane-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropyl-1,2,4-oxadiazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-3,10,12-trihydroxy-7-(3-isopropyl-1,2,4-oxadiazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-4-(dimethylamino)-1,3,10,12-tetrahydroxy-11-oxo-7-(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-4-(dimethylamino)-1,3,10,11-tetrahydroxy-7-morpholino-12-oxo-4,4a,5,5a,6,12-hexahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR)-7-(dimethylamino)-1,3,10,11-tetrahydroxy-4-morpholino-12-oxo-4,4a,5,5a,6,12-hexahydrotetraphenyl-2-carboxamide (4R,4aS,5aR,12aS)-4-(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidan-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-2-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropyl-1H-pyrrolo-2-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropyl-1H-pyrrolo-2-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-5-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-(1H-pyrazol-5-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1H-imidazol-2-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1H-imidazol-2-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1H-imidazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1H-imidazol-5-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aR,5aR,12aR)-3,10,12-trihydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropyl-1,2,4-oxadiazol-5-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(3,3-dimethylazacyclobutane-1-yl)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-7-(pyrrolidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropyl-1,2,4-oxadiazol-5-yl)-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-7-(1H-pyrazol-5-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-5-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopentyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-(3,3-dimethylcyclobutyl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-(3,3-dimethylcyclobutyl)-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidine-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(methyl(2-oxaspiro[3.3]heptane-6-yl)amino)-1,11-dioxo-7-(pyrrolidine-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((1,1-dioxano-tetrahydro-2H-thiopyran-4-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((1,1-dioxano-tetrahydro-2H-thiopyran-4-yl)amino)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((3-cyano-3-methylcyclobutyl)amino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopentyl-4-((1-(2,2-difluoroethyl)piperidin-4-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((1-(2,2-difluoroethyl)piperidin-4-yl)amino)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((3,3-difluorocyclobutyl)amino)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(methyl(2-oxaspiro[3.3]heptane-6-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((1,1-dioxano-tetrahydro-2H-thiopyran-4-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((1,1-dioxano-tetrahydro-2H-thiopyran-4-yl)(methyl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(((1s,3S)-3-cyano-3-methylcyclobutyl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(((1r,3R)-3-cyano-3-methylcyclobutyl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((1-(2,2-difluoroethyl)piperidin-4-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-cyclopentyl-3,10,12,12a-tetrahydroxy-4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-propyl-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-7-((S)-1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-7-((R)-1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-((S)-1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-((R)-1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(2-oxopyrrolidone-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(((3-methyloxetane-3-yl)methyl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(methyl((3-methyloxetane-3-yl)methyl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-4-(methyl(2-oxaspiro[3.3]heptane-6-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-(2-oxopyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(2-oxopyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-(cyclohexylamino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-4-((3,3-dimethylcyclobutyl)amino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-7-(trifluoromethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-chloro-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(piperidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,11,12a-tetrahydroxy-4-(((1-methyl-1H-pyrazol-4-yl)methyl)amino)-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,11,12a-tetrahydroxy-4-(((1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-(((1-methyl-1H-pyrazol-4-yl)methyl)amino)-1,11-dioxo-7-(2-oxopyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, and (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1,4-oxazetane-4-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, or a pharmaceutically acceptable salt thereof.
[0246] In some embodiments, this document provides a compound selected from the group consisting of: 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(pyridazin-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-4-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1-methyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1-methyl-1H-pyrazol-3-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(pyridazin-4-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1-methyl-1H-pyrazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1-isopropyl-1H-pyrazol-3-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(3,6-dihydro-2H-pyran-4-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(tetrahydro-2H-pyran-4-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(3,3,3-trifluoroprop-1-en-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-methylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-vinyl-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1-methyl-1H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(2-methyl-2H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-methyl-1,2,4-oxadiazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,12a-Dihydroxy-10,12-dimethoxy-N,N-dimethyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,12,12a-trihydroxy-10-methoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 12,12a-Dihydroxy-3,10-dimethoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-9-(2-(pyrrolidin-1-yl)acetamido)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 9-(2-(tert-butylamino)acetamido)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-1,5,5a,6,11,12a-hexahydrotetraphenyl-2-carboxamide, 7-(cyclopent-1-en-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 7-Cyclopentyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-1,12-dioxo-7-(tetrahydro-2H-pyran-4-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-1,12-dioxo-7-(3,3,3-trifluoroprop-1-en-2-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(3-Cyclopropylisoxazol-5-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-1,12-dioxo-7-(1,1,1-trifluoropropane-2-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11-Trihydroxy-1,12-dioxo-7-(1,1,1-trifluoropropane-2-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-hydroxyazacyclobutane-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-3,10,12-trihydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(2-oxaspiro[3.3]hept-5-en-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(2-oxaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(2-oxaspiro[3.3]heptane-6-yl)-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, 4-(diethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(hydroxyimino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(Ethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dipropylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(propylamino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Acetamido-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3-Carbamoyl-2,4a,5,7-tetrahydroxy-4,6-dioxo-1,4,4a,6,11,11a,12,12a-octahydrotetraphenyl-1-yl)carbamate, 4-(cyclobutylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(cyclobutyl(methyl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methoxyimino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12-trihydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-11-oxo-4-(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-11-oxo-4-(piperidin-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-4-(diethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopentyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(diethylamino)-1,3,10,12-tetrahydroxy-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 4-Amino-7-cyclopropyl-1,3,10,12-tetrahydroxy-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-4-(dimethylamino)-1,3,10,12-tetrahydroxy-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-4-(diethylamino)-1,3,10,12-tetrahydroxy-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methoxyimino)-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-1,3,10,12-tetrahydroxy-11-oxo-7-(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 4-(3-Carbamoyl-2,4a,5,7-tetrahydroxy-4,6-dioxo-1,4,4a,6,11,11a,12,12a-octahydrotetraphenyl-1-yl)piperazine-1-carboxylic acid tert-butyl ester, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(piperazin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-methylpiperazin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(4-acetylpiperazin-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-(methylsulfonyl)piperazin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(4-Cyclopropylpiperazin-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-(2-methoxyethyl)piperazin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-4-(methoxyimino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(diethylamino)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-1,11-dioxo-4-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-3,10,12,12a-Tetrahydroxy-4-(methoxyimino)-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, 4-Amino-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-4-(diethylamino)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-3,10,11,12a-Tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(1-isopropyl-1H-pyrazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-7-(1-isopropyl-1H-pyrazol-3-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(methoxyimino)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(piperazin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(4-acetylpiperazin-1-yl)-7-cyclopropyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-3,10,12,12a-Tetrahydroxy-4-(4-(Methylsulfonyl)piperazin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-7-(3-methylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-methylisoxazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(4-acetylpiperazin-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(4-(methylsulfonyl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-1,12-dioxo-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(4-(2-methoxyethyl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 4-(4-Cyclopropylpiperazin-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 7-Cyclopropyl-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-4-(diethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 12-Amino-4-(dimethylamino)-3,10,12a-trihydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-12,12a-dihydroxy-3,10-dimethoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-((4-methoxybenzyl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-((4-methoxybenzyl)(methyl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methylamino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(piperazin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 4-(4-acetylpiperazin-1-yl)-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methoxyimino)-7-(1-methyl-1H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1-methyl-1H-1,2,3-triazol-4-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methoxyimino)-7-(2-methyl-2H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(2-methyl-2H-1,2,3-triazol-4-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(1,4-oxazacycloheptane-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide 3,10,12,12a-Tetrahydroxy-4-(1,4-oxazetane-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(azacycloheptan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(azacyclooctane-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(7-oxo-3,6-diazabicyclo[3.2.1]octane-3-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(4,4-difluoropiperidin-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(3-azabicyclo[3.1.0]hexane-3-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(5-oxo-1,4-diazacycloheptane-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-methyl-1,2,4-oxadiazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,11,12a-tetrahydroxy-7-isopropyl-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-isopropyl-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-methylisothiazo-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(dimethylamino)-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-(3-methylisoxazol-5-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(4-(2-methoxyethyl)piperazin-1-yl)-7-(3-methylisoxazol-5-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-isopropyl-4-(4-(2-methoxyethyl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,11,12a-tetrahydroxy-7-(3-methylisothiazo-5-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-(3-methylisothiazo-5-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(4-(2-methoxyethyl)piperazin-1-yl)-7-(3-methylisothiazo-5-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropyl-1H-pyrazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(3-Cyclopropylisoxazol-5-yl)-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(4-(2-hydroxyethyl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(4-(oxecyclobutan-3-yl)piperazin-1-yl)-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4,7-dimorpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-morpholino-1,11-dioxo-4-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-4-morpholino-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-7-(pyrimidin-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4,7-bis(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-4-morpholino-11-oxo-7-(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 4-(Ethylamino)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-4,7-dimorpholino-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-7-(oxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(isoxazo-4-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-Amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-4-morpholino-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-11-oxo-4,7-bis(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,11-Tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-4-morpholino-12-oxo-4,4a,5,5a,6,12-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-7-(1H-pyrrolo-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-11-oxo-4-((tetrahydro-2H-pyran-4-yl)amino)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-11-oxo-4-((tetrahydro-2H-pyran-4-yl)amino)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(4-isopropylthiazo-2-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-7-(4-isopropylthiazo-2-yl)-4-morpholino-11-oxo-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 7-(azacyclobutan-1-yl)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-morpholino-1,11-dioxo-4-(piperidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(diethylamino)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 1,3,10,12-Tetrahydroxy-11-oxo-7-(pyrrolidone-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12-trihydroxy-7-(4-hydroxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4,7-Di(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropyl-1,2,4-oxadiazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12-Trihydroxy-7-(3-isopropyl-1,2,4-oxadiazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-1,3,10,12-tetrahydroxy-11-oxo-7-(pyrrolidone-1-yl)-4,4a,5,5a,6,11-hexahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-1,3,10,11-tetrahydroxy-7-morpholino-12-oxo-4,4a,5,5a,6,12-hexahydrotetraphenyl-2-carboxamide, 7-(dimethylamino)-1,3,10,11-tetrahydroxy-4-morpholino-12-oxo-4,4a,5,5a,6,12-hexahydrotetraphenyl-2-carboxamide, 4-(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-2-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrrolo-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(4-isopropyl-1H-pyrrolo-2-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(4-isopropyl-1H-pyrrolo-2-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-5-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-7-(1H-pyrazol-5-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(4-isopropyloxazol-2-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1H-imidazol-2-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1H-imidazol-2-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1H-imidazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(1H-imidazol-5-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12-Trihydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropyl-1,2,4-oxadiazol-5-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(3,3-Dimethylazacyclobutane-1-yl)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-7-(pyrrolidin-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(4-isopropyloxazol-2-yl)-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropyl-1,2,4-oxadiazol-5-yl)-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(4-methoxypiperidin-1-yl)-1,11-dioxo-7-(1H-pyrazol-5-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1H-pyrazol-5-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopentyl-3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclobutyl-3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(pyrrolidin-1-yl)-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(3,3-Dimethylcyclobutyl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 7-(3,3-Dimethylcyclobutyl)-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidine-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methyl(2-oxaspiro[3.3]heptane-6-yl)amino)-1,11-dioxo-7-(pyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((1,1-dioxano-tetrahydro-2H-thiopyran-4-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(pyrrolidine-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((1,1-dioxano-tetrahydro-2H-thiopyran-4-yl)amino)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((3-cyano-3-methylcyclobutyl)amino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopentyl-4-((1-(2,2-difluoroethyl)piperidin-4-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((1-(2,2-difluoroethyl)piperidin-4-yl)amino)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((3,3-difluorocyclobutyl)amino)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methyl(2-oxaspiro[3.3]heptane-6-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((1,1-dioxano-tetrahydro-2H-thiopyran-4-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((1,1-dioxano-tetrahydro-2H-thiopyran-4-yl)(methyl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((3-cyano-3-methylcyclobutyl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((1-(2,2-difluoroethyl)piperidin-4-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Cyclopentyl-3,10,12,12a-Tetrahydroxy-4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-7-propyl-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-7-(1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-7-(1,1,1-trifluoropropane-2-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(2-oxopyrrolidone-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(((3-methyloxetane-3-yl)methyl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(methyl((3-methyloxetane-3-yl)methyl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-4-(methyl(2-oxaspiro[3.3]heptane-6-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-7-(2-oxopyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(2-oxopyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((2-oxaspiro[3.3]heptane-6-yl)amino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-(cyclohexylamino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 4-((3,3-dimethylcyclobutyl)amino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyloxazol-2-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-7-(trifluoromethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Fluoro-3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-Chloro-3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-7-(piperidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-morpholino-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(((1-methyl-1H-pyrazol-4-yl)methyl)amino)-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-4-(((1-methyl-1H-1,2,3-triazol-4-yl)methyl)amino)-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-4-(((1-methyl-1H-pyrazol-4-yl)methyl)amino)-1,11-dioxo-7-(2-oxopyrrolidone-1-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, and 3,10,12,12a-tetrahydroxy-7-(1,4-oxazetane-4-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, or a pharmaceutically acceptable salt thereof.
[0247] In some embodiments, a compound, its tautomer or stereoisomer, or a pharmaceutically acceptable salt of any of the above is provided, wherein the compound is: , , , , , , , , , or .
[0248] In some embodiments, a compound, its tautomer or stereoisomer, or a pharmaceutically acceptable salt of any of the above is provided, wherein the compound is: , , , , , , , , or .
[0249] In some implementations, the compounds are selected from the group consisting of: (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,12aS)-7-(3-cyclopropylisoxazol-5-yl)-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,11,12a-tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-7-(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-propyl-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, and (4R,4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, or a pharmaceutically acceptable salt thereof.
[0250] In some implementations, the compounds are selected from the group consisting of: 3,10,12,12a-Tetrahydroxy-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-4-morpholino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(3-Cyclopropylisoxazol-5-yl)-3,10,11,12a-tetrahydroxy-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,11,12a-Tetrahydroxy-7-(4-isopropyl-1H-1,2,3-triazol-1-yl)-4-morpholino-1,12-dioxo-1,4,4a,5,5a,6,12,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 7-(azacyclobutan-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4-((tetrahydro-2H-pyran-4-yl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-Tetrahydroxy-7-isopropyl-4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, 3,10,12,12a-tetrahydroxy-4-morpholino-1,11-dioxo-7-propyl-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, and 3,10,12,12a-tetrahydroxy-7-isopropyl-1,11-dioxo-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide, or a pharmaceutically acceptable salt thereof.
[0251] The term "pharmaceutically acceptable salt" includes salts of active compounds prepared from relatively non-toxic acids or bases, depending on the specific substituents present on the compounds described herein. In some embodiments, the salt is a chloride salt. In other embodiments, the salt is an acetate salt.
[0252] Pharmaceutical Composition In some aspects, a pharmaceutical composition is provided comprising any of the compounds described herein or a pharmaceutically acceptable salt thereof, or a composition (including pharmaceutical compositions); and at least one pharmaceutically acceptable excipient. Such compounds include compounds of formulas (Ia), (Ib), (II), (III), (IV-a), (IV-b), (Va), and (Vb), as well as the compounds in Tables 1A and 1B, or pharmaceutically acceptable salts thereof.
[0253] The term "pharmaceutically acceptable excipient" means that the excipient is not biologically or otherwise undesirable; for example, the material can be added to a pharmaceutical composition and administered to a subject without causing significant undesirable effects.
[0254] The compounds or pharmaceutical compositions disclosed herein can be administered by various methods, such as oral, rectal, oral, intranasal, and transdermal routes. In some embodiments, the pharmaceutical compositions can be administered intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
[0255] The compounds and pharmaceutical compositions disclosed herein can be administered to an individual in any generally accepted oral composition form (e.g., tablets, coated tablets, hard-shell or soft-shell gel capsules, emulsions, or suspensions).
[0256] Treatment In some aspects, a method is provided for treating a disease or ailment of a subject in need, the method comprising administering a therapeutically effective amount of any of the compounds described herein or a pharmaceutically acceptable salt or composition thereof (including pharmaceutical compositions). In some embodiments, such compounds include compounds of formulas (Ia), (Ib), (II), (III), (IV-a), (IV-b), (Va), and (Vb), as well as compounds in Tables 1A and 1B, or pharmaceutically acceptable salts thereof. In some embodiments, such compounds include one or more of the synthetic intermediates provided in the following examples.
[0257] In some implementations, the subjects are humans.
[0258] In some embodiments, the compounds provided herein lack significant antibiotic activity. In some variants, the compounds have minimal effect on the growth of normally sensitive bacteria to minocycline and / or cycline antibiotics. The compounds of the present invention lacking antibiotic activity will have less than 50% of the antibacterial activity of the relevant tetracycline antibiotic, and in some variants, less than 10%, as measured in standard MIC assays. In some embodiments, the compounds are not substantially antibiotics, meaning they have very little or no antibacterial activity at suitable concentrations against microorganisms such as those cultured for use. Escherichia coli Staphylococcus aureus Compounds whose antibiotic activity is measured in standard antibiotic susceptibility tests, such as [examples of tests performed on these compounds]. In some variants, the compound exhibits antibiotic activity at suitable concentrations using cultured microorganisms such as [examples of microorganisms]. Escherichia coli Staphylococcus aureus The compounds exhibit antibiotic activity of less than 10%, less than 5%, or less than 1% as measured in standard antibiotic susceptibility testing. In some embodiments, the compounds provided herein are suitable for treating non-infectious indications.
[0259] In some variants, certain compounds presented herein are suitable for treating peripheral diseases, and such compounds may not have a good ability to cross the blood-brain barrier.
[0260] Among other variants, some of the other compounds described herein are suitable for the treatment of central nervous system indications, and such compounds have a good ability to cross the blood-brain barrier.
[0261] In some embodiments, the compounds provided herein inhibit translational activity in cells such as eukaryotic cells or neurons. In some embodiments, the compounds provided herein are eukaryotic translation inhibitors. In some embodiments, the compounds specifically inhibit polyribosomal translation. In some embodiments, the compounds are polyribosomal translation inhibitors. In some embodiments, the compounds lack significant antibiotic activity and are suitable for treating non-infectious indications.
[0262] In some embodiments, the compounds are suitable for treating diseases or conditions associated with excessive translational activity in cells, such as overtranslation in neurons. In some embodiments, the diseases or conditions are rheumatoid arthritis, inflammatory bowel disease, epilepsy, acute ischemic stroke, traumatic brain injury, neuropathic pain, Fragile X syndrome, antipsychotic drug-induced hyperphagia, Prader-Willi syndrome, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, spinal cord injury, diabetic macular edema, dermatitis, periodontitis, osteoporosis, atherosclerosis, tumors / cancer, malaria, HIV, light chain amyloidosis, transthyretin amyloidosis, schizophrenia, bipolar disorder, or depression. In some embodiments, the disease or condition is Fragile X syndrome (FXS). In some embodiments, the compounds provided herein are capable of reversing the FXS behavioral phenotype. In some embodiments, the disease or condition is epilepsy. In some embodiments, the compounds provided herein exhibit higher brain exposure (e.g., stronger central nervous system effects) and are suitable for the treatment of seizures and / or epilepsy. In some embodiments, the epilepsy is drug-resistant epilepsy, such as drug-resistant temporal lobe epilepsy and infection-induced epilepsy.
[0263] In some embodiments, this document provides a method for treating a disease or condition associated with excessive translational activity in cells, such as overtranslation in neurons, wherein said method comprises administering to a subject in need a therapeutically effective amount of one or more of the following compounds or pharmaceutically acceptable salts thereof: , , , , , , , , , or In some embodiments, the disease or condition is Fragile X syndrome (FXS). In some embodiments, the disease or condition is rheumatoid arthritis. In some embodiments, the disease or condition is Alzheimer's disease.
[0264] In some embodiments, this document provides a method for treating a disease or condition associated with excessive translational activity in cells, such as overtranslation in neurons, wherein said method comprises administering to a subject in need a therapeutically effective amount of one or more of the following compounds or pharmaceutically acceptable salts thereof: , , , , , , , , or In some embodiments, the disease or condition is Fragile X syndrome (FXS). In some embodiments, the disease or condition is rheumatoid arthritis. In some embodiments, the disease or condition is Alzheimer's disease.
[0265] In some variations, the term "therapeuticly effective" when applied to dosage or amount means that the amount of a compound or pharmaceutical preparation, such as those described elsewhere in this document, is sufficient to produce the desired clinical benefit upon administration to a patient in need. It should be understood that an effective amount may be achieved in one or more doses; for example, a single dose or multiple doses may be required to achieve the desired therapeutic endpoint.
[0266] The specific safe or therapeutically effective dose will vary depending on factors such as the specific disease being treated, the subject's physical condition, the duration of treatment, the nature of any concurrent therapies, and the structure of the specific formulation and compound or its derivatives used.
[0267] As used herein, the term “treating / treatment” refers to a method or procedure used to obtain a beneficial or desired outcome (e.g., clinical outcome). Beneficial or desired outcomes may include: (1) alleviating one or more symptoms caused by or associated with a disease, condition, or disorder; (2) reducing the severity of a disease, disorder, or disorder; (3) slowing or stopping the development or progression of one or more symptoms caused by or associated with a disease, condition, or disorder (e.g., stabilizing a disease, condition, or disorder); and (4) alleviating a disease, for example, by causing the resolution of one or more clinical symptoms (e.g., improving the disease state, enhancing the effect of another medication, delaying or stopping the progression of the disease, improving quality of life, and / or prolonging survival).
[0268] In some embodiments, the treatments described herein effectively alleviate one or more symptoms of Fragile X syndrome (FXS) in patients. For example, treatment with a therapeutically effective amount of the compounds described herein effectively improves ADHD, anxiety disorder, hippocampal-dependent activities of daily living, cognitive abilities, social memory, stereotyped behaviors, and / or aggressive behaviors. In some embodiments, the treatments described herein effectively alleviate one or more symptoms of rheumatoid arthritis in patients. For example, treatment with a therapeutically effective amount of the compounds described herein effectively improves arthritis lesions, clinical scores, and / or pathological outcomes.
[0269] In some embodiments, this document provides for the use of compounds or pharmaceutical compositions as described elsewhere herein in any of the methods described elsewhere herein. In other embodiments, this document provides for the use of compounds or pharmaceutical compositions as described elsewhere herein for manufacturing a medicament used in any of the methods described elsewhere herein. In other embodiments, this document provides for the use of compounds or pharmaceutical compositions as described elsewhere herein in any of the methods described herein.
[0270] In some respects, this document also provides articles comprising any compound described herein or a pharmaceutically acceptable salt or composition thereof (including pharmaceutical compositions) in a suitable container. The container may be a vial, wide-mouth bottle, ampoule, pre-filled syringe, or intravenous infusion bag.
[0271] This disclosure further provides a kit for carrying out the methods of the invention. The kit may contain any compound described herein or a pharmaceutically acceptable salt thereof, or a composition (including pharmaceutical compositions), and suitable packaging. The kit may include one or more containers containing any compound described herein. In one aspect, the kit includes a compound of this disclosure or a pharmaceutically acceptable salt thereof, and a label and / or instructions for using said compound to treat the disease or ailment described herein. The kit may contain unit dosage forms of the compound.
[0272] In some respects, this document provides articles (such as kits) comprising: (i) an effective amount of any compound described herein or a pharmaceutically acceptable salt or composition thereof (including pharmaceutical compositions); and (ii) instructions for use in treating the diseases or ailments described herein.
[0273] Example A better understanding of the subject matter disclosed herein will be achieved by referring to the following examples, which are provided as examples of the invention and not as limitations. It should be understood that Examples 1A-48a provide exemplary synthesis and characterization of the compounds disclosed in Table 1A or their free bases, and Examples 1B-238B provide exemplary synthesis and characterization of the compounds disclosed in Table 1B or their free bases.
[0274] Example 1A: (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-pyridazine-3-yl-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4) S ,4a S ,5a R,12a S )-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq ) and MeI (10 eq The solution in acetone was stirred at 30°C for 48 hours. The reaction mixture was concentrated under reduced pressure. The crude product was prepared with acetone / petroleum ether (1:1). (1S,4aS,11aR,12aS)-3-carbamoyl-2,4a,5,7-tetrahydroxy-N,N,N-trimethyl-4,6-dioxo-1,4,4a,6,11,11a,12,12a-octahydrotetraphenyl-1-ammonium iodide (74.5% yield) was given as a yellow solid. 1 H NMR (400 MHz, DMSO- d 6): δ 15.01 (s, 1H), 11.50 (s, 1H), 9.70-9.20 (m, 2H), 7.72 (s, 1H), 7.50-7.43 (m,1H), 6.88-6.79 (m, 2H), 2.89-2.56 (m, 2H), 4.39 (s, 1H), 3.50 (s, 9H), 3.25-2.90 (m, 4H), 2.85-2.70 (m, 1H), 2.30-2.10 (m, 1 H), 1.60-1.35 (m, 1 H).
[0275] (1S,4aS,11aR,12aS)-3-carbamoyl-2,4a,5,7-tetrahydroxy-N,N,N-trimethyl-4,6-dioxo-1,4,4a,6,11,11a,12,12a-octahydrotetraphenyl-1-ammonium iodide (1.0) eq ) and Zn (4.1 eq The solution of HOAc (3 mL) and H2O (3 mL) was stirred at 25 °C for 30 min. The reaction mixture was diluted with H2O (15 mL) and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC. A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (15.7% yield). LC-MS (ESI) +m / z: 372.0 [M+H] + HPLC: 98.5% purity at 254 nm. 1 H NMR (400 MHz, DMSO- d 6): δ 15.02 (s, 1H), 11.58 (s, 1H), 8.95-8.76 (m, 2H), 7.46-7.40 (m, 1H), 6.82-6.69 (m, 3H), 3.21-3.01 (m, 1H), 2.89-2.56 (m, 2H), 2.45-2.20 (m, 3H), 2.03-1.85 (m, 1H), 1.55-1.30 (m, 1H).
[0276] NIS (1.0) was placed at 0℃. eq Slowly add to (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq A solution of 4a was prepared in TFA (30 mL). The resulting solution was then heated to 25 °C and stirred at 25 °C for 16 hours. The reaction solution was diluted with H2O (100 mL) and filtered. The obtained yellow solid was washed with H2O (15 mL x 3) and dried under reduced pressure. A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (60.1% yield). LC-MS (ESI) + m / z: 497.9 [M+H] + HPLC: 99.6% purity at 254 nm. 1 H NMR (400 MHz, DMSO-) d 6) δ 14.88 (1H, brs), 11.84 (s, 1H), 9.13-8.71 (m, 2H), 7.89(d, J= 8.8 Hz, 1H), 6.79-6.63 (m, 2H), 4. 22- 4. 00 (m, 1H), 3.13-3.03 (m,1H), 2.98-2.83 (m, 2H), 2.43-2.30 (m, 3H), 2.09-1.97 (m,1H), 1.55-1.38 (m,1H).
[0277] (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq ), Pd(dppf)Cl2(0.1 eq ), Tributyl(pyridazin-3-yl)stanane (1.2) eq ) and CuI (0.05) eq The solution of 4a in dioxane (3 mL) was stirred at 110 °C under N2 for 6 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (HCOOH). A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-pyridazine-3-yl-4a,5,5a,6-tetrahydro-4 H -2-benzoxyl-2-carboxamide (14.3% yield). LC-MS (ESI+) m / z: 449.9 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6): δ 14.95(s, 1H), 11.99 (s, 1H), 9.24 (s, 1H), 8.81-8.76 (m, 2H), 7.90-7.65 (m, 3H),7.02 (d, J = 8.8 Hz, 1H), 6.71 (s, 1H), 3.21-3.01 (m, 1H), 2.89-2.50 (m, 3H), 2.45-2.20 (m, 2H), 2.03-1.85 (m, 1H), 1.55-1.30 (m, 1H).
[0278] Example 2A: (4a) S ,5a R ,12aS )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-pyrrolidine-1-yl-4a,5,5a,6-tetrahydro-4 H -tetraphenyl-2-carboxamide and (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-pyrrolo-1-yl-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide KNO3(1.2) was added at 0℃. eq Slowly add to (4a) S , 5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq A solution of (4a) was prepared in H2SO4 (40 mL) and MeOH (10 mL). The reaction mixture was stirred at 0 °C for 3 hours. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were concentrated under reduced pressure. The residue was purified by preparative HPLC. A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (7.6% yield). LC-MS (ESI) + m / z: 417.0 (M+H) + .
[0279] (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq ) and Pd(OH)2(0.1 eqThe reaction mixture in dioxane (6 mL) and MeOH (6 mL) was stirred at 25 °C under a H2 balloon for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure. The desired product (95.8% yield) was obtained as a yellow solid and could be used in the next step without further purification. LC-MS (ESI) + m / z: 387.0 (M+H) + .
[0280] At 0℃, add 2.5g of H2SO4 aqueous solution. eq Add to 2,5-dimethoxytetrahydrofuran (3.0) eq A solution in THF (1 mL) and MeOH (1 mL). Add the resulting solution to (4a) S ,5a R ,12a S )-7-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq Add the solution to THF (1 mL) and MeOH (1 mL), and then add NaBH3CN (4.0 g). eq The reaction solution was heated to 25°C and stirred at 25°C for 12 h. The reaction was concentrated under reduced pressure. The residue was purified by preparative HPLC to separate the two desired compounds.
[0281] (4a) was obtained as a yellow solid. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-pyrrolidine-1-yl-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (3% yield). LC-MS (ESI) + m / z: 441.0 (M+H) + . 1 H NMR (400 MHz, MeOD) δ 7.75 (d, J = 8.8 Hz, 1H), 7.01 (d, J= 8.8 Hz, 1H),3.95-3.40 (m, 4H), 3.25-2.15 (m, 2H), 3.05–2.85 (m, 1H), 2.60–2.35 (m, 3H),2.35–2.20 (m, 4H), 2.20-2.07 (m, 1H), 1.75-1.55 (m, 1H).
[0282] (4a) was obtained as a yellow solid. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-pyrrolo-1-yl-4a,5,5a,6-tetrahydro-4 H 2-Phenylene-2-carboxamide (2% yield). LC-MS (ESI) + m / z: 437.0 (M+H) + . 1 H NMR (400 MHz, MeOD) δ 7.40 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.74(s, 2H), 6.24 (s, 2H), 2.90-2.70 (m, 1H), 2.50-2.25 (m, 4H), 2.08-1.80 (m,2H), 1.60-1.42 (m, 1H).
[0283] Example 3A: (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1 H -pyrazol-4-yl)-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide To (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Add 1 eq. of tetraphenyl-2-carboxamide (1 eq.) to a solution of dioxane (2 mL) and H2O (0.2 mL). H-pyrazole-4-ylboronic acid (2 eq.), Xantphos-Pd-G3 (0.125 eq.), and K3PO4 (3 eq.). The mixture was degassed with N2 and purged three times. The mixture was stirred at 60 °C under N2 atmosphere for 3 h. The reaction mixture was concentrated under reduced pressure to obtain the residue. It was purified by preparative HPLC. Most of CH3CN was removed under reduced pressure, and the remaining solvent was removed by lyophilization to give a yellow solid (4a). S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1 H -pyrazol-4-yl)-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (7% yield). LC-MS (ESI) + m / z: 438.0 (M+H) + . 1 H NMR (500 MHz, CD3CN) δ 14.85 (1H, brs), 11.85 - 12.03 (1H, m), 9.01 (1H, brs), 7.78 (2H, brs), 7.52 (1H, brd, J = 8.1 Hz), 6.90 (1H, brd, J = 8.4 Hz), 6.79 (1H,brs), 3.13 - 3.24 (1H, m), 2.97 (1H, brd, J = 16.0 Hz), 2.75 - 2.88 (2H, m), 2.54 (2H, brd, J = 15.6 Hz), 2.46 (2H, brs), 1.98 (2H, brs), 1.55 - 1.61 (1H,m).
[0284] Example 4A: (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1 H -pyrazol-3-yl)-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide To (4a) S ,5a R ,12aS )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Add 1 eq. of tetraphenyl-2-carboxamide (1 eq.) to a solution of dioxane (2 mL) and H2O (0.2 mL). H -pyrazole-3-ylboronic acid (2 eq.), Xantphos-Pd-G3 and K3PO4 (3 eq.). The mixture was degassed with N2 and purged three times. The mixture was stirred at 60 °C under N2 atmosphere for 3 h. The reaction mixture was concentrated under reduced pressure to give the residue. It was purified by preparative HPLC. Most of CH3CN was removed under reduced pressure, and the remaining solvent was removed by lyophilization to give a yellow solid (4a). S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1 H -pyrazol-3-yl)-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (5% yield). LC-MS (ESI) + m / z: 438.0 (M+H) + . 1 H NMR (400 MHz, CD3CN) δ 14.83 (s, 1H), 12.03 (brs, 1H), 8.99 (brs, 1H), 7.86 (brs, 1H), 7.60 (d, J =8.4 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.78 (brs, 1H), 6.51 (brs, 1H), 3.18(dd, J = 18.4, 5.6 Hz, 1H), 3.00 (dd, J = 15.6, 4.4 Hz, 1H), 2.80 (dt, J = 9.2,4.67 Hz, 2H), 2.62-2.58 (2H, m), 2.12 (brs, 2H), 1.88-1.62 (m, 2H), 1.57-1.49(m, 1H).
[0285] Example 5A: (12a) S )-3,10,12,12a-tetrahydroxy-7-(1-methylpyrazol-4-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H Synthesis and characterization of -tetraphenyl-2-carboxamide (12a) S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H A mixture of 1,4-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)pyrazole (2.0 eq.), K3PO4 (2.5 eq.), and XantPhos-Pd-G3 (0.1 eq.) in dioxane (60 mL) and H2O (30 mL) was degassed with N2 and purged three times. The mixture was then stirred at 70 °C under N2 atmosphere for 4 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse-phase column chromatography to remove the catalyst, followed by HPLC purification. A yellow solid (12a) was obtained. S )-3,10,12,12a-tetrahydroxy-7-(1-methylpyrazol-4-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 2-Phenylene-2-carboxamide (28% yield). LC-MS (ESI) + m / z: 452.2 (M+H) + . 1 H NMR (400MHz, MeOD) δ 1.48 - 1.68 (m, 1 H), 1.91 - 2.04 (m, 1 H), 2.31 - 2.55 (m, 3 H), 2.71 - 2.88 (m, 1 H), 2.96 - 3.09 (m, 1 H), 3.19 - 3.30 (m, 1 H), 3.91 - 4.09 (m, 3 H), 6.76 - 6.94 (m, 1 H), 7.39 - 7.52 (m, 1 H), 7.59 - 7.69 (m, 1 H), 7.74- 7.85 (m, 1 H).
[0286] Example 6A: (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-(1-methylpyrazol-3-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide To (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)pyrazole (1.5 eq.), Xantphos-Pd-G3 (0.125 eq.), and K3PO4 (3.0 eq.) were added to a solution of tetraphenyl-2-carboxamide (1 eq.) in H2O (0.1 mL) and dioxane (1 mL). The mixture was degassed with N2 and purged three times. The mixture was stirred at 60 °C under N2 atmosphere for 5 h. The reaction mixture was concentrated under reduced pressure to give a residue. It was purified by preparative HPLC. Most of CH3CN was removed under reduced pressure, and the remaining solvent was removed by lyophilization to give a yellow solid (4a S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-(1-methylpyrazol-3-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (16% yield). LC-MS (ESI) + m / z: 452.0 (M+H) + . 1 H NMR (400 MHz, CD3CN) δ 14.79 (brs,1H), 12.06 (brs, 1H), 8.97 (brs, 1H), 7.75 (s, 1H), 7.68 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 6.81 (brs, 1H), 6.48 (s, 1H), 4.07 (s, 3H), 3.17 (d, J = 16.0 Hz, 1H), 3.05 (dd, J = 16.0, 4.0 Hz, 1H), 2.95-2.74 (m, 1H), 2.62 (brs,2H), 2.57-2.55 (m, 2H), 2.09-1.97 (m, 2H), 1.64-1.49 (m, 1H), Example 7A: (4aS, 5a) R , 12aS )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-pyridazine-4-yl-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide K3PO4 (3 eq.) was added to a solution of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (1 eq.), 4-(4,4,5,5-tetramethyl-1,3,2-dioxane-2-yl)pyridazine (1.5 eq.) and XantPhos-Pd-G3 in dioxane (2 mL) and water (0.2 mL) at 20 °C. The mixture was purged with N2 and degassed three times, and then stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC. A yellow solid (4aS,5aR,12aS) was obtained. R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-pyridazine-4-yl-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (12% yield). LC-MS (ESI) + ) m / z 450.0 (M+H) + . 1 H NMR (400 MHz, DMSO- d 6): δ 14.93(br s, 1H), 11.95 (s, 1H), 9.32 - 9.09 (m, 2H), 9.02 - 8.65 (m, 2H), 7.69(dd, J = 2.54, 5.2 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.84 - 6.57 (m, 1H), 2.78 - 2.65 (m, 2H), 2.57 (br d, J = 11.2 Hz, 2H), 2.39 -2.26 (m, 2H), 1.90 (br d, J = 12.4 Hz, 1H), 1.47 - 1.33 (m, 1H).
[0287] Example 8A: (4a S ,5a R ,12a S )-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide Add InCl3(1.2) eq The sample was dried under reduced pressure at 120°C, and then 0.5 M magnesium bromo(cyclobutyl) was slowly added to THF at -78°C. eq The resulting solution was stirred at -78°C for 15 min and then warmed to 25°C. The solution was stirred at 25°C for 15 min, and then (4a) was added. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq ) and Pd[P( t -Bu)3]2(0.1 eq The reaction mixture was stirred at 70°C for 2 hours. The reaction mixture was quenched with H2O (2 mL) and concentrated under reduced pressure. The residue was purified by preparative HPLC and further purified by SFC (column: DAICEL CHIRALCEL OD-H (250 mm * 30 mm, 5 μm); mobile phase: [0.1% NH3H2OETOH]; B%: 30%-30%, min). A yellow solid (4a) was obtained. S ,5a R ,12a S )-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (7% yield). LC-MS (ESI) + m / z: 426.0 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6): δ 14.94 (s, 1H), 11.61 (s,1H), 8.99-8.76 (m, 2H), 7.41(d, J = 8.8 Hz, 1H), 6.80 (d, J= 8.8 Hz, 1H), 6.71(s, 1H), 3.60-3.45 (m, 1H), 3.25-3.01 (m, 1H), 2.95-2.60 (m, 3H), 2.45-2.10(m, 5H), 2.05-1.80 (m, 3H), 1.80-1.65 (m, 1H), 1.60-1.31 (m, 1H).
[0288] Example 9A: (4a) S ,5a R ,12a S )-7-Cyclopropyl-3,10,12,12a-Tetrahydroxy-1,11-Dioxo-4a,5,5a,6-Tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide Add InCl3(1.2) eq The sample was dried under reduced pressure at 120°C, and then 0.5 M magnesium bromo(cyclopropyl) was slowly added to THF at -78°C. eq The resulting solution was stirred at -78°C for 15 min, then warmed to 25°C and stirred at 25°C for 15 min. Add (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq ) and Pd[P( t -Bu)3]2(0.2 eq The resulting solution was stirred at 70°C for 2 hours. The reaction mixture was quenched with H2O (0.5 mL) and concentrated under reduced pressure. The residue was purified by HPLC and further purified by SFC (column: DAICEL CHIRALCEL OD-H (250 mm * 30 mm, 5 μm); mobile phase: [0.1% NH3H2O ETOH]; B%: 40%-40%, min). A yellow solid (4a) was obtained. S ,5a R ,12a S )-7-Cyclopropyl-3,10,12,12a-Tetrahydroxy-1,11-Dioxo-4a,5,5a,6-Tetrahydro-4 H 2-Phenylene-2-carboxamide (19% yield). LC-MS (ESI) + m / z: 412.0 [M+H] + .1 H NMR (400 MHz, DMSO- d 6): δ 14.97 (s, 1H), 11.64 (s, 1H), 8.99-8.76 (m,2H), 7.22 (d, J = 8.8 Hz, 1H), 6.72 (d, J = 8.8 Hz, 1H), 6.68 (s, 1H), 3.25-3.00(m, 1H), 2.90-2.72 (m, 1H), 2.45-2.20 (m, 3H), 2.10-1.95 (m, 1H), 1.85-1.70(m, 1H), 1.60-1.33 (m, 1H), 0.95-0.65 (m, 2H), 0.65-0.40 (m, 2H).
[0289] Example 10A: (4 aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(2-methylpyrazol-3-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4) aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-iodo-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H 1 eq. of tetraphenyl-2-carboxamide, 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaneborane-2-yl)pyrazole (2.5 eq.), K3PO4 (2.5 eq.), and XantPhos-Pd-G3 (0.1 eq.) were added to a mixture of dioxane (6 mL) and H2O (2 mL). The reaction mixture was stirred at 80 °C under N2 for 10 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (HCl conditions). A yellow solid (4... aS 5 aR ,12 aS )-3,10,12,12 a-Tetrahydroxy-7-(2-methylpyrazol-3-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H 2-Phenylene-2-carboxamide (19% yield). LC-MS (ESI) + ) m / z : 452.0 (M+H) + . 1 H NMR (400 MHz, DMSO- d 6): δ 14.98 (s, 1H), 11.89 (s, 1H), 8.95-8.75 (m, 2H), 7.50-7.43 (m, 2H), 6.98-6.92 (m, 1H), 6.69 (br, 1H), 6.24-6.22 (m, 1H), 3.58 (s, 3H), 3.17-3.05(m, 1H), 2.82-2.78 (m, 1H), 2.42-2.30 (m, 4H), 1.90-1.88 (m, 1H), 1.42-1.38(m, 1H).
[0290] Example 11A: (4 aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(1-isopropylpyrazole-3-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide 3-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1 H 1 eq. of pyrazole was added to 10 mL of DMF, followed by 1.5 eq. of NaH. The reaction mixture was stirred at 25 °C for 30 min, and then... i-PrI (1.2 eq.), the reaction mixture was stirred at 25 °C for 11.5 h. The reaction mixture was quenched with H2O, diluted with EtOAc (100 mL), washed successively with H2O (30 mL x 2), brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to remove the solvent. 1-Isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)pyrazole (32.9% yield) was obtained as a pale yellow solid and used directly in the next step without further purification.
[0291] (4) aS 5 aR ,12 aS )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 1 eq. of tetraphenyl-2-carboxamide, 1-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)pyrazole (1.5 eq.), [2-(2-aminophenyl)phenyl]-methylsulfonyloxy-palladium; (5-diphenylphosphino-9,9-dimethyl-oxanthracene-4-yl)-diphenyl-phosphine (0.1 eq.), and K3PO4 (2 eq.) were added to a mixture of dioxane (6 mL) and H2O (3 mL). The reaction mixture was stirred at 80 °C under N2 for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (HCl conditions). Repurification by preparative HPLC yielded a yellow solid (4... aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(1-isopropylpyrazole-3-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H -Tetraphenyl-2-carboxamide (10% yield). LC-MS (ESI) + ) m / z 480.0 (M+H) + . 1 HNMR (400 MHz, DMSO- d 6): δ14.91 (br, 1H), 11.90 (br, 1H), 8.97-8.78 (m, 2H), 7.81-7.80 (m, 1H), 7.69-7.66 (m, 1H), 6.89-6.86 (m, 1H), 6.67 (br, 1H), 6.37(s, 1H), 4.55-4.47 (m, 1H), 3.26-3.20 (m, 1H), 2.75-2.72 (m, 2H), 2.40-2.33(m, 3H), 1.95-1.92 (m, 1H), 1.47-1.42 (m, 7H).
[0292] Example 12A: (4a S ,5a R ,12a S )-7-(3,6-dihydro-2 H (-pyran-4-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide Add 1.0 M LDA to THF, 14.98 mL, 3.0 eq Slowly add to the solution of tributyltinane (4.36 g, 14.98 mmol, 3.96 mL, 3.0 mL). eq A solution of tetrahydropyran-4-one (0.50 g, 4.99 mmol, 458.7 uL, 1.0 μL) in THF (30 mL) was added. The reaction mixture was cooled to -78 °C, and then tetrahydropyran-4-one (0.50 g, 4.99 mmol, 458.7 uL, 1.0 μL) was added. eq The reaction mixture was stirred at -78°C for 30 min. Then MeSO₂Cl (2.29 g, 19.98 mmol, 1.55 mL, 4.0 mmol) was added. eq ) and TEA (3.79 g, 37.46 mmol, 5.21 mL, 7.5 eq The reaction mixture was heated to 25°C and stirred at 25°C for 20 hours. The reaction mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 5 / 1). Tributyl(3,6-dihydro-2H-pyran-4-yl)stanane (700 mg, 37.5% yield) was given as a colorless oil. 1 H NMR (400 MHz, CDCl3): δ5.75 (s, 1H), 4.07 (s, 2H), 3.75-3.65 (m, 2H), 2.62 (s, 2H), 1.56-1.10 (m, 13H), 0.95-0.65 (m, 15H).
[0293] (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq ), Pd(dppf)Cl2(0.1 eq ), tributyl(3,6-dihydro-2) H -pyran-4-yl)stanane (1.2) eq ) and CuI (0.05) eq The solution in DMF (2 mL) was stirred at 70 °C for 8 hours. The reaction mixture was quenched with KF aqueous solution (1 M, 10 mL) and extracted with EtOAc. The combined organic layers were concentrated under reduced pressure. The residue was purified by preparative HPLC and further separated by SFC (column: DAICEL CHIRALCEL OD-H (250 mm * 30 mm, 5 μm); mobile phase: [0.1% NH3H2O ETOH]; B%: 55%-55%, min). A yellow solid (4a) was obtained. S ,5a R ,12a S )-7-(3,6-dihydro-2 H (-pyran-4-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (7% yield). LC-MS (ESI) + m / z: 454.0 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6): δ 14.85(s, 1H), 11.72 (s, 1H), 8.96-8.74 (m, 2H), 7.32 (d, J = 8.4 Hz, 1H), 6.81 (d, J=8.4 Hz, 1H), 6.68 (s, 1H), 5.59 (s, 1H), 4.15 (s, 2H), 3.79 (s, 2H), 3.20-3.00 (m, 1H), 2.90-2.60 (m, 3H), 2.45-2.21 (m, 4H), 2.15-1.88 (m, 2H), 1.55-1.30 (m, 1H).
[0294] Example 13A: (4a S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-tetrahydropyran-4-yl-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4a) S ,5a R ,12a S )-7-(3,6-dihydro-2 H (-pyran-4-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq ) and Pd / C (0.2 eq The reaction of (4a) in MeOH (3 mL) and EtOAc (3 mL) was stirred at 25 °C under a H2 balloon for 30 min. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC. A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-tetrahydropyran-4-yl-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (12% yield). LC-MS (ESI) + m / z: 456.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6): δ 14.91 (s,1H), 11.80 (s, 1H), 9.00 (s, 1H), 7.46 (d, J= 8.8 Hz, 1H), 6.84-6.81 (m, 2H), 4.05-3.85 (m, 2H), 3.6-3.39 (m, 2H), 3.30-3.10 (m, 2H), 2.55-2.40 (m, 2H), 2.40-2.25 (m, 1H), 2.15-2.00 (m, 1H), 1.85-1.70 (m, 1H), 1.65-1.40 (m, 4H).
[0295] Example 14A: (4 aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-7-(1,2,3,6-tetrahydropyridin-4-yl)-4 a ,5,5 a ,6-Tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide LDA (4 eq.) was added to THF (100 mL) at 0 °C, followed by the slow addition of tributyltin hydride (4 eq.) at 0 °C. The reaction mixture was then cooled to -78 °C, and 4-oxopiperidin-1-carboxylic acid was added at -78 °C. Uncle Butyl ester (1 eq.). The reaction mixture was heated to 25 °C, and then methanesulfonyl chloride (8 eq.) and TEA were added to the reaction mixture. The reaction mixture was stirred at 25 °C for 12 hours. The reaction mixture was quenched with KF (aqueous solution), transferred to a separatory funnel containing hexane (100 mL), and washed with water (3 × 100 mL) (using brine to separate the emulsion). The combined aqueous layers were extracted with hexane (100 mL), and the combined organic layers were washed with brine (30 mL) and concentrated under reduced pressure. The crude reaction mixture was purified by silica gel column chromatography. 4-Tributyltinyl-3,6-dihydro-2-butyltinyl ester was given as a grayish-white oil. H -pyridine-1-carboxylic acid Uncle Butyl ester (34% yield).
[0296] (4) aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-iodo-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H-tetraphenyl-2-carboxamide (1 eq.), 4-tributyltinyl-3,6-dihydro-2 H -pyridine-1-carboxylic acid Uncle Butyl ester (1.2 eq.), Pd(dppf)Cl2 (0.1 eq.), and CuI (0.05 eq.) were added to DMF (3 mL), and the reaction mixture was stirred at 70 °C under N2 for 10 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (HCl). 4-[(6-] aS 10 aS ,11 aR )-8-carbamoyl-4,6,6 a 9-Tetrahydroxy-5,7-dioxo-10 a ,11,11 a ,12-Tetrahydro-10 H [-[-tetraphenyl-1-yl]-3,6-dihydro-2- H -pyridine-1-carboxylic acid Uncle Butyl ester (32% yield). LC-MS (ESI) + ) m / z 553.0 (M+H) + .
[0297] 4-[(6) aS 10 aS ,11 aR )-8-carbamoyl-4,6,6 a 9-Tetrahydroxy-5,7-dioxo-10 a ,11,11a,12-tetrahydro-10 H [-[-tetraphenyl-1-yl]-3,6-dihydro-2-] H -pyridine-1-carboxylic acid Uncle Butyl ester (1 eq.) was added to 4M HCl / MeOH (2 mL), and the reaction was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (HCl). A yellow solid (4...) was obtained. aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-7-(1,2,3,6-tetrahydropyridin-4-yl)-4 a ,5,5 a ,6-Tetrahydro-4 H HCl salt of 2-benzoxyl-2-carboxamide (44% yield). LC-MS (ESI) + ) m / z: 453.0 (M+H) + . 1 H NMR (400 MHz, DMSO- d 6): δ 13.92 (br, 1H), 9.15 (s, 1H), 8.19 (s, 1H), 7.10-6.66 (m, 2H), 5.48 (s, 1H), 3.65 (s, 2H), 3.01-2.98 (m, 1H), 2.77-2.63 (m, 3H), 2.26-2.12 (m, 6H), 1.81-1.78 (m, 1H), 1.48-1.44 (m, 1H).
[0298] Example 15A: (4 aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(1-methyl-3,6-dihydro-2- H (-pyridin-4-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4) aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-7-(1,2,3,6-tetrahydropyridin-4-yl)-4 a ,5,5 a ,6-Tetrahydro-4 H 1 eq. of tetraphenyl-2-carboxamide was added to THF (2 mL), followed by 10 eq. of HCHO, and then 2 eq. of NaBH3CN. The reaction mixture was stirred at 25 °C for 2 hours. The reaction mixture was quenched with 2N HCl and then concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (HCOOH conditions). A yellow solid (4 eq.) was obtained. aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(1-methyl-3,6-dihydro-2- H (-pyridin-4-yl)-1,11-dioxo-4 a ,5,5 a,6-Tetrahydro-4 H -Tetraphenyl-2-carboxamide (49% yield). LC-MS (ESI) + ) m / z 467.0 (M+H) + . 1 H NMR (400 MHz, DMSO- d 6): δ 12.34 (br, 1H), 9.06 (s, 1H), 8.69 (s,1H), 8.15 (s, 1H), 3.93-3.90 (m, 4H), 3.10-3.07 (m, 4H), 2.82 (s, 3H).
[0299] Example 16A: (4a S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[(1 S* [-2,2,2-trifluoro-1-methyl-ethyl]-4a,5,5a,6-tetrahydro-4 H -tetraphenyl-2-carboxamide and (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[(1 R* [-2,2,2-trifluoro-1-methyl-ethyl]-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (*Randomly assigned stereochemistry) Synthesis and characterization (4) aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-iodo-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H 1 eq of tetraphenyl-2-carboxamide, 1 eq of tributyl-[1-(trifluoromethyl)vinyl]stanane, 0.2 eq. of Pd(dppf)Cl2, and 0.1 eq. of CuI were added to DMF (2 mL). The reaction mixture was stirred at 90 °C under N2 for 8 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (HCl conditions). A yellow solid (4...) was obtained. aS 5 aR,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-7-[1-(trifluoromethyl)vinyl]-4 a ,5,5 a ,6-Tetrahydro-4 H 2-Phenylene-2-carboxamide (22% yield). LC-MS (ESI) + ) m / z 465.9 (M+H) + . 1 H NMR (400 MHz, MeOD): δ 7.36-7.33 (m, 1H), 6.88-6.85 (m, 1H), 6.20 (s, 1H), 5.60 (s, 1H), 3.29-3.22 (m, 1H), 2.92-2.84 (m, 2H), 2.49-2.36 (m, 3H), 2.06-2.01 (m, 1H), 1.62-1.30 (m, 1H).
[0300] (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[1-(trifluoromethyl)vinyl]-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq ) and Pd(OH)2(0.1 eq The solution in MeOH (5 mL) was stirred at 25 °C under a H2 balloon for 2 h. The reaction mixture was filtered and concentrated under reduced pressure to give crude compound 16-2. The residue was purified by SFC (column: DAICL CHIRALPAK IG (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH3H2OETOH]; B%: 50%-50%, min) to give compound 16A with a retention time of 1.021 min and compound 16B with a retention time of 2.050 min. As indicated by asterisks, the absolute stereochemistry of the stereocenters produced by 16A or 16B is not determined and is randomly assigned in the figure to indicate that they are different stereoisomers.
[0301] Compound 16A, which is a yellow solid, was obtained: (4a S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[(1 S*[-2,2,2-trifluoro-1-methyl-ethyl]-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (8% yield). LC-MS (ESI) + m / z: 468.1 (M+H) + . 1 H NMR (400 MHz, MeOD) δ 7.58 (d, J = 8.8 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 4.10-3.85 (m, 1H), 3.35-3.07 (m, 2H), 2.93–2.75(m, 1H), 2.65–2.35 (m, 2H), 2.35–2.18 (m, 1H), 2.15-2.00 (m, 1H), 1.70-1.55(m, 1H), 1.51 (d, J = 7.2 Hz, 3H). (*Randomly assigned stereochemistry) Compound 16B (4a) was obtained as a yellow solid. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[(1 R* [-2,2,2-trifluoro-1-methyl-ethyl]-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (11% yield). LC-MS (ESI) + m / z: 468.1 (M+H) + . 1 H NMR (400 MHz, MeOD) δ 7.56 (d, J = 8.8 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 4.07-3.85 (m, 1H), 3.35-3.10 (m, 2H), 2.90–2.75(m, 1H), 2.55–2.25 (m, 3H), 2.23–1.95 (m, 1H), 1.70-1.55 (m, 1H), 1.32 (d, J =7.2 Hz, 3H). (*Randomly specified stereochemistry).
[0302] Example 17A: (Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-methylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)isoxazole (1.5%) eq ), (4a S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq XantPhos Pd G3 (0.1) eq ) and K3PO4 (2.0 eq The reaction mixture in dioxane (2 mL) and H₂O (1 mL) was stirred at 90 °C for 3 hours. The reaction mixture was diluted with H₂O (10 mL) and extracted with EtOAc (10 mL x 3). The combined layers were concentrated under reduced pressure. The residue was purified by preparative HPLC. A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-(3-methylisoxazol-5-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (9% yield). LC-MS (ESI) + ) m / z : 453.2 (M+H) + HPLC: 98.0% purity at 254 nm. 1 H NMR (400 MHz, CD3OD) δ ppm 7.72 (d, J = 8.8 Hz, 1H), 6.93 (d, J = 8.8Hz, 1H), 6.39 (s, 1H), 3.33-3.05 (m, 2 H), 2.95-2.75 (m, 1H), 2.60-2.35 (m, 3H), 2.33 (s, 3 H), 2.08-1.95 (m, 1 H), 1.61 (q, J = 11.8 Hz, 1 H).
[0303] Example 18A: Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-vinyl-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide CuI (0.1 eq.) was added to a solution of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (1 eq.), tributyl(vinyl)stanane (2 eq.), and Pd(dppf)Cl2 (0.1 eq.) in toluene (2 mL) at 20 °C. The mixture was purged with N2 and degassed three times, and then stirred at 100 °C for 6 h. The reaction mixture was cooled to 20 °C, quenched with saturated KF solution (20 mL), and extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by preparative HPLC. A yellow solid (4aS,5aR,12aS) was obtained. S , 5a R , 12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-vinyl-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (14% yield). LC-MS (ESI) + ) m / z 398.0 (M+H) + HPLC: 99.7% purity at 254 nm. 1 H NMR (400 MHz, DMSO- d 6): δ 14.92 (br s, 1H), 11.88 (s, 1H), 9.30 - 8.56 (m,2H), 7.70 (br d, J = 8.8 Hz, 1H), 6.93 - 6.81 (m, 2H), 6.79 - 6.62 (m, 1H), 5.60 (br d, J = 17.2 Hz, 1H), 5.27 (br d, J = 11.2 Hz, 1H), 3.23 - 3.11 (m, 1H), 3.07 (br dd, J= 4.0, 15.6 Hz, 1H), 2.86 - 2.73 (m, 1H), 2.44 - 2.36 (m, 2H), 2.35 - 2.21 (m, 2H), 2.05 - 1.97 (m, 1H), 1.52 - 1.39 (m, 1H).
[0304] At 20℃ towards (4a) S , 5a R , 12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-vinyl-4a,5,5a,6-tetrahydro-4 H 1 eq. of tetraphenyl-2-carboxamide was added to a solution of EtOH (2 mL) with Pd / C (0.5 eq.), and the mixture was purged with H2 and degassed three times, and then stirred at 20 °C under H2 (15 Psi) for 2 h. The reaction mixture was filtered to remove Pd / C, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC. A yellow solid (4a) was obtained. S ,5a R ,12aS)-7-ethyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 2-(25%) tetraphenyl-2-carboxamide. LC-MS (ESI) + ) m / z 400.0 (M+H) + HPLC: 93.4% purity at 254 nm. 1 H NMR (400 MHz, CD3CN): δ 14.94 (s, 1H), 11.71 (s, 1H), 9.01 (br d, J = 2.4 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 6.77 (br d, J = 8.6 Hz, 2H), 4.70 (br d, J = 4.6 Hz, 1H), 3.22 (br dd, J = 6.6, 18.8 Hz, 1H), 3.02 (dd, J =4.3, 15.9 Hz, 1H), 2.87 (dq, J= 4.4, 9.4 Hz, 1H), 2.63 - 2.56 (m, 2H), 2.55 -2.46 (m, 2H), 2.33 (br d, J = 15.3 Hz, 3H), 1.68 - 1.58 (m, 1H), 1.13 (t, J = 7.4Hz, 3H).
[0305] Example 19A: Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(1-methyl-1H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide To (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H A mixture of β-tetraphenyl-2-carboxamide (500 mg, 1.01 mmol, 1.0 eq), ethynyl(trimethyl)silane (395.1 mg, 4.0 mmol, 557.2 μL, 4.0 eq), and TEA (356.1 mg, 3.5 mmol, 489.9 μL, 3.5 eq) in DMF (5 mL) was supplemented with CuI (38.3 mg, 201.1 μmol, 0.2 eq) and Pd(PPh3)2Cl2 (141.2 mg, 201.1 μmol, 0.2 eq). The reaction mixture was degassed with N2 and purged three times, and stirred at 90 °C under N2 atmosphere for 2 h. TBAF (3.94 g, 15.08 mmol, 4.14 mL, 15 eq) was added. The mixture was stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure to obtain the residue. The crude product was purified by reverse-phase column chromatography to remove the catalyst, followed by preparative HPLC (column: YMC-Actus Triart C18 150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 38%-78%, 9 min). A yellow solid (4a) was obtained. S ,5a R ,12a S )-7-ethynyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (38% yield).
[0306] N2 downwards (4a) S ,5a R ,12a S A solution of 7-ethynyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (100 mg, 253 μol, 1.0 eq) and azidomethyl(trimethyl)silane (163.4 mg, 1.26 mmol, 187.9 μL, 5.0 eq) in DMSO (1.5 mL) was mixed with DIEA (65.4 mg, 505.9 μol, 88.1 μL, 2.0 eq) and CuI (9.6 mg, 50.6 μol, 0.2 eq). The mixture was stirred at 25 °C for 2 hours, and then TBAF (1 M, 1.52 mL, 6.0 eq) was added. The resulting solution was stirred at 25 °C for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain the residue. The residue was purified by preparative HPLC (column: YMC-ActusTriart C18 150*30mm*5um; mobile phase: [water (HCl)-ACN]; B%: 18%-58%, 9 min). A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-(1-methyltriazol-4-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (37.6% yield). LCMS: C 22 H 20 Calculated N4O7 value: 452.1, measured value: [M+H] + 453.1. 1 H NMR (400 MHz, MeOD) δ 8.01 (s, 1 H), 7.66 (d, J = 8.6 Hz, 1 H), 6.90(d, J = 8.4 Hz, 1 H), 4.15 (s, 3 H), 3.20 - 3.27 (m, 1 H), 3.05 (dd, J = 15.9,4.3 Hz, 1 H), 2.75 - 2.93 (m, 1 H), 2.31 - 2.56 (m, 3 H), 1.98 (br d, J= 13.4Hz, 1H), 1.48 - 1.67 (m, 1H), 1.20 - 1.42 (m, 1H).
[0307] Example 20A: Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(2-methyl-2H-1,2,3-triazol-4-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide Butyllithium (2.5 M, 2.5 mL) was added to a solution of 4-bromo-2-methyltriazole (500 mg, 3.1 mmol) in THF (5 mL), and the mixture was stirred at -78 °C under N2 for 0.5 h. Trimethyl borate (962 mg, 9.3 mmol) was then added, and the mixture was stirred at -78 °C and then heated to 25 °C under N2 for 16 h. The mixture was quenched with water (10 mL), filtered, and concentrated under reduced pressure to obtain the residue. The crude product (2-methyltriazole-4-yl)boronic acid was used in the next step without further purification. LC-MS (ESI) + ) m / z 128.0 (M+H) + .
[0308] (2-methyltriazol-4-yl)boronic acid (130 mg, 1 mmol), (4 aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-iodo-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H A mixture of 2-benzoxyl-2-carboxamide (101.4 mg, 204 μmol), Pd(dppf)Cl2 (74.6 mg, 102 μmol), and KOAc (300.3 mg, 3.1 mmol) in dioxane (2 mL) and H2O (0.2 mL) was degassed with N2 and purged three times. The mixture was then stirred at 80 °C under N2 atmosphere for 2 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The crude product was purified by preparative HPLC (HCl) to give a product as a yellow solid (4... aS 5 aR ,12 aS )-3,10,12,12 a-Tetrahydroxy-7-(2-methyltriazol-4-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H -2-benzoxyl-2-carboxamide (1% yield) MS: C 22 H 20 Calculated N4O7 value: 452.13, measured value: [M+H] + 453.1. 1 H NMR (DMSO- d 6, 400MHz): δ 14.9 (s, 1H), 11.92 (s, 1H), 8.60-9.15(m, 1H), 7.92 (s, 1H), 7.70(d, J = 8.8 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H),6.69 (s,1H), 4.18 (s, 3H), 2.99-3.10 (m, 2H), 2.74-2.82 (m,1H), 2.29-2.42 (m, 3H),1.95-2.03 (m, 2H), 1.43-1.50 (m, 1H).
[0309] Example 21A: Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-methyl-1,2,4-oxadiazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H A mixture of 2,5-dioxopyrrolidone (500 mg, 1.0 mmol), 1-hydroxypyrrolidone-2,5-dione (520.8 mg, 4.5 mmol), Pd(PPh3)4 (232.4 mg, 0.2 mmol), and DIEA (259.9 mg, 2.0 mmol, 0.35 mL) in NMP (3 mL) was stirred at 60 °C under CO (15 Psi) for 1 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue (2,5-dioxopyrrolidone-1-yl)(6a) as a yellow liquid. S ,10aS ,11a R )-8-carbamoyl-4,6,6a,9-tetrahydroxy-5,7-dioxo-10a,11,11a,12-tetrahydro-10 H 1,4-benzophenone-1-carboxylate (500 mg, 0.98 mmol) was used in the next step without further purification. LCMS: C 24 H 20 N2O 11 Calculated value: 512.11, Measured value: [M+H] + 512.9.
[0310] (2,5-dioxopyrrolidone-1-yl)(6a) S ,10a S ,11a R )-8-carbamoyl-4,6,6a,9-tetrahydroxy-5,7-dioxo-10a,11,11a,12-tetrahydro-10 H A mixture of 1,4-benzo[a]-tetraphenyl-1-carboxylate (500 mg, 0.98 mmol) and N-hydroxyacetamidine (159 mg, 2.2 mmol) in NMP (3 mL) was stirred at 25 °C for 12 hours. The crude product was concentrated under reduced pressure to obtain a residue. The crude product was purified by reversed-phase HPLC (FA). A yellow solid (6a) was obtained. S ,10a S ,11a R )-4,6,6a,9-Tetrahydroxy-N1-[( E [-N-hydroxy-C-methyl-carboimino]-5,7-dioxo-10a,11,11a,12-tetrahydro-10 H 1,8-Dibenzo-p-tetraphenyl-1,8-dicarboxamide (56% yield). LCMS: C 22 H 21 Calculated N3O9 value: 471.13, measured value: [M+H] + 472.3.
[0311] (6a) S ,10a S ,11a R )-4,6,6a,9-tetrahydroxy-N1-[( E [-N-hydroxy-C-methyl-carboimino]-5,7-dioxo-10a,11,11a,12-tetrahydro-10 HA mixture of 100 mg, 0.2 mmol benzo-1,8-dicarboxamide (4a) in dioxane (6 mL) was stirred at 130 °C for 8 hours. The mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC: Welch Ultimate C18 150 * 25 mm * 5 μm; mobile phase: [water (FA)-ACN]; B%: 34% - 64%, 10 min. A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-(3-methyl-1,2,4-oxadiazol-5-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 2-Phenylene-2-carboxamide (23%). LCMS: C 22 H 19 Calculated N3O8 value: 453.12, measured value: [M+H] + 453.9 1 H NMR (400MHz, acetonitrile-) d 3 ) δ= 14.75 (s, 1H), 12.47 (s, 1H), 9.01 (s, 1H), 8.11 (d, J = 8.8 Hz, 1H), 7.01(d, J = 8.8 Hz, 1H), 6.77 (s, 1H), 4.71 (s, 1H), 3.83 -3.77 (m, 1H), 3.25 -3.19 (m, 1H), 2.94 - 2.88 (m, 1H), 2.62 - 2.49 (m, 2H), 2.49 (s, 3H), 2.05(d, J = 13.6 Hz, 2H), 1.74 - 1.63 (m, 1H) Example 22A: Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (100 mg, 0.2 mmol) and Xantphos Pd G3 (19.1 mg, 20.1 μmol, 0.1 μmol) were added. eq ), 3-propane-2-yl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1,2-oxazole (71.5 mg, 0.3 mmol, 1.5 mg). eq ) and K3PO4 (213.5 mg, 1.0 mmol, 5 eq The mixture in DMF (2 mL) and H2O (0.5 mL) was degassed with N2 and purged three times, and then stirred at 60 °C under N2 atmosphere for 16 hours. It was then filtered and concentrated under reduced pressure to obtain the residue. The crude product was purified by reversed-phase HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water (TFA)-ACN]; B%: 28%-58%, 23 min). (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisooxazol-5-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetraphenyl-2-carboxamide (2% yield) was obtained as a white solid. LCMS: C 25 H 24 Calculated N₂O₈ value: 480.15, measured value: [M+H] + 481.1. 1 HNMR (400 MHz, methanol-d) 4 ) δ = 7.74 (d, J = 8.8 Hz, 1H), 7.04 - 6.89 (m, 1H), 6.52- 6.41 (m, 1H), 3.20 - 3.02 (m, 2H), 2.96 - 2.79 (m, 1H), 2.65 - 2.32 (m,3H), 2.13 - 1.93 (m, 1H), 1.71 - 1.52 (m, 1H), 1.46 - 1.23 (m, 7H).
[0312] Example 23A: (4) aS 5 aR ,12 aS )-3,12a-dihydroxy-10,12-dimethoxy- N , N-Dimethyl-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4) aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H 1 eq. of tetraphenyl-2-carboxamide was added to DMF (4 mL), followed by the addition of NaH (10 eq.). The reaction mixture was stirred at 20 °C for 30 min, then MeI (8 eq.) was added, and the mixture was stirred at 40 °C for 1 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (HCl conditions). A yellow solid (4 eq.) was obtained. aS 5 aR ,12 aS )-3,12a-dihydroxy-10,12-dimethoxy- N , N -Dimethyl-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H -Tetraphenyl-2-carboxamide (17% yield). LC-MS (ESI) + ) m / z : 428.1 (M+H) + LCMS: C 23 H 25 Calculated value of NO7: 427.2, Measured value: [M+H] + 428.1. HPLC: 97.2% purity at 254 nm. 1 H NMR (400 MHz, DMSO- d 6): δ 7.50–7.44 (m, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.87 (d, J= 7.6 Hz, 1H), 3.83(s, 3H), 3.26 (s, 3H), 2.96-2.94 (m, 1H), 2.82 (s, 6H), 2.78-2.68 (m, 3H),2.40-2.28 (m, 2H), 2.04-2.02 (m, 1H), 1.47-1.38 (m, 1H).
[0313] Example 24A: Synthesis and characterization of (4aS,5aR,12aS)-3,12,12a-trihydroxy-10-methoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide (4) aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H 1 eq. of tetraphenyl-2-carboxamide was stirred in DMF (2 mL), NaH (2 eq.) was added, and the reaction mixture was stirred at 25 °C for 15 min, followed by the addition of MeI (1.5 eq). The reaction mixture was stirred at 60 °C for 45 min. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (HCl conditions). A yellow solid (4 eq) was obtained. aS 5 aR ,12 aS )-3,12,12 a -trihydroxy-10-methoxy-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H -Tetraphenyl-2-carboxamide (11% yield). LC-MS (ESI) + ) m / z 386.0 (M+H) + HPLC: 93.3% purity at 254 nm. 1 HNMR (400 MHz, DMSO- d 6): δ 8.93 (br, 1H), 8.71 (br, 1H), 7.48-7.44 (m, 1H), 7.03(d, J = 8.0 Hz, 1H), 6.87 (d, J= 8.0 Hz, 1H), 6.53 (br, 1H), 3.83 (s, 3H), 3.14-3.10 (m, 1H), 2.74-2.68 (m, 2H), 2.43-2.34 (m, 3H), 1.99-1.96 (m, 1H), 1.44-1.34 (m, 1H).
[0314] Example 25A: Synthesis and Characterization of (4aS,5aR,12aS)-12,12a-dihydroxy-3,10-dimethoxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide (4) aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 1 eq. of tetraphenyl-2-carboxamide was stirred in DMF (4 mL), then NaH (5 eq.) was added, and the reaction mixture was stirred at 2 °C for 15 min, followed by the addition of MeI (4 eq.). The reaction mixture was stirred at 60 °C for 45 min. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (HCl conditions). A yellow solid (4 eq.) was obtained. aS 5 aR ,12 aS )-12,12 a -Dihydroxy-3,10-dimethoxy-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H -Tetraphenyl-2-carboxamide (12% yield). LC-MS (ESI) + ) m / z 400.0 (M+H) + HPLC: 98.4% purity at 254 nm. 1 H NMR (400 MHz, DMSO- d 6): δ 8.96-8.82 (m, 2H), 7.48-7.44 (m, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.87 (d, J= 7.6 Hz, 1H), 3.83 (s, 3H), 3.25 (s, 3H), 3.03-2.98(m, 1H), 2.74-2.68 (m, 2H), 2.43-2.34 (m, 3H), 2.07-2.01 (m, 1H), 1.47-1.34(m, 1H).
[0315] Example 26A: Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-(2-(pyrrolidone-1-yl)acetamido)-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide hydrochloride KNO3(1.5) was added at 0℃. eq Slowly add to (4) S ,4a S ,5a R ,12a S )-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (1.0 eq A solution of H2SO4 (8 mL) was prepared. The reaction mixture was stirred at 0 °C for 2 h. The reaction mixture was added dropwise to a stirred solution of cold petroleum ether (150 mL). The obtained solid was filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC to give a yellow solid (4... S ,4a S ,5a R ,12a S )-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (45% yield). LC-MS (ESI+) m / z: 460.0 (M+H) + .
[0316] To (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq Add Pd(OH)₂ (0.1g) to a solution of dioxane (2 mL) and MeOH (2 mL). eqThe mixture was degassed with H2 and purged three times, then stirred at 25°C under H2 atmosphere for 30 minutes. The reaction mixture was filtered and concentrated under reduced pressure. A red solid (12a) was obtained. S )-9-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (37% yield). LC-MS (ESI) + m / z: 386.9 (M+H) + . 1 H NMR (400MHz, DMSO- d 6): δ 15.06 (brs, 1H), 11.62 (brs, 1H), 9.11-8.59 (m, 2H), 6.80 (d, J = 7.6 Hz, 1H), 6.62 (brs, 1H), 6.51 (d, J = 7.6 Hz, 1H), 5.34-4.37 (m,2H), 3.12 (d, J = 16.0 Hz, 1H), 2.83-2.73 (m, 1H), 2.62 (dd, J = 4.4, 15.1 Hz,2H), 2.42-2.22 (m, 3H), 1.94 (d, J = 8.8 Hz, 1H), 1.46-1.34 (m, 1H).
[0317] At 25°C, 2-pyrrolidone-1-ylacetic acid (1.0...) eq Add DMF (0.1 g) to the DCM (3 mL) solution. eq ) and oxalyl chloride (2.0) eq The mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated under reduced pressure. 2-Pyrrolidine-1-ylacetyl chloride was given as a white solid (95% yield).
[0318] To (4a) S ,5a R ,12a S )-9-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq Add NaHCO3 (10.0g) to a solution of H2O (2 mL) and CH3CN (1 mL). eq) and 2-pyrrolidine-1-ylacetyl chloride (6.0) eq The mixture was stirred at 25°C for 4 hours. The reaction mixture was filtered and concentrated under reduced pressure, and separated by SFC (column: DAICEL CHIRALCEL OJ (250mm*30mm, 10µm); mobile phase: [0.1% NH3H2O ETOH]; B%: 50%-50%, min). A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(2-pyrrolidine-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4 H 2-(21%) tetraphenyl-2-carboxamide. LC-MS (ESI) + m / z: 498.1 (M+H) + . 1 H NMR (400MHz, MeOD): δ8.26 (d, J = 8.0 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 3.42 (s, 2H), 3.24 (dd, J =6.0, 18.1 Hz, 1H), 2.87 (d, J = 9.6 Hz, 1H), 2.80 (s, 5H), 2.53-2.34 (m, 3H), 2.02 (d, J = 9.2 Hz, 1H).
[0319] Example 27A: Synthesis and Characterization of (4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide At 25℃, towards 2-( Uncle Butylated amino)acetic acid (1.0) eq Add DMF (0.1 g) to the DCM (3 mL) solution. eq ) and oxalyl chloride (2.0) eq The mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated under reduced pressure. 2-( Uncle Butylaminoacetyl chloride (83% yield) can be used without further purification.
[0320] To (4a) S ,5a R ,12a S )-9-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (1.0) eq Add NaHCO3 (10.0g) to a solution of H2O (2 mL) and CH3CN (1 mL). eq ) and 2-( Uncle Butylamino)acetyl chloride (6.0) eq The mixture was stirred at 25°C for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure, then purified by preparative HPLC. A yellow solid (4a) was obtained. S ,5a R ,12a S )-9-(2-(tert-butylamino)acetamido)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetraphenyl-2-carboxamide (26% yield). LC-MS (ESI) + m / z: 500.1 (M+H) + HPLC: 98.5% purity at 254 nm. 1 H NMR (400MHz, MeOD): δ 8.18 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 8.0 Hz,1H), 4.06 (s, 2H), 3.35-3.16 (m, 1H), 3.01-2.72 (m, 2H), 2.58-2.30 (m, 3H), 2.10-1.98 (m, 1H), 1.65-1.47 (m, 1H), 1.43 (s, 9 H).
[0321] Example 28A: Synthesis and characterization of (5aS,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,5,5a,6,11,12a-hexahydrotetraphenyl-2-carboxamide (1S,4aS,11aR,12aS)-3-carbamoyl-2,4a,5,7-tetrahydroxy-N,N,N-trimethyl-4,6-dioxo-1,4,4a,6,11,11a,12,12a-octahydrotetraphenyl-1-ammonium iodide (1.0) eq) and NaN3 (11.7 mg, 179.7 μmol, 2.0 μmol) eq The solution of 5a in NMP (2 mL) was stirred at 100 °C for 16 hours. The reaction mixture was extracted with EtOAc (3 mL) and concentrated under reduced pressure. The residue was purified by preparative HPLC. A yellow solid (5a) was obtained. S ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-5a,6-dihydro-5 H -Tetraphenyl-2-carboxamide (38% yield). LCMS: C 19 H 15 NO7 calculated value: 369.1, measured value: [M+H] + 370.0. HPLC: 94.9% purity at 254 nm. 1 H NMR (400MHz, DMSO- d 6): δ 11.9 (s, 1H), 9.36 (s, 1H), 9.50-8.90 (m, 2H), 7.70-7.50 (m,1H), 7.04-6.90 (m, 2 H), 6.53 (s, 1H), 3.91 (s, 1H), 3.35-3.00 (m, 3H), 2.90-2.74 (m, 1H), 2.45-2.30 (m, 1H), 1.75-1.58 (m, 1H).
[0322] Example 29A: (4aS,12aS)-7-(cyclopenten-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4) aS ,12 aS )-3,10,11,12a-tetrahydroxy-7-iodo-1,12-dioxo-4 a ,5-dihydro-4 H 2-(cyclopenten-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaneborane (156.8 mg, 808 μmol, 5 μmol) eq ), K2CO3 (111.6 mg, 808 umol, 5 eq ) and Pd(PPh3)4 (18.7 mg, 16.2 μmol, 0.1 μmol) eq The mixture in DMF (1.0 mL) and H2O (1.0 mL) was degassed with N2 and purged three times, and then stirred at 70 °C under N2 atmosphere for 16 hours. It was then filtered and concentrated under reduced pressure to obtain the residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 200*40mm*10um; mobile phase: [water (TFA)-ACN]; B%: 40%-70%, 10 min). A yellow solid (4aS,12aS)-7-(cyclopenten-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4aS was obtained. H 2-Phenylene-2-carboxamide (28% yield). LCMS: C 24 H 21 Calculated value of NO7: 435.13, Measured value: [M+H] + 436.0. 1 H NMR (400 MHz, CD3OD- d 4) δ 7.31 - 7.25 (m, 1H),7.24 - 7.21 (m, 1H), 6.71 - 6.64 (m, 1H), 5.72 - 5.66 (m, 1H), 3.40 - 3.28(m, 1H), 2.95 - 2.81 (m, 2H), 2.78 - 2.72 (m, 1H), 2.64 - 2.57 (m, 2H), 2.53 - 2.48 (m, 2H), 2.46 - 2.39 (m, 1H), 2.05 - 1.95 (m, 2H).
[0323] Example 30A: Synthesis and characterization of (4aS,12aS)-7-cyclopentyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (4aS,12aS)-7-(cyclopenten-1-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4 H 2-Phenylene-2-carboxamide (25 mg, 57.4 μmol, 1) eq ) and Pd(OH)2 / C (8.1 mg, 57.4 μmol, 1 eqThe mixture in dioxane (0.5 mL) was degassed with H2 and purged three times, and then stirred at 25 °C under an H2 atmosphere for 0.5 h. It was then filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water (HCl)-ACN]; B%: 45%-75%, 17 min). (4aS,12aS)-7-cyclopentyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (29% yield) was obtained as a yellow solid. LCMS: C 24 H 23 Calculated value of NO7: 437.15, Measured value: [M+H] + 438.0. 1 HNMR (400 MHz, CD3CN- d 3) δ 15.08 - 14.93 (m, 1H), 9.55 (s, 1H), 9.04 - 8.94 (m,1H), 7.60 - 7.53 (m, 1H), 7.51 - 7.46 (m, 1H), 6.93 - 6.86 (m, 1H), 6.84 -6.81 (m, 1H), 5.20 - 5.12 (m, 1H), 3.62 - 3.55 (m, 1H), 3.55 - 3.47 (m, 1H), 3.09 - 2.98 (m, 1H), 2.96 - 2.87 (m, 2H), 2.73 - 2.59 (m, 1H), 1.83 - 1.74(m, 5H), 1.72 - 1.60 (m, 4H).
[0324] Example 31A: Synthesis and characterization of (4aS,12aS)-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-tetrahydropyran-4-yl-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (4aS,12aS)-3,10,11,12a-tetrahydroxy-7-iodo-1,12-dioxo-4a,5-dihydro-4 H -Tetraphenyl-2-carboxamide (100 mg, 201.9 μmol, 1) eq ), 2-(3,6-dihydro-2 H(-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxane (212 mg, 1.0 mmol, 5 eq ), K2CO3 (139.5 mg, 1.0 mmol, 5 eq ) and Pd(PPh3)4 (23.3 mg, 20.2 μmol, 0.1 μmol) eq The mixture in DMF (1.0 mL) and H2O (1.0 mL) was degassed with N2 and purged three times, and then stirred at 70 °C under N2 atmosphere for 2 hours. It was then filtered and concentrated under reduced pressure to obtain the residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 200*40mm*10um; mobile phase: [water (TFA)-ACN]; B%: 40%-60%, 10 min). (4aS,12aS)-7-(3,6-dihydro-2H-pyran-4-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (22% yield) was obtained as a yellow solid.
[0325] (4aS,12aS)-7-(3,6-dihydro-2H-pyran-4-yl)-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (15 mg, 33.2 μmol, 1) eq ) and Pd(OH)2 (4.7 mg, 33.3 μmol, 1 eq A mixture of dioxane (0.5 mL) and MeOH (0.5 mL) was degassed with H2 and purged three times, and then stirred at 25 °C under an H2 atmosphere for 1 hour. The mixture was then filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water (HCl)-ACN]; B%: 22%-52%, 17 min). (4aS,12aS)-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-tetrahydropyran-4-yl-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (23% yield) was obtained as a yellow solid. LCMS: C 24 H 23 Calculated value of NO8: 453.14, Measured value: [M+H] + 454.0. 1¹H NMR (400 MHz, acetonitrile-d³) δ = 15.09 - 14.96 (m, 1H), 9.67 - 9.54 (m, 1H), 9.09 - 8.93 (m, 1H), 7.54 (d, J = 8.3 Hz, 1H),7.48 (s, 1H), 6.96 - 6.89 (m, 1H), 6.85 (d, J = 8.3 Hz, 1H), 5.26 - 5.11 (m,1H), 4.09 - 3.99 (m, 2H), 3.71 - 3.60 (m, 2H), 3.57 - 3.47 (m, 1H), 3.46 -3.36 (m, 1H), 3.10 - 2.99 (m, 1H), 2.90 (br s, 2H), 2.72 - 2.59 (m, 1H), 1.86 - 1.75 (m, 5H).
[0326] Example 32A: (4a S ,12a S Synthesis and characterization of 7-cyclobutyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide Indium trichloride (201 mg, 909 μmol, 58 μL, 1.5 μg / L) was added. eq ) and cyclobutylmagnesium bromide (434 mg, 2.7 mmol, 4.5 mmol) eq Mix at -78°C for 15 minutes, and then add bis(tri-tert-butylphosphine)palladium (61.9 mg, 121 μmol, 0.2 μg) to the mixture at 25°C for 15 minutes. eq ) and (4a S ,12a S 3,10,11,12a-tetrahydroxy-7-iodo-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (300 mg, 606 μmol, 1.0 μg) eq The mixture was stirred at 70°C for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 100*30mm*4um; mobile phase: [water (HCl)-ACN]; B%: 62%-92%, 9.5 min). A yellow solid (4a) was obtained. S ,12a S7-Cyclobutyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (41% yield). LC-MS (ESI) + ) m / z 424.0 (M+H) + LCMS: C 23 H 21 NO7 calculated value: 423.1, measured value: [M+H] + 424.0. 1H NMR (400 MHz, CD3OD- d 4) δ 7.42 (d, J = 8.1 Hz, 1H), 7.25 -7.16 (m, 1H), 6.90 - 6.68 (m, 1H), 4.01 - 3.85 (m, 1H), 3.49 - 3.41 (m, 1H), 3.07 - 2.96 (m, 2H), 2.90 - 2.82 (m, 1H), 2.59 - 2.42 (m, 3H), 2.24 - 2.09 (m, 3H), 1.94 - 1.81 (m, 1H).
[0327] Example 33A: Synthesis and characterization of (4aS, 12aS)-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-[1-(trifluoromethyl)vinyl]-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (12aS)-3,10,11,12a-tetrahydroxy-7-iodo-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (250 mg, 505 μmol, 1) eq Tributyl-[1-(trifluoromethyl)vinyl]stanane (583 mg, 1.5 mmol, 3) eq ), CuI (14.4 mg, 75.7 umol, 0.15 eq ), Pd(PPh3)2Cl2(53.2 mg, 75.7 umol, 0.15 eq The mixture in DMF (8 mL) was degassed and purged three times with N2, and then stirred at 70 °C under N2 atmosphere for 5 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The residue was then subjected to... PreparativePurification was performed by HPLC (column: Phenomenex Synergi C18 100*30mm*4um; mobile phase: [water (HCl)-ACN]; B%: 45%-75%, 8 min). A yellow solid (4aS, 12aS)-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-[1-(trifluoromethyl)vinyl]-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (27% yield) was obtained. LC-MS (ESI) - m / z: 462.0 (M-1) - LCMS: C 28 H 31 Calculated N₅O₈: 463.36, Measured: [MH] - 462.0. 1 H NMR (400 MHz, methanol-) d 4) δ ppm2.38 - 2.50 (m, 1 H) 2.71 - 2.81 (m, 1 H) 2.83 - 2.97 (m, 2 H) 3.28 - 3.35(m, 1 H) 5.55 - 5.61 (m, 1 H) 6.14 - 6.28 (m, 1 H) 6.68 - 6.84 (m, 1 H) 6.98- 7.15 (m, 1 H) 7.29 - 7.43 (m, 1 H) Example 34A: Synthesis and characterization of (12aS)-3,10,11,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide 3-Isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)isoxazole (96 mg, 404 μmol, 2) eq ), Pd(t-Bu3P)2(10.3 mg, 20.2 umol, 0.1 eq ), K3PO4 (107 mg, 505 umol, 2.5 eq The mixture in dioxane (4 mL) and H₂O (2 mL) was degassed with N₂ and purged three times, and then stirred at 80 °C under N₂ atmosphere for 4 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The residue was then subjected to... PreparativePurification was performed by HPLC (column: Phenomenex Synergi C18 100*30mm*4um; mobile phase: [water (HCl)-ACN]; B%: 55%-85%, 7.8 min). A yellow solid (12aS)-3,10,11,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,12-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (18% yield) was obtained. LC-MS (ESI) + m / z: 479.0 (M+H) + LCMS: C 25 H 22 Calculated N₂O₈ value: 478.1, measured value: [M+H] + 479.0. 1 H NMR (400MHz, DMSO- d 6) δ ppm 1.13 - 1.25 (m, 1 H) 1.28 - 1.31 (m, 3 H) 1.31 - 1.33 (m, 3 H) 2.81 - 2.87 (m, 1 H) 2.94 - 3.03 (m, 2 H) 3.05 - 3.17 (m, 2 H) 6.81 -6.86 (m, 1 H) 6.90 - 6.99 (m, 1 H) 7.36 - 7.47 (m, 1 H) 7.79 - 7.90 (m, 1 H)8.79 - 9.17 (m, 2 H).
[0328] Example 35A: Synthesis and characterization of (4aS, 12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropyltriazol-1-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (4S,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (5.0 g, 12.1 mmol, 1 eq ) and dibenzyl azodicarbonate (4.32 g, 14.48 mmol, 1.2 g) eq The solution was dissolved in TFA (100 mL), and the mixture was then stirred at 0 °C for 8 hours. The reaction mixture was concentrated under reduced pressure to obtain a residue. A yellow solid was obtained. N-[(6aS,10S)-8-carbamoyl-10-(dimethylamino)-4,6,6a,9-tetrahydroxy-5,7-dioxo-10a,11,11a,12-tetrahydro-10H-benzotetraphenyl-1-yl]-N-(benzyloxycarbonylamino)carbamate (8.6 g). LC-MS (ESI) + m / z: 713.2 (M+H) + The crude compound is used in the next step.
[0329] Will N -[(6aS,10S)-8-carbamoyl-10-(dimethylamino)-4,6,6a,9-tetrahydroxy-5,7-dioxo-10a,11,11a,12-tetrahydro-10H-tetraphenyl-1-yl]-N-(benzyloxycarbonylamino)carbamate (8.0 g, 11.2 mmol, 1 eq ) and Pd / C (1.2 g, 1.1 mmol, 10%, 0.1 eq The mixture in MeOH (100 mL) was stirred at 25 °C under a H2 atmosphere for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The residue was then subjected to... Preparative Purification was performed by HPLC (column: Welch Xtimate C18 100*40mm*3um; mobile phase: [water (HCl)-ACN]; B%: 0%-25%, 8 min). A red solid (4S,12aS)-7-amino-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (62.2% yield) was obtained. LC-MS (ESI) + m / z: 430.0 (M+H) + .
[0330] (4S,12aS)-7-amino-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (2.8 g, 6.5 mmol, 1 eq ), Fluoroboric acid aqueous solution (3.6 g, 19.6 mmol, 2.5 mL, 48%, 3) eq ), nitrite Uncle Butyl ester (1.0 g, 9.8 mmol, 1.2 mL, 1.5 mmol) eq ) and NaN3 (466.3 mg, 7.2 mmol, 1.1 eqThe mixture in MeOH (70.00 mL) was degassed with N2 and purged three times, and then stirred at 0 °C under N2 atmosphere for 6 hours. The reaction mixture was filtered to remove solids, and the filtrate was dried under reduced pressure to give a residue. The reaction mixture was stirred with diethyl ether (200 mL), then filtered to remove the solvent to give a residue. (4S,12aS)-7-azido-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetraphenyl-2-carboxamide (84% yield) was given as a red solid. LC-MS (ESI) + m / z: 456.0 (M+H) + .
[0331] 3-Methylbut-1-yne (2.09 g, 30.7 mmol, 3.14 mL, 10 eq (4S,12aS)-7-azido-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (1.4 g, 3.1 mmol, 1 eq Sodium ascorbate (2.44 g, 12.3 mmol, 4) eq A mixture of copper sulfate (981 mg, 6.2 mmol) in H₂O (10 mL) and MeOH (5 mL) was degassed with N₂ and purged three times, and then stirred at 25 °C under N₂ atmosphere for 16 hours. The reaction mixture was filtered to obtain a filtrate, which was then concentrated under reduced pressure to obtain a residue. The residue was purified by reverse-phase column chromatography (HCl conditions). A yellow solid (4S,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyltriazol-1-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetraphenyl-2-carboxamide (42% yield) was obtained. LC-MS (ESI) + m / z: 524.2 (M+H) + .
[0332] (4S,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-(4-isopropyltriazol-1-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (80 mg, 153 μmol, 1) eq Add Zn (50 mg, 763 μmol, 5 μg) to a solution of HOAc (1.5 mL) and H2O (1.5 mL). eqThe mixture was stirred at 25°C for 16 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The residue was then passed through... Preparative Purification was performed by HPLC (column: Phenomenex Synergi C18 100*30mm*4um; mobile phase: [water (HCl)-ACN]; B%: 40%-70%, 7.8 min). A yellow solid (4aS, 12aS)-3,10,12,12a-tetrahydroxy-7-(4-isopropyltriazol-1-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetraphenyl-2-carboxamide (8% yield) was obtained. LC-MS (ESI) + m / z: 481.1 (M+H) + LCMS: C 24 H 24 Calculated N4O7 value: 480.16, measured value: [M+H] + 481.1. 1 H NMR (400 MHz, methanol-) d 4) δppm 1.35 - 1.38 (m, 3 H) 1.39 - 1.42 (m, 3 H) 1.47 - 1.59 (m, 1 H) 1.87 -2.01 (m, 1 H) 2.32 - 2.51 (m, 4 H) 2.79 - 2.94 (m, 1 H) 3.14 - 3.28 (m, 2 H)6.97 - 7.11 (m, 1 H) 7.50 - 7.64 (m, 1 H) 8.00 - 8.10 (m, 1 H) Example 36A: (4aS, 12aS) -7-(3-Cyclopropylisoxazol-5-yl)- 3,10,11,12a -Tetrahydroxy-1,12-dioxo- 4a,5,5a,6 -Tetrahydrogen- 4H -Tetraphenyl-2-carboxamide of Synthesis and Characterization Hydroxylamine hydrochloride (19.8 g, 285.4 mmol) and Na₂CO₃ (60.5 g, 570.7 mmol) were added to a solution of cyclopropaneformaldehyde (10 g, 143 mmol, 10.7 mL) in EtOH (50 mL). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was diluted with H₂O (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give the residue. A white solid was obtained. (E) - Cyclopropane-formaldehyde oxime (29% yield). The residue can be used in the next step without further purification.
[0333] Towards (E) A solution of cyclopropaneformaldehyde oxime (500 mg, 5.9 mmol) in DCM (25 mL) was mixed with benzyltrimethylammonium tetrachloroiodate (2.46 g, 5.9 mmol). The mixture was stirred at 25 °C for 1 hour. Then diisopropyl ether (44 mL) was added. The reaction mixture was filtered and concentrated under reduced pressure to give the residue. A yellow oily substance was obtained. (Z)-N - Hydroxycyclopropanemimine chloride (17% yield). The residue can be used in the next step without further purification.
[0334] Towards (Z)-N K₂CO₃ (193 mg, 1.4 mmol) was added to a solution of 197.3 mg (1.7 mmol) and tributyl(ethynyl)stanane (400 mg, 1.3 mmol) in DCM (5 mL). The mixture was stirred at 25 °C for 24 h. The reaction mixture was quenched by adding H₂O (18 mL) at 25 °C and then extracted with DCM (15 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by rapid silica gel chromatography (ISCO®; 40 g SepaFlash® silica gel column, eluent 20–25% DCM / petroleum ether gradient, 40 mL / min). A colorless oil was obtained. three Butyl-(3-cyclopropylisoxazol-5-yl)stanane (40% yield).
[0335] Tributyl-(3-cyclopropylisoxazol-5-yl)stanane (144 mg, 362 μmol), (12aS)-3,10,11, 12a -Tetrahydroxy-7-iodine-1,12-dioxo- 4a,5,5a,6 -Tetrahydrogen-4H 1,4-benzo-2-carboxamide (150 mg, 302 μmol), DIEA (78 mg, 603 μmol, 105 μL), CuI (5.8 mg, 30.2 μmol), and Pd(dppf)Cl2 (33.1 mg, 45.3 μmol) in DMF (3 mL) were degassed with N2 and purged three times. The mixture was then stirred at 70 °C under N2 atmosphere for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain the residue. The crude product was purified by reversed-phase HPLC (column: Welch Xtimate C18 100*40mm*3 μm; mobile phase: [water (HCl)-ACN]; B%: 40%-70%, 8 min). A yellow solid was obtained. (4aS, 12aS) -7-(3-Cyclopropylisoxazol-5-yl)- 3,10,11,12a -Tetrahydroxy-1,12-dioxo- 4a,5,5a,6 -Tetrahydrogen- 4H -Tetraphenyl-2-carboxamide (14% yield). LC-MS (ESI) + ) m / z 479.0 (M+H) + LCMS: C 25 H 22 N2O8 . (HCl) Calculated value: 478.14, Measured value: [M+H] + 479.0. 1 H NMR(400MHz, MeOD): 7.61-7.80 (m, 1H), 6.94 (br d, 1H), 6.18-6.36 (m, 1H), 3.26(br m, 1H), 3.05-3.13 (m, 1H), 2.79-2.93 (m, 1H), 2.36-2.59 (m, 3H), 2.00-2.09 (m, 2H), 1.55-1.71 (m, 1H), 1.05-1.16 (m, 2H), 0.84-0.93 (m, 2H).
[0336] Example 37A: (4a) S ,12a S )-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-(2,2,2-trifluoro-1-methyl-ethyl)-4a,5-dihydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4a) S ,12aS )-3,10,11,12a-tetrahydroxy-7-iodo-1,12-dioxo-4a,5-dihydro-4 H -2-benzo[a]tetraphenyl-2-carboxamide (300 mg, 606 μmol, 1.0 μg) eq Tributyl[1-(trifluoromethyl)vinyl]stanane (700 mg, 1.8 mmol, 3.0 mmol) eq ), cuprous iodide (17.3 mg, 90.8 μmol, 0.1 μmol). eq )and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (63.7 mg, 90.8 μmol, 0.1 μmol) eq The mixture in DMF (8 mL) was degassed with N2 and purged three times, and then stirred at 70 °C under N2 atmosphere for 5 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (Phenomenex Synergi C18100*30mm*4um; mobile phase: [water (HCl)-ACN]; B%: 50%-80%, 8 min). A yellow solid (4a) was obtained. S ,12a S )-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-(2,2,2-trifluoro-1-methyl-ethyl)-4a,5-dihydro-4 H -Tetraphenyl-2-carboxamide (8.5% yield). LC-MS (ESI) + ) m / z 466.1 (M+H) + LCMS: C 22 H 18 Calculated value of NO7F3: 465.1, Measured value: [M+H] + 466.1. 1H NMR (400 MHz, MEOD-d4) δ 7.68 (d, J = 8.4 Hz, 1H),7.47 - 7.40 (m, 1H), 6.88 (d, J = 8.4 Hz, 1H), 4.38 (td, J = 7.8, 15.6 Hz, 1H),3.52 - 3.46 (m, 1H), 3.13 - 2.99 (m, 2H), 2.92 - 2.83 (m, 1H), 2.63 - 2.51(m, 1H), 1.56 (d, J = 7.0 Hz, 3H).
[0337] Example 38A: (4a S )-Synthesis and characterization of 3,10,11-trihydroxy-1,12-dioxo-7-(2,2,2-trifluoro-1-methyl-ethyl)-4,4a,5,12a-tetrahydrotetracene-2-carboxamide To a mixture of (4a S ,12a S )-3,10,11,12a-tetrahydroxy-1,12-dioxo-7-(2,2,2-trifluoro-1-methyl-ethyl)-4a,5-dihydro-4 H -tetracene-2-carboxamide (20 mg, 43 μmol, 1.0 eq ) in HOAc (1.0 mL) and H2O (1.0 mL) was added Zn (96 mg, 1.7 mmol, 40 eq ). The mixture was stirred at 25°C for 36 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (Phenomenex Synergi C18 100*30mm*4um; mobile phase: [Water(HCl)-ACN]; B%: 60%-90%, 10min). (4a S )-3,10,11-Trihydroxy-1,12-dioxo-7-(2,2,2-trifluoro-1-methyl-ethyl)-4,4a,5,12a-tetrahydrotetracene-2-carboxamide was obtained as a yellow solid (4.7% yield). LC-MS (ESI+) m / z: 450.0 (M+H)+. LCMS: C 22 H 18 NO6F3 calculated value: 449.1, found value: [M+H] + 450.0. 1H NMR (400 MHz, MEOD- d 4) δ 7.61 - 7.55 (m, 1H), 7.44 -7.39 (m, 1H), 6.95 - 6.77 (m, 1H), 4.45 - 4.30 (m, 1H), 3.39 - 3.36 (m, 1H),3.22 - 3.13 (m, 2H), 3.10 - 3.05 (m, 1H), 2.74 - 2.70 (m, 1H), 1.61 - 1.55(m, 3H) Example 39A: (4a S ,5a R ,12a S)-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4a) S ,5a R ,12a S )-7-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H A mixture of 1-bromo-2-(2-bromoethoxy)ethane (54 mg, 0.23 mmol), NaI (46.6 mg, 0.31 mmol), and DIEA (100 mg, 0.78 mmol) in DMF (1 mL) was purged three times with N2 and then stirred at 65 °C for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The residue was then subjected to... Preparative HPLC column purification: Phenomenex Luna C18 150*25 mm*10 μm; mobile phase: [water (FA)-ACN]; B%: 33%-63%, 10 min. A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-morpholino-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (14% yield). LCMS: C 23 H 24 Calculated N₂O₈: 456.15, Measured value: [M+H] + 457.0. 1 H NMR (400 MHz, methanol-) d 4 ) δ 7.38 (d, J = 9.2 Hz, 1H), 6.81 (d, J = 8.8 Hz, 1H), 4.52 - 4.48 (m, 1H), 3.84 (s, 2H), 3.80 - 3.76(m, 2H), 3.46 - 3.41 (m 1H), 3.29 - 3.25 (m, 1H), 3.00 - 2.85 (m, 2H), 2.80(d, J= 3.6 Hz, 1H), 2.70 (d, J = 6.4 Hz, 2H), 2.50 - 2.40 (m, 2H), 2.18 - 2.07 (m, 2H) 1.68 - 1.62 (m, 1H).
[0338] Example 40A: (5a) R ,12a S )-3,10,12,12a-tetrahydroxy-7-(4-hydroxy-1-piperidinyl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide At 0℃ towards (4a) S ,5a R ,12a S )-7-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H ⁻¹Tetraphenyl-2-carboxamide (60 mg, 0.16 mmol), 3-hydroxyglutaraldehyde (288.5 mg, 1.24 mmol) were added to a mixture of H₂O (1.5 mL) and THF (1.5 mL) with NaBH₃CN (48.8 mg, 0.78 mmol), and then stirred at 0 °C for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC column: Welch Xtimate C18 150 * 25 mm * 5 μm; mobile phase: [water (HCl)-ACN]; B%: 3%-33%, 10 min. A yellow solid (5a) was obtained. R ,12a S )-3,10,12,12a-tetrahydroxy-7-(4-hydroxy-1-piperidinyl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (19% yield). LCMS: C 24 H 26 Calculated N₂O₈: 470.17, Measured value: [M+H] + 471.1. 1 H NMR (400 MHz, CD3OD- d 4) δ7.88-7.83 (m, 1H), 7.05-7.04 (m, 1H), 4.19-4.05 (m, 2H), 3.83-3.63 (m, 2H), 3.53-3.45 (m, 2H), 3.27(s, 2H), 2.97-2.94 (m, 1H), 2.52 (d, J = 7.2 Hz, 2H), 2.44 (d, J = 18.4 Hz, 2H), 2.17 (d, J = 11.2 Hz, 2H), 2.06 (d, J = 7.2 Hz, 2H), 1.73 - 1.64 (m, 1H).
[0339] Example 41A: (12a) S )-7-(azacyclobutane-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide To (12a) S )-7-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 2-Phenylene-2-carboxamide (100 mg, 259 μmol, 1.0 μmol) eq ) and 1,3-dibromopropane (78.3 mg, 388 μmol, 39.5 μL, 1.5 eq Add NaI (193.9 mg, 1.29 mmol, 5.0 mg) to the mixture in DMF (3.0 mL). eq ) and DIEA (167 mg, 1.3 mmol, 225 μL, 5.0 eq The mixture was stirred at 70°C for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (1-Welch Ultimate 75*40mm*3um; mobile phase: [water(FA)-ACN]; gradient: 15%-45% B over 8 min). A yellow solid (12a) was obtained. S )-7-(azacyclobutane-1-yl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -Tetraphenyl-2-carboxamide (4% yield). LC-MS (ESI) + ) m / z 427.0 (M+H) + LCMS: C 22 H 22 Calculated N₂O₇: 426.1, Measured value: [M+H] + 427.0. 1H NMR (400 MHz, CD3OD- d 4) δ 7.04 - 6.96 (m, 1H), 6.83 - 6.75 (m, 1H), 3.95 (q, J = 7.3Hz, 2H), 3.63 (q, J = 7.0 Hz, 2H), 3.30 - 3.22 (m, 1H), 2.90 ( J = 4.3, 15.3 Hz,1H), 2.85 - 2.74 (m, 1H), 2.53 - 2.41 (m, 2H), 2.27 (quin, J = 6.9 Hz, 2H), 2.21 - 2.07 (m, 2H), 1.65 - 1.54 (m, 1H).
[0340] Example 42A: (4a S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-(3-hydroxyazycyclobutane-1-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide (4a) S ,5a R ,12a S )-7-amino-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H -2-benzoxylene-2-carboxamide (50 mg, 129 μmol, 1 eq A mixture of 1,3-dibromoprop-2-ol (141 mg, 0.65 mmol), NaI (77.6 mg, 0.52 mmol), and DIEA (134 mg, 1.04 mmol) in DMF (1 mL) was purged three times with N2 and then stirred at 65 °C for 12 hours. The reaction mixture was filtered under reduced pressure. The residue was strained through... PreparativeHPLC column purification: Phenomenex Luna C18 150 * 25 mm * 10 μm; mobile phase: [water (FA)-ACN]; gradient: 10%-40% B, min. A yellow solid (4a) was obtained. S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-7-(3-hydroxyazycyclobutane-1-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 2-Phenylene-2-carboxamide (21% yield). LCMS: C 22 H 22 Calculated N₂O₈: 442.14, Measured value: [M+H] + 443.2. 1 H NMR (400 MHz, CD3OD- d 4 ) δ 6.93 (d, J = 8.8 Hz, 1H), 6.73 (d, J = 8.8 Hz, 1H), 4.59 - 4.52 (m, 2H), 4.15 ( s, 1H), 3.88 - 3.85(m, 1H), 3.65 - 3.62 (m, 1H), 3.54 - 3.49 (m, 1H), 2.91 - 2.87 (m, 1H), 2.78- 2.72 (m, 1H), 2.46 - 2.35 (m, 2H), 2.17 - 2.02 (m, 2H), 1.60 (d, J = 12 Hz, 1H).
[0341] Example 43A: Synthesis and characterization of (4aS,5aR)-7-cyclobutyl-3,10,12-trihydroxy-1,11-dioxo-4,4a,5,5a,6,12a-hexahydrotetraphenyl-2-carboxamide Zn (415 mg, 6.4 mmol) was added to a solution of (4aS,5aR,12aS)-7-cyclobutyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (180 mg, 423.10 μmol) in H₂O (5 mL) and AcOH (5 mL). The mixture was stirred at 25 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 100*30mm*4µm; mobile phase: [water (HCl)-ACN]; gradient: 60%-90% B over 10 min). (4aS,5aR)-7-cyclobutyl-3,10,12-trihydroxy-1,11-dioxo-4,4a,5,5a,6,12a-hexahydrotetraphenyl-2-carboxamide was obtained as a yellow solid (12% yield). LC-MS (ESI+) m / z: 410.0 (M+H)+. LCMS: C 23 H 23 Calculated NO6 value: 409.15, Measured value: [M+H] + 410.0. 1 H NMR (400 MHz, CD3OD- d 4): δ 7.51-7.35 (m, 1H), 6.77 (t, J = 7.9 Hz, 1H), 3.69 -3.58 (m, 1H), 3.13 (dd, J = 1.8, 3.3 Hz, 1H), 3.03 - 2.93 (m, 1H), 2.51 (d, J= 18.8 Hz, 1H), 2.41 - 2.34 (m, 1H), 2.31 - 2.24 (m, 1H), 2.23 - 2.14 (m,2H), 2.05 - 2.01 (m, 1H), 1.88 - 1.79 (m, 1H), 1.64 - 1.55 (m, 1H), 1.33 (s, 3H).
[0342] Example 44A: ( Synthesis and characterization of (4aS,5aR)-1,3,10,12-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-11-oxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide Zn (1.03 g, 15.82 mmol) was added to a solution of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (190 mg, 0.4 mmol) in AcOH (2 mL) and H2O (2 mL). The mixture was stirred at 25 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 100*30mm*4µm; mobile phase: [water (HCl)-ACN]; gradient: 60%-90% B over 8 min). A yellow solid, (4aS,5aR)-1,3,10,12-tetrahydroxy-7-(3-isopropylisoxazol-5-yl)-11-oxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide, was obtained (17% yield). LC-MS (ESI+) m / z: 465.1 (M+H)+. LCMS: C 25 H 24 Calculated N₂O₇: 464.16, Measured value: [M+H] + 465.1. 1 H NMR (400 MHz, CD3OD- d 4): δ 7.77 - 7.64 (m, 1H), 6.96 - 6.88 (m, 1H), 6.53 - 6.46 (m, 1H), 4.87 - 4.85 (m, 1H), 3.71 - 3.61(m, 1H), 3.21 - 3.03 (m, 3H), 2.85 - 2.72 (m, 1H), 2.59 - 2.55 (m, 1H), 2.50 - 2.49 (m, 1H), 2.58 - 2.45 (m, 3H), 1.96 - 1.84 (m, 1H), 1.62 - 1.49 (m,1H), 1.39 - 1.32 (m, 7H).
[0343] Example 45A: Synthesis and characterization of (4aS,12aS)-7-cyclopropyl-3,10,11,12a-tetrahydroxy-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetraphenyl-2-carboxamide (4a) S ,12a S)-3,10,11,12a-tetrahydroxy-7-iodo-1,12-dioxo-4a,5-dihydro-4 H A mixture of 100.0 mg (0.20 mmol) benzo-2-carboxamide, cyclopropylboronic acid (173.5 mg (2.02 mmol)), K₂CO₃ (139.5 mg (1.01 mmol)), and bis((tri-tert-butyl)phosphine)palladium (103.2 mg (0.2 mmol)) in dioxane (4 mL) was degassed with N₂ and purged several times, and then the mixture was stirred at 120 °C under N₂ atmosphere for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure. The residue was then subjected to a preparative process. HPLC Column purification: Welch Xtimate C18 150 * 25mm * 5um; mobile phase: [water (HCl)-ACN]; B%: 30%-60%, 19 min. A yellow solid (4a) was obtained. S ,12a S )-7-Cyclopropyl-3,10,11,12a-Tetrahydroxy-1,12-dioxo-4a,5-dihydro-4 H -Tetraphenyl-2-carboxamide (11% yield). LCMS: C 22 H 19 Calculated value of NO7: 409.12, Measured value: [M+H] + 409.8. 1 H NMR (400MHz, acetonitrile-) d 3 ) δ = 14.97 (s,1H), 9.49 (s, 1H), 8.99 (s, 1H), 7.73 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 6.94(s, 1H), 6.76 (d, J = 8.0 Hz, 1H), 5.19 (s, 1H), 3.53 (d, J = 17.6 Hz, 1H), 3.10- 3.01 (m, 1H), 2.96 - 2.89 (m, 2H), 2.67 - 2.59 (m, 1H), 2.66 - 2.64 (m,1H), 2.66 - 2.64 (m, 1H), 2.65 - 2.59 (m, 1H), 1.05 - 1.01 (m, 2H), 0.67 -0.63 (m, 2H).
[0344] Example 46A: Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(2-oxaspiro[3.3]hept-6-en-6-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide KHMDS (1.0 M in THF, 4.3 mL, 4.3 mmol) was added to a mixture of 2-oxaspiro[3.3]hepta-6-one (400 mg, 3.57 mmol) in THF (5.0 mL) at -78 °C under N2. The mixture was stirred at -78 °C under N2 for 0.5 h, and PhNTf2 (1.53 g, 4.3 mmol) was added dropwise to THF (1.0 mL) at -78 °C. The reaction mixture was stirred at -78 °C under N2 for 2 h. The reaction mixture was quenched by adding H2O (30 mL) at 0 °C and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain a residue, which was purified by rapid silica gel chromatography (ethyl acetate / petroleum ether = 0% to 40%) to give 2-oxaspiro[3.3]hept-6-en-6-yl trifluoromethanesulfonic acid as a colorless oil (32.1% yield). 1 H NMR (400 MHz, CDCl3 -d ) δ 5.51 (s, 1H), 4.85 - 4.70 (m, 4H), 3.01 (s, 2H).
[0345] (4) aS ,12 aS )-3,10,11,12 a -Tetrahydroxy-7-iodo-1,12-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H2,4,5,5-Tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1,3,2-dioxacyclopentaborane (306.4 mg, 1.2 mmol), XPhos (19.2 mg, 40.2 μmol), Pd[(t-Bu)3P)]2 (20.6 mg, 40.2 μmol), and AcOK (79.0 mg, 0.8 mmol) were placed in DMSO (3.0 mL) and the mixture was microwave-stirred at 100 °C under N2 for 2 hours. The mixture was filtered and purified by preparative HPLC (HCl) to obtain a yellow solid (4... aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-4 a ,5,5 a ,6-Tetrahydro-4 H -Tetraphenyl-2-carboxamide (60% yield). LCMS: C 25 H 28 BNO9 calculated value: 497.19, measured value: [M+H] + 498.2.
[0346] (4a) S ,5a R ,12a S )-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-4 a ,5,5 a ,6-Tetrahydro-4 H 2-(3,3)-benzoxyl-2-carboxamide (150 mg, 0.3 mmol), 2-oxaspiro[3,3]hepta-6-en-6-yl trifluoromethanesulfonate (110.5 mg, 0.45 mmol), Cs2CO3 (294.8 mg, 0.9 mmol), and Pd(dppf)Cl2 (22.1 mg, 30.2 μmol) were placed in dioxane (3.0 mL) and H2O (1.0 mL), and the reaction mixture was stirred at 95 °C under N2 for 6 hours. The reaction mixture was filtered and purified by reversed-phase column chromatography (FA) and preparative HPLC (FA) to obtain a yellow solid (4... aS 5 aR ,12 aS )-3,10,12,12a -Tetrahydroxy-7-(2-oxaspiro[3.3]hept-6-en-6-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H 2-Phenylene-2-carboxamide (11.8% yield). LCMS: C 25 H 23 Calculated value of NO8: 465.14, Measured value: [M+H] + 466.2 HPLC: 97.4% purity at 254 nm. 1 H NMR (400 MHz, CD3OD- d 4 ) δ 7.43 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 8.8 Hz, 1H), 6.27 (s,1H), 4.92 (d, J = 1.6 Hz, 2H), 4.89 (s, 2H), 3.55 - 3.44 (m, 1H), 3.28 - 3.25(m, 1H), 3.17 (d, J = 12.8 Hz, 1H), 3.00 (d, J = 12.8 Hz, 1H), 2.92 - 2.82 (m,1H), 2.53 - 2.46 (m, 1H), 2.45 - 2.32 (m, 2H), 2.12 - 2.07 (m, 1H), 1.70 -1.61 (m, 1H).
[0347] Example 47A: Synthesis and characterization of (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-7-(2-oxaspiro[3.3]heptane-6-yl)-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-benzotetraphenyl-2-carboxamide (4) aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(2-oxaspiro[3.3]hept-6-en-6-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 HA mixture of 40.0 mg (85.9 μmol) benzo-2-carboxamide and 120 mg (528.5 μmol) in THF (5.0 mL) was degassed with H2 and purged three times. The mixture was then stirred at 20 °C under an H2 atmosphere for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The crude product was purified by reversed-phase HPLC (FA) to give a yellow solid (4... aS 5 aR ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(2-oxaspiro[3.3]heptane-6-yl)-1,11-dioxo-4 a ,5,5 a ,6-Tetrahydro-4 H -Tetraphenyl-2-carboxamide (16.6% yield). LC-MS (ESI) + ) m / z 468.3 (M+H) + LCMS: C 25 H 25 Calculated value of NO8: 467.16, Measured value: [M+H] + 468.3. HPLC: 98.2% purity at 254 nm. 1 H NMR (400MHz, CD3OD): δ 8.40 (s, 1.0H), 7.38 (d, J =8.4 Hz, 1.0H), 6.79 (d, J = 8.4 Hz, 0.9H), 4.51-4.72 (m, 4.0H), 3.44 (t, J =8.8Hz, 0.9H), 3.22-3.32 (m, 3.0H), 2.94 (dd, J =15.6, 4.4 Hz, 1.0H), 2.76-2.88 (m,1.0H), 2.58-2.74 (m, 2.0H), 2.45-2.52 (m, 1.0H), 2.38-2.44 (m, 1.0H), 2.31-2.38 (m, 1.0H), 2.12-2.45 (m, 4.0H), 2.12-2.28 (m, 2.0H), 2.07-2.11 (m,1.0H), 1.55-1.68 ppm (m, 1.2H).
[0348] Example 48A: Synthesis and characterization of (4aS,12aS)-3,10,12,12a-tetrahydroxy-7-(2-oxaspiro[3.3]heptane-6-yl)-1,11-dioxo-4a,5-dihydro-4H-tetraphenyl-2-carboxamide (4) aS ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-iodo-1,11-dioxo-4 a ,5-dihydro-4 H -Tetraphenyl-2-carboxamide (400 mg, 752.3 μmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-1,3,2-dioxacyclopentaborane (382.1 mg, 1.5 mmol), AcOK (147.7 mg, 1.5 mmol), Pd[( t A mixture of -Bu)3P]2 (38.5 mg, 75.2 μmol) and XPhos (35.9 mg, 75.2 μmol) in DMSO (7.0 mL) was degassed with N2 and purged three times, and then the mixture was stirred at 100 °C under N2 atmosphere at MW for 2 hours. The reaction mixture was filtered to obtain the residue. The crude product was purified by preparative HPLC (FA). A yellow solid (4) was obtained. aS ,12 aS )-3,10,12,12 a -Tetrahydroxy-1,11-dioxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-4 a ,5-dihydro-4 H -Tetraphenyl-2-carboxamide (169 mg). LC-MS (ESI) + ) m / z : 496.2 (M+H) + .
[0349] To trifluoromethanesulfonic acid 2-oxaspiro[3.3]hept-6-en-6-yl ester (124.5 mg, 509.8 μmol) and (4 aS 5 aR ,12 aS )-3,10,11,12 a -Tetrahydroxy-1,12-dioxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxacyclopentaborane-2-yl)-4 a ,5,5 a,6-Tetrahydro-4 H 1,4-benzo[a]-tetraphenyl-2-carboxamide (169 mg, 339.8 μmol, 1 eq) was added to a solution of dioxane (10.0 mL) and H2O (3.0 mL) with Pd(dppf)Cl2 (24.9 mg, 34.0 μmol) and Cs2CO3 (332.2 mg, 1.0 mmol). The mixture was degassed with N2 and purged three times, and then stirred at 95 °C under N2 atmosphere for 3 h. The reaction mixture was filtered to obtain the residue. The crude product was purified by reversed-phase HPLC (column: C18 150 × 30 mm; mobile phase: [water (FA)-MeCN]; gradient: 18%–58% B over 9 min). A green solid (4...) was obtained. aS ,12 aS )-3,10,11,12 a -Tetrahydroxy-7-(2-oxaspiro[3.3]hept-6-en-6-yl)-1,12-dioxo-4 a ,5-dihydro-4 H -Tetraphenyl-2-carboxamide (88.9% yield). LC-MS (ESI) + ) m / z 463.9 (M+H) + .
[0350] (4) aS ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(2-oxaspiro[3.3]hept-6-en-6-yl)-1,11-dioxo-4 a ,5-dihydro-4 H A mixture of 100 mg, 215.8 μmol benzoyl-2-carboxamide and 147 mg, 647.3 μmol PtO2 in 5.0 mL THF was degassed with H2 and purged three times. The mixture was then stirred at 20 °C under an H2 atmosphere for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The crude product was purified by reversed-phase HPLC (column: C18 150 × 30 mm; mobile phase: [water (FA)-MeCN]; gradient: 17%–57% B over 9 min). A yellow solid (4...) was obtained. aS ,12 aS )-3,10,12,12 a -Tetrahydroxy-7-(2-oxaspiro[3.3]heptane-6-yl)-1,11-dioxo-4 a ,5-dihydro-4 H -Tetraphenyl-2-carboxamide (4.4% yield). LCMS: C25 H 23 Calculated value of NO8: 465.14, Measured value: [M+H] + 466.1. HPLC: 97.0% purity at 254 nm. 1 H NMR (400MHz, CD3OD): δ 7.4-7.5 (m, 1H), 7.21(s, 1H), 6.7-6.9 (m, 1H), 4.63 (s, 3H), 3.7-3.8 (m, 1H), 3.4-3.6 (m, 1H),3.0-3.1 (m, 2H), 2.8-2.9 (m, 4H), 2.5-2.6 (m, 1H), 2.3-2.4 (m, 3H).
[0351] Example 1B: (4) R , 4a S , 5a R , 12a S )-4-(diethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H Synthesis and characterization of -tetraphenyl-2-carboxamide At 20℃ towards (4) S , 4a S , 5a R , 12a S )-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4 H 1 eq. of tetraphenyl-2-carboxamide was added to a solution of hydroxylamine (15 M, 50% purity) in DMF (0.5 mL), and the mixture was stirred under air at 80 °C for...
Claims
1. A compound of formula (I)-R: (I)-R, Or its pharmaceutically acceptable salt, wherein: The carbon atom at * has ( R Configuration; Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Wherein R' is H, an optionally substituted alkyl group, or an optionally substituted alkoxy group; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups. R a2 is OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 is OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 is OR z , Where R z It is H or an alkyl group that is optionally substituted.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 All are H.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 All are alkyl groups that have been optionally substituted.
4. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 All are methyl groups.
5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R m For H.
6. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R m It is a methyl group.
7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R b1 OR p .
8. The compound of claim 7 or a pharmaceutically acceptable salt thereof, wherein R p For H.
9. The compound of claim 7 or a pharmaceutically acceptable salt thereof, wherein R p It is a methyl group.
10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R x For H.
11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R d1 For H.
12. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R d1 It is a haloalkyl group.
13. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optional substituted cyclopentyl, or Choose any substituted heterocyclic group from the group consisting of: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , Wherein R is H or an alkyl group that is optionally substituted.
14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R z For H.
15. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R z It is a methyl group.
16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R f and R g Together with the nitrogen atoms to which they are attached, they form cyclic groups optionally substituted with one or more alkyl, haloalkyl groups, wherein the alkyl group is substituted with -OR, halo, -OR, -COOR, -C(=O)R, -SO2R, or oxo. Wherein R is H or an alkyl group that is optionally substituted.
17. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R a1 It is a cyclic group with 3-10 ring atoms that are optionally substituted.
18. The compound of claim 17 or a pharmaceutically acceptable salt thereof, wherein R a1 It is an optionally substituted cyclic group having 3-10 ring atoms and one or more additional ring atoms, wherein the one or more additional ring atoms are heteroatoms independently selected from nitrogen and oxygen.
19. The compound of claim 17 or 18 or a pharmaceutically acceptable salt thereof, wherein the cyclic group has two fused rings.
20. The compound of claim 17 or 18 or a pharmaceutically acceptable salt thereof, wherein the cyclic group is a bridged cyclic group.
21. The compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein R a1 For any substituted cyclic group selected from the group consisting of: , , , , , , , , , ,and , Where R 10 It can be an optionally substituted alkyl, optionally substituted alkenyl, halogenated, C(=O)alkyl, C(=O)-O-alkyl, SO2(alkyl), optionally substituted cycloalkyl or optionally substituted alkoxy.
22. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R f C replaced by 3 to 10-membered heterocycles 1-3 Alkyl, and R g For H.
23. The compound of claim 22, and its pharmaceutically acceptable salt, wherein R f For being , , or Replacement C 1-3 alkyl.
24. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R f It is a heterocyclic alkyl group and R g For H.
25. The compound of claim 24, and its pharmaceutically acceptable salt, wherein R f for , , ,or Each of them is optionally controlled by one or more Cs 1-3 Alkyl or C 1-3 Halogenated alkyl substituted, wherein R is H or C. 1-3 alkyl.
26. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (Ii)-R: (I-i)-R, Or its pharmaceutically acceptable salt.
27. A compound of formula (IC)-R: (I-C)-R, Or its pharmaceutically acceptable salt, wherein: The carbon atom at * has ( R Configuration; Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R f H, an optionally substituted alkyl group, or an optionally substituted heterocyclic alkyl group; R g Alkyl groups that are optionally substituted R a2 is O or R m , Where R m H or an alkyl group that is optionally substituted; R b1 is O or R p , Where R p H or an alkyl group that is optionally substituted; R b2 is OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; where each R t R u R n and R o Alkyl groups that are independently H or optionally substituted; R d3 is OR z , Where R z It is H or an alkyl group that is optionally substituted.
28. The compound of claim 27 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (ICi): (I-C-i), Or its pharmaceutically acceptable salt.
29. A compound of formula (ID): (I-D), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Where R' is H, alkyl, or alkoxy; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups. R a2 is O or R m , Where R m H, an optionally substituted alkyl group, or an optionally substituted heteroaryl group; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 is OR x , Where R x H or an alkyl group that is optionally substituted; R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optionally substituted cyclopentyl groups, Choose any substituted heterocyclic group from the group consisting of: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , Where R is H or alkyl; R d2 For H; and R d3 is OR z , Where R z It is H or alkyl. The condition is when R d1 Cyclopropyl, cyclopentyl, or When, then R a1 It is not N(CH3)2.
30. A compound of formula (ID)-R: (I-D)-R, Or its pharmaceutically acceptable salt, wherein: The carbon atom at * has ( R Configuration, Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Where R' is H, alkyl, or alkoxy; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups. R a2 is O or R m , Where R m H, an optionally substituted alkyl group, or an optionally substituted heteroaryl group; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 is OR x , Where R x H or an alkyl group that is optionally substituted; R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Optionally substituted cyclopentyl groups, Choose any substituted heterocyclic group from the group consisting of: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , Where R is H or alkyl; R d2 For H; and R d3 is OR z , Where R z It is H or alkyl.
31. A compound of formula (IE): (IE), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R k Alkyl groups that are optionally substituted; R a2 is OR m , Where R m It is H or an optionally substituted alkyl or an optionally substituted heteroaryl; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 is O or R x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 is OR z , Where R z It is H or alkyl.
32. The compound of claim 31 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (IEi): (IEi), Or its pharmaceutically acceptable salt.
33. A compound of formula (III): (III), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Wherein R' is H, an optionally substituted alkyl group, or an optionally substituted alkoxy group; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups. R a2 is OR m , Where R m H or an alkyl group that is optionally substituted; R a3 is OR L , Where R L H or an alkyl group that is optionally substituted; R b1 is O or R p , Each R p It is H or alkyl; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; where each R t and R u Alkyl groups that are independently H or optionally substituted; Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 is O or R z , Where R z It is an H or optionally substituted alkyl group, The condition is when R a1 When it is N(CH3)2, then R d1 Not H.
34. The compound of claim 33 or a pharmaceutically acceptable salt thereof, wherein R a1 It is NH2.
35. The compound of claim 33 or a pharmaceutically acceptable salt thereof, wherein R f and R g Together with the nitrogen atoms to which they are attached, they form heterocyclic alkyl groups.
36. The compound of any one of claims 33 to 35, or a pharmaceutically acceptable salt thereof, wherein R d1 It is a cycloalkyl group.
37. The compound of any one of claims 33 to 36, or a pharmaceutically acceptable salt thereof, wherein... R a2 It is OH; R a3 It is OH; R b1 It is OH; and R d3 It is OH.
38. The compound of any one of claims 33 to 37, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (III-i): (III-i), Or its pharmaceutically acceptable salt.
39. A compound of formula (IV): (IV), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g , Each R f and R g Independently, it is H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocycloalkyl group, or -C(=O)R', wherein R' is H, an optionally substituted alkyl group, or an optionally substituted alkoxy group; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups. R a2 is OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Where R p Alkyl groups that are optionally substituted; Each R q and R s Alkyl groups that are independently H or optionally substituted; R b2 is OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic, halogenated, or NR. t R u ; where each R t and R u Alkyl groups that are independently H or optionally substituted; Each R t R u R n and R o Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 is OR z , Where R z It is H or an alkyl group that is optionally substituted.
40. The compound of claim 39 or a pharmaceutically acceptable salt thereof, wherein: R a2 It is OH; R a3 It is OH; and R d3 It is OH.
41. The compound of claim 39 or 40, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (IV-i): (IV-i), Or its pharmaceutically acceptable salt.
42. A compound of formula (V): (V), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a1 For NR f R g or = NOR k , Each R f and R g Independently, it can be H, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted heterocyclic alkyl group, or -C(=O)R'. Wherein R' is H, an optionally substituted alkyl group, or an optionally substituted alkoxy group; Or R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; Where R k Alkyl groups that are optionally substituted; R a2 is O or R m , Where R m H or an alkyl group that is optionally substituted; R b2 is OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u ; Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 is O or z , Where R z It is H or alkyl.
43. The compound of claim 42 or a pharmaceutically acceptable salt thereof, wherein: R f and R g Together with the nitrogen atoms to which they are attached, they form cyclic groups optionally substituted with one or more alkyl, haloalkyl groups, wherein the alkyl group is substituted with -OR, halo, -COOR, -C(=O)R, -SO2R, cycloalkyl, or oxo. Wherein R is H or an alkyl group that is optionally substituted.
44. The compound of claim 42 or a pharmaceutically acceptable salt thereof, wherein: R f and R g Together with the nitrogen atoms to which they are attached, they form optionally substituted heterocyclic groups.
45. The compound of claim 42 or a pharmaceutically acceptable salt thereof, wherein: R a1 It can be optionally substituted with piperidinyl, optionally substituted with piperazine, or optionally substituted with morpholino.
46. The compound of claim 42 or a pharmaceutically acceptable salt thereof, wherein: R d1 It is an unsubstituted cycloalkyl group.
47. The compound of any one of claims 42 to 46, or a pharmaceutically acceptable salt thereof, wherein: R a2 It is OH; R a3 It is OH; R b1 It is OH; and R d3 It is OH.
48. The compound of any one of claims 42 to 47, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (Vi): (Vi), Or its pharmaceutically acceptable salt.
49. A compound selected from the compounds in Table 1B, or a pharmaceutically acceptable salt thereof.
50. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is: , , , , , , , , , or .
51. A compound of formula (IA): (I-A), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a2 is OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Each R p R q and R s Alkyl groups that are independently H or optionally substituted; R b2 is H or OR x , Where R x H or an alkyl group that is optionally substituted; R d1 for: Optionally substituted cyclopropyl, Optionally substituted nitrogen-containing heterocyclic butyl groups, Optionally substituted oxobutyrans, Optionally substituted cyclobutyl groups Substituted cyclopentyl, Optional substituted 5-membered heterocyclic alkyl groups, Optional substituted heterocyclic groups, wherein the heterocyclic groups are selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and , Wherein R is H or an substituted alkyl group, R d2 For H or NHR y , Where R y For -C(=O)(CH2) n NR v R w , Where n is an integer greater than or equal to 1; Each R v and R w Independently H or optionally substituted alkyl, or R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; and R d3 is OR z , Where R z It is H or an alkyl group that is optionally substituted.
52. The compound of claim 51 or a pharmaceutically acceptable salt thereof, wherein: Each R 1 and R 2 For H; R a2 It is OH; R b1 It is OH; R b2 It is OH; R d2 For H; and R d3 It is OH.
53. The compound of claim 51 or 52 or a pharmaceutically acceptable salt thereof, wherein R d1 for: Unsubstituted cyclopropyl, or cyclopropyl substituted with one or more alkyl, haloalkyl or halogroups; Unsubstituted aza-butanediol, or aza-butanediol substituted with one or more alkyl, haloalkyl or halogroups; Unsubstituted oxetane, or oxetane substituted with one or more alkyl, haloalkyl or halogroups; Unsubstituted cyclobutyl, or cyclobutyl substituted with one or more alkyl, haloalkyl or halogroups; Cyclopentyl group substituted with one or more alkyl, haloalkyl, or halogroups; Unsubstituted 5-membered heterocyclic alkyl, or 5-membered heterocyclic alkyl substituted with one or more alkyl, haloalkyl or halogroups; An unsubstituted heterocyclic group, or a heterocyclic group substituted with one or more alkyl, haloalkyl, -OH, or halogroups; wherein the heterocyclic group is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , and , where R is H or an optionally substituted alkyl group.
54. The compound of claim 51 or 52 or a pharmaceutically acceptable salt thereof, wherein R d1 It is a pyrazol group substituted with an alkyl group.
55. A compound of formula (IAi): (I-A-i), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 For H; and Ring D5 is: Substituted cyclopentyl, Choose any substituted 5-membered heterocyclic group from the group consisting of: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , Wherein R is H or an alkyl group that is optionally substituted.
56. The compound of claim 55 or a pharmaceutically acceptable salt thereof, wherein: Ring D5 is , or , where R is an alkyl group that can be optionally substituted.
57. The compound of claim 55 or a pharmaceutically acceptable salt thereof, wherein: Ring D5 is , where R is an alkyl group that can be optionally substituted.
58. A compound of formula (IA-ii): (IA-ii), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 For H; and Ring D6 is a 6-membered heterocyclic group with optional substitutions selected from the group consisting of: 、 、 、 、 、 、 、 Wherein R is H or an alkyl group that is optionally substituted.
59. The compound of any one of claims 55 to 58 or a pharmaceutically acceptable salt thereof, wherein the heterocyclic group is substituted with one or more alkyl, haloalkyl, or halogroups.
60. A compound of formula (II): (II), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a2 is OR m , Where R m H or an alkyl group that is optionally substituted; R b1 is OR p , Each R p H or an alkyl group that is optionally substituted; R b2 is OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u , Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H; and R d3 is OR z , Where R z It is H or an alkyl group that is optionally substituted.
61. The compound of claim 60 or a pharmaceutically acceptable salt thereof, wherein: R a2 It is OH; R b1 It is OH; R b2 It is OH; R d2 For H; and R d3 It is OH.
62. The compound of claim 60 or 61, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (II-i): (II-i), Or its pharmaceutically acceptable salt.
63. A compound of formula (IV): (IV), Or its pharmaceutically acceptable salt, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a2 is OR m , Where R m H or an alkyl group that is optionally substituted; R b1 OR p or NR q R s , Where R p Alkyl groups that are optionally substituted; Each R q and R s Alkyl groups that are independently H or optionally substituted; R b2 is O or R x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclic or NR t R u , Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H, NHR y Or halogenated, Where R y For H or -C(=O)(CH2) n NR v R w , Where n is an integer greater than or equal to 1; Each R v and R w Independently H or optionally substituted alkyl, or R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; and R d3 is OR z , Where R z It is H or an alkyl group that is optionally substituted.
64. The compound of claim 63 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (IV-i): (IV-i), Or its pharmaceutically acceptable salt.
65. A compound of formula (V): (V), Or its tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein: Each R 1 and R 2 Alkyl groups that are independently H or optionally substituted; R a2 is OR m , Where R m H or an alkyl group that is optionally substituted; R b2 is H or OR x , Where R x H or an alkyl group that is optionally substituted; R d1 H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclic or NR t R u , Each R t and R u Alkyl groups that are independently H or optionally substituted; R d2 For H, NHR y Or halogenated, Where R y For H or -C(=O)(CH2) n NR v R w , Where n is an integer greater than or equal to 1; Each R v and R w Independently H or optionally substituted alkyl, or R v and R w Together with the nitrogen atoms to which they are attached, they form optionally substituted cyclic groups; and R d3 is OR z , Where R z It is H or alkyl.
66. The compound of claim 65 or a pharmaceutically acceptable salt thereof, wherein: R a2 It is OH; and R d3 It is OH.
67. The compound of claim 65 or 66, or a pharmaceutically acceptable salt thereof, wherein: R d1 It is H or an optional substituted cycloalkyl group.
68. The compound of any one of claims 65 to 67, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (Vi): (Vi), Or its pharmaceutically acceptable salt.
69. A compound selected from the compounds in Table 1A, or a pharmaceutically acceptable salt thereof.
70. A composition comprising a compound of formula (Ii-16A) or (Ii-16B): (Ii-16A)or (Ii-16B), Or its pharmaceutically acceptable salt.
71. A composition comprising a substantially pure enantiomer of the compound of formula (Ii-16A) of claim 70 or a pharmaceutically acceptable salt thereof.
72. A composition comprising a substantially pure enantiomer of the compound of formula (Ii-16B) of claim 70 or a pharmaceutically acceptable salt thereof.
73. The composition of claim 71 or 72, wherein less than 5% of the composition is another enantiomer of the compound or a pharmaceutically acceptable salt thereof.
74. A pharmaceutical composition comprising: The compound of any one of claims 1 to 69 or a pharmaceutically acceptable salt thereof, or the composition of any one of claims 70 to 73; and At least one pharmaceutically acceptable excipient.
75. A method for treating a disease or disorder in a subject in need, wherein the disease or disorder is rheumatoid arthritis, inflammatory bowel disease, epilepsy, acute ischemic stroke, traumatic brain injury, neuropathic pain, Fragile X syndrome, drug-induced hyperphagia, Prader-Willi syndrome, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, spinal cord injury, diabetic macular edema, dermatitis, periodontitis, osteoporosis, atherosclerosis, tumor / cancer, malaria, HIV, light chain amyloidosis, transthyretin amyloidosis, schizophrenia, bipolar disorder, or depression. The method includes: The subject is given a therapeutically effective amount of any one of claims 1 to 69 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition as described in claim 74.
76. The method of claim 75, wherein the disease or ailment is Fragile X syndrome.
77. The method of claim 75, wherein the disease or ailment is rheumatoid arthritis.
78. The method of claim 75, wherein the disease or ailment is Alzheimer's disease.
